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Hemophilia B is a bleeding disorder resulting from congenital deficiency of coagulation protein Factor IX. 
Without optimal therapy, patients suffer crippling debilitations, chronic pain, and cognitive impairment. 
Optimal therapy - frequent dosing with Factor IX to reduce bleeding episode frequency - is currently available 
to only a small fraction of U.S. patients, largely because of cost and limited supply; 80% of the world's 
hemophilia patients receive no therapy. The long-term goal of this research is development of an abundant, 
pure, safe, and effective therapy for the global hemophilia patient population using recombinant human 
coagulation proteins produced in the milk of transgenic pigs. This proposal describes studies that are based 
upon innovative bioengineering technologies to refine and scale-up production of clinical grade Factor IX, 
characterize product formulated for intravenous dosage, complete animal studies required for clinical trials, 
and ultimately develop an oral dosage form to provide optimal therapy for U.S. hemophilia B patients. This 
approach capitalizes on existing genetically engineered transgenic pigs that synthesize up to 1000 IU/ml (4 
g/L) of human Factor IX in milk and preliminary evidence for favorable hemostatic and pharmacokinetic 
properties of this purified Factor IX in a hemophilia B mouse model.  A high probability of success is 
expected because of the soundness and state of development of the basic research already completed and 
the breadth and complimentarity of the strengths of the team. Dr. J. Cooper of ProGenetics LLC will supply 
FDA- and USDA-compliant Factor IX milk. At the Univ. Nebraska-Lincoln, Dr. M. Meagher provides expertise 
in bioprocess engineering and current Good Manufacturing Practices production of recombinant proteins; 
Drs. W. Velander and K. Van Cott contribute expertise in transgenic animal engineering and characterization 
of human Factor IX. Dr. M. Manning of Colorado State University brings expertise in the formulation of 
stabilized liquid and lyophilized proteins for oral and injectable dosing. Dr. S. Abramson of LifeSci Partners 
has two decades of biopharmaceutical development experience encompassing clinical, technical, and 
regulatory expertise, including AlphaNine®SD (purified plasma-derived Factor IX).  Drs. P. Monahan and T. 
Nichols of UNC-Chapel Hill have unique preclinical experience with hemophilia B mice and dogs that will be 
used to test the safety and efficacy of the Factor IX products. 
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LifeSci Partners, Altadena, CA 
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Summary Budget--Direct Costs
UNL Activities
Analytical Methods and Characterization $308,076 $214,970 $184,611 $183,584 $183,166 $1,074,407
Purification 0 186,350 176,250 75,120 0 437,720
cGMP Production 45,000 34,500 0 267,885 225,741 573,126
Quality Assurance 156,048 160,729 165,551 170,518 175,633 828,479
Quality Control 210,648 275,385 248,621 211,738 205,319 1,151,711
UNL Project Management 226,134 232,918 239,906 247,103 254,516 1,200,577
UNL Subtotal $945,906 $1,104,852 $1,014,939 $1,155,948 $1,044,375 $5,266,020
Subawards
Colorado State Univ.--M. Manning, W. Dernell
Formulation--direct costs 163,318 178,205 0 0 0 341,523
UNC-Chapel Hill
P. Monahan 
Mouse Model Experiments--direct costs 51,507 0 55,114 56,844 0 163,465
T. Nichols
Dog Trials--direct costs 0 0 125,458 0 163,994 289,452
LifeSci Partners
Clinical trial development--direct costs 86,150 88,735 91,397 94,138 96,963 457,383
Progenetics LLC
Provide milk--direct costs 125,860 0 65,776 67,749 69,782 329,167
Subawards Subtotal 426,835 266,940 337,745 218,731 330,739 1,580,990
Yearly Totals $1,372,741 $1,371,792 $1,352,684 $1,374,679 $1,375,114 $6,847,010
Analytical Methods and Characterization (UNL)
Principal Investigator/Program Director (Last, first, middle): Velander, William H.
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1/1/2005 12/31/2005
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PROJECT
TYPE 
APPT.  
(months)
EFFORT 
ON 
PROJ.
INST. 
BASE 
SALARY
SALARY 
REQUESTED
FRINGE 
BENEFITS
TOTAL
co-PI 9 33% 85,490 $28,212 $7,335 $35,547
co-PI 12 10% 71,585 $7,159 $1,861 $9,020
Scientist 12 90% 50,000 $45,000 $11,700 $56,700
Scientist 12 90% 45,000 $40,500 $10,530 $51,030
Scientist 12 90% 45,000 $40,500 $10,530 $51,030
$0
$161,370 $41,956 $203,326
$11,250
$50,000
Chormatograph
ic
(Capillary & 
slab) 
Electrophoret Immunoassay
APTT and 
Chromogeni
c
Peptide 
Maps
Spectroscop
ic and Fluor. 
tests
Columns 6,000 500 0 0 3,000 0
Reagents 6,000 2,000 3,000 2,000 1,000 500
Disposables 2,000 1,000 1,000 250 500 500
Gels 0 1,500 0 0 0 0
Standards 0 1,000 1,250 3,000 500 500
Kits 0 1,000 0 0 0 0
$40,500
2,000
$1,000
$308,076
$308,076
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ASH or ACS meeting, one person
SUBTOTALS
SUPPLIES (Itemize by category)
PATIENT CARE COST
INPATIENT
OUTPATIENT
Beckman ALC Advance Coagulation Analyzer
EQUIPMENT (Itemize)
CONSULTANT COSTS  Outside Contract Services - N-terminal sequencing, amino acid analysis, Gla analysis, Maintenance 
contracts 
General lab supplies--lab notebooks, labeling tape, toner cartriges, media, 2,500
TRAVEL
DETAILED BUDGET FOR INITIAL BUDGET 
DIRECT COST ONLY
TBN Reesearch Technologist I
TBN Research Technologist I
TBN Research Technologist II
Kevin Van Cott
S. Todd Swanson
NAME
TOTAL DIRECT COSTS FOR INITIAL BUDGET PERIOD  (Item 7a, Face Page)
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ALTERATIONS AND RENOVATIONS (Itemize by category)
Publications costs, 500, overnight shipping for samples and documents, 500
SUBTOTAL DIRECT COST FOR INITIAL BUDGET PERIOD
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COSTS
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Analytical Methods and Characterization (UNL)
INITIAL BUDGET
PERIOD
(from form Page 4) 2nd 3rd 4th 5th
PERSONNEL: Salary and
fringe benefits. Applicant
organization only. 203,326 152,220 138,109 142,252 142,252
CONSULTANT COSTS 11,250 16,875 11,250 11,250 11,250
EQUIPMENT 50,000 0 0 0 0
SUPPLIES 40,500 42,550 31,850 26,600 26,350
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OTHER EXPENSES 1,000 1,265 1,280 1,296 1,063
SUBTOTAL DIRECT COSTS 308,076 214,970 184,611 183,584 183,166
DIRECT
F&A
TOTAL DIRECT COSTS 308,076 214,970 184,611 183,584 183,166
TOTAL DIRECT COSTS FOR THE ENTIRE PROPOSED PROJECT PERIOD (Item 8A, Face Page) $1,074,407
SBIR/STTR Only
Fee Requested 0 0 0 0 0
SBIR/STTR Only: Total Fee Requested for Entire Propposed Project Preiod
$0
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BUDGET CATEGORY
TOTALS
BUDGET FOR THE ENTIRE PROPOSED PROJECT PERIOD
DIRECT COSTS ONLY
ADDITIONAL YEARS OF SUPPORT REQUESTED
PATIENT
CARE
COSTS
CONSORTIUM/
CONTRACTUAL
COSTS
Analytical Methods Development will begin in Year 1 and have the following tasks:
1. Characterize the structure and function of transgenic Factor IX
2. Generate SOPs that will support analysis of samples from Process Development, Quality Control, and 
cGMP production of transgenic Factor IX.
As such, the general plan for Methods Development research is as follows
• Year 1 – Develop Characterization assays and help generate SOPs.
• Year 2 – Perform in-process assays to support Process Development and develop lot-release assays 
and help generate SOPs.
• Years 3-5 – Perform routine characterization, in-process, lot release, and stability assays to support 
Process Development and cGMP production.
Principal Investigator/Program Director (Last, First, Middle):    Velander, William H. 
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UNL Analytical Methods and Characterization, Budget Justification, continued 
 
 
PERSONNEL 
 
Kevin E. Van Cott, Ph.D., Lead Investigator  
Dr. Van Cott will oversee the development of Factor IX-specific analytical methods that are required for 
molecular structure characterization, analysis of purity, and determination of activity and stability. He will work 
with Dr. Swanson to coordinate in-house operations with out-sourcing activities, review project development 
reports and monthly reports, teleconference with other Lead Investigators, and interface with Dr. Meagher and 
the Quality Control, Quality Assurance, Process Development, and cGMP Manufacturing groups. Dr. Van Cott 
will spend 35% of his time on this project, and a salary is requested for the duration of this project. 
 
S. Todd Swanson, Ph.D., Key Person  
Dr. Swanson will oversee the development of general protein chemistry analytical methods that are used to 
characterize Factor IX structure and coordinate out-sourcing activities (e.g., amino acid analysis, N-terminal 
sequencing). He will spend 10% of his time on this component of the project in Year 1, 5% in Year 2, and then 
he will transition to Quality Control efforts. A salary is requested for his efforts. 
 
TBN, Research Technologists 
Three scientists will be required to develop the analytical methods for this project. Two Research Technologist 
I and one Research Technologist II scientists will jointly contribute 270% of their time in Year 1. We foresee 
that one Research Technologist I scientist will be responsible for Factor IX-specific assays – aPTT, 
chromogenic, phosphorylation, and SDS-PAGE). One Research Technologist I scientist will be responsible for 
development of carbohydrate analyses and isoelectric focusing (both using capillary electrophoresis). One 
Research Technologist II scientist will be responsible for more general protein chemistry assays – HPLC 
methods, peptide mapping, gamma-carboxyglutamate content, amino acid analysis, and N-terminal 
sequencing. SOPs for these methods will be generated during Year 1. In Year 3, one of the Research 
Technologists will transition to Quality Control.  
 
EQUIPMENT  
We are requesting $25,000 toward the purchase of a Beckman ACL-100 automated coagulation analyzer for 
aPTT assays. The aPTT assay is notorious for operator-dependent variability, and an automated analyzer (as 
opposed to a manual coagulometer) will simplify writing of the SOP and reproducibility of the results. 
 
CONTRACT SERVICES 
1. University of Nebraska Medical Center − Protein Structure Core Facility offers quality services at our 
institutional rate 
a. Protein Sequencing Services – 5 N-terminal sequences @ $350/sample ($1,750) 
b. Amino acid analysis (acid hydrolysis) – 5 samples @ $100/sample - $500 
2. Commonwealth Biotechnologies (Richmond, VA) 
a. gamma-carboxyglutamate (Gla) analysis by basic amino acid hydrolysis – 10 samples @ 
$200/sample - $2,000) 
3. HPLC Contract maintenance ($7,000) – covers maintenance contract with manufacturer’s service 
technician: preventative maintenance to keep machines operating and guarantees rapid repair if 
necessary. Two HPLCs will be maintained for this aspect of the project. 
 
SUPPLIES COSTS 
Columns:  
1. Chromatographic: HPLC analysis of Factor IX purity and concentration – two Vydac C4 reverse 
phase columns ($445/ea), two Vydac C8 reverse phase columns ($445/ea), two Vydac C18 reverse 
phase columns ($445/ea). MonoP and MonoQ high performance ion exchange columns 
($1,000/ea). Corresponding guard columns kits ($160/ea) and refill cartridges ($150/pk). 
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2. Electrophoretic: Fused silica capillary columns for isoelectric focusing (cIEF) analysis and 
carbohydrate analysis by capillary electrophoresis 
3. Peptide Mapping: one Vydac C4 reverse phase columns ($445/ea), one Vydac C8 reverse phase 
columns ($445/ea), one Vydac C18 reverse phase columns ($445/ea). Corresponding guard 
columns kits ($160/ea) and refill cartridges ($150/pk). 
 
Reagents:   
1. Chromatographic – high purity solvents, buffers and salts, ion pairing agents, and Millipore water 
polishing cartridges 
2. Electrophoretic 
a. sample buffers, running buffers for SDS PAGE ($30/liter) 
b. reagents for carbohydrate analysis - fluorescent labeling reagents ($134/10mg). 
3. Immunoassays 
a. Primary and secondary antibodies needed for sandwich ELISAs ($50-100/mg) 
b. Colorigenic reagents for ELISA plate development ($160/50 assays) 
c. Buffers and salts 
d. Protein standards for ELISAs (porcine immunoglobulins and albumin) 
e. PVDF membrane and colorigenic reagents for western blot development 
4. aPTT and Chromogenic FIX assays - aPTT reagent ($60/20ml), Factor IX-deficient plasma 
($100/6ml), Calcium chloride ($56/10ml), Owrens Buffer ($33/100ml), Imidazole buffer 
($41/120ml); Normal Reference plasma ($125/10ml); Factor XIa ($50/100micrograms); 
Chromogenic substrate 
5. Peptide Mapping - High-purity proteomics-grade trypsin ($60/50mg), Factor XIa 
($50/100micrograms), and other proteases required to proteolyze Factor IX (e.g., Staph. aureus 
protease - $250/5mg); High purity solvents and ion pair agents 
6. Spectroscopic and Fluorescent tests 
a. Calcium-induced fluorescent quenching assays for Factor IX – Factor IX standards 
 
Disposables:  
1. Chromatographic – fraction collection tubes, tubing, fittings, inline filters. 
2. Electrophoretic 
a. SDS PAGE – pipet tips, gel loading tips, filter paper 
b. Carbohydrate analysis – autosampler vials, washers and fittings, pipet tips; vacuum-
sealed vials (for hydrolysis) and crimper 
4. Immunoassays - 96-well microtiter plates ($170/case of 60); pipet tips; reagent boats; 
microcentrifuge tubes 
5. aPTT and Chromogenic FIX assays – 96-well microtiter plates; pipet tips; microcentrifuge tubes 
6. Peptide Mapping – autosampler and fraction collection vials; pipet tips 
 
Gels:  
1. Electrophoretic – Precast gels (Invitrogen, $10/gel) for SDS PAGE and western blots; 2D gels 
and IPG strips. 
 
Standards:  
1. Electrophoretic 
a. SDS PAGE – MW Standards 
b. Carbohydrate analysis – monosaccharide and oligosaccharide standards 
2. Immunoassays – porcine albumin and immunoglobulin standards (IgG, IgA, IgM) 
3. aPTT and Chromogenic FIX assays – FIX standards BeneFIX™ ($1600) and Mononine® 
($1600); Factor IXa standard ($260/0.5mg) 
4. Peptide Mapping – BeneFIX™ and Mononine® 
5. Spectroscopic and Fluor tests - BeneFIX™ and Mononine® 
 
Kits: 
Principal Investigator/Program Director (Last, First, Middle):    Velander, William H. 
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   1. Electrophoretic – oligosaccharide profiling kit (contains standards, capillaries, buffers). 
 
  General Supplies: Funds are requested for official lab notebooks, toner cartridges for printing reports 
and data, sample labeling tape (resistant to temperature change), media for data backup (CD-RW disks). 
 
Other Notes: 
1. LAL assay development will be incorporated in Year 2.  
 
Purification (UNL)
Principal Investigator/Program Director (Last, first, middle): Velander, William H.
FROM THROUGH
1/1/2006 12/31/2006
Personnel (Applicant organization only) % DOLLAR AMOUNT REQUESTED (omit cents)
ROLE ON 
PROJECT
TYPE 
APPT.  
(months)
EFFORT 
ON 
PROJ.
INST. 
BASE 
SALARY
SALARY 
REQUESTED
FRINGE 
BENEFITS
TOTAL
PDL Manager 12 30% 55,000 $16,500 $4,290 $20,790
Scientist 12 90% 45,000 $40,500 $10,530 $51,030
Scientist 12 90% 45,000 $40,500 $10,530 $51,030
$97,500 $25,350 $122,850
$0
$0
58,000
4000
1,500
$186,350
$186,350
Page 10 Form Page 4
TOTAL DIRECT COSTS FOR INITIAL BUDGET PERIOD  (Item 7a, Face Page)
SBIR/STTR Only: FEE REQUESTED
PHS 398 (Rev. 05/01)
ALTERATIONS AND RENOVATIONS (Itemize by category)
Overnight Shipping to Colorado State Univ. (10 lb dry ice with samples)  $50/shipment- 30 shipments
SUBTOTAL DIRECT COST FOR INITIAL BUDGET PERIOD
DIRECT COSTS 
FACILITIES AND ADMINISTRATIVE COSTS
CONSORTIUM/CONTRACTUAL COSTS
TBN Research Tech I
Rick Barent
TBN Research Tech I
NAME
DETAILED BUDGET FOR INITIAL BUDGET 
DIRECT COST ONLY
TRAVEL AIChE Annual Meeting--2 people
OTHER EXPENSES (Itemize by category)
SUBTOTALS
SUPPLIES (Itemize by category)
PATIENT CARE COST INPATIENT
OUTPATIENT
EQUIPMENT (Itemize)
CONSULTANT COSTS   
Service Agrements on BioCads and Maintanence of PDL equipment, 15,000 
Membranes for Cross flow microfiltration and ultrafiltration studies (bench and pilot scale), 15,000
 Chromatography Resins for Process Development, 10,000
General Laboratory Supplies (reagents, SDS-PAGE Gels, columns, resins, etc.), 18,000
Principal Investigator/Program Director (Last, first, middle): Velander, William H.
Purification (UNL)
INITIAL BUDGET
PERIOD
(from form Page 4) 2nd 3rd 4th 5th
PERSONNEL: Salary and
fringe benefits. Applicant
organization only. 0 122,850 115,630 37,126 0
CONSULTANT COSTS 0 0 0 0
EQUIPMENT 0 0 0 0 0
SUPPLIES 0 58,000 55,000 33,500 0
TRAVEL 0 4,000 4,120 4,244 0
INPATIENT
OUTPATIENT
ALTERATIONS AND
RENOVATIONS
OTHER EXPENSES 0 1,500 1,500 250 0
SUBTOTAL DIRECT COSTS 0 186,350 176,250 75,120 0
DIRECT
F&A
TOTAL DIRECT COSTS 0 186,350 176,250 75,120 0
TOTAL DIRECT COSTS FOR THE ENTIRE PROPOSED PROJECT PERIOD (Item 8A, Face Page) $437,720
SBIR/STTR Only
Fee Requested 0 0 0 0 0
SBIR/STTR Only: Total Fee Requested for Entire Propposed Project Preiod
$0
JUSTIFICATION. Follow the budget justification instructions exactly. Use continuation pages as needed.
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TOTALS
BUDGET FOR THE ENTIRE PROPOSED PROJECT PERIOD
DIRECT COSTS ONLY
ADDITIONAL YEARS OF SUPPORT REQUESTED
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CARE
COSTS
CONSORTIUM/
CONTRACTUAL
COSTS
PERSONNEL
Rick Barent, M.S., Scientist
Mr. Barent will spend 30% of his time on the project managing the research technologists that will be 
doing the bench-scale research. He will have the responsibility of assisting in planning experiments, 
collection of data and electronic archiving, interpretation of data, report writing, overseeing the 
Purification Development Laboratory’s (PDL) responsibility on writing the Production Batch Records, and 
will be involved in running experiments. Mr. Barent also will oversee the non-cGMP production of Factor 
IX in the PDL. 
Principal Investigator/Program Director (Last, First, Middle):    Velander, William H. 
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UNL Purification, budget justification, continued 
 
TBN, Two Research Technologists I 
These scientists will be responsible for running recovery and purification experiments. One Research 
Technologist I will focus a majority of his/her efforts on recovery methods, while the second Research 
Technologist I will focus on purification/polishing steps leading to a highly purified Factor IX suitable for clinical 
testing. The two research technologists will also be responsible for producing Factor IX under non-cGMP 
conditions using the Production Batch Records.  
 
SUPPLIES COSTS 
Membrane for Crossflow Studies: Membrane modules for pilot-scale studies (2 to 20 ft2) that range in cost 
from $1,000 to $3,000 each will be needed for both microfiltration and ultrafiltration studies. The membranes 
will be used primarily for recovery studies, but also for concentration and buffer exchange of Factor IX. New 
membranes will be required for the non-cGMP production runs. 
 
General Laboratory Supplies: This category is to cover the costs of reagents, such as chemicals, dry goods, 
electrophoresis gels and reagents, packed columns, individual membrane modules for small studies (0.05 to 
0.5 ft2), tubing, empty columns, etc.  In order to balance the budget in accordance with the requirements of the 
RFA, a small amount of general laboratory supplies ($5,000) originally scheduled to be purchased in year 4 will 
be purchased in year 3. 
 
Chromatography Resins: Five to ten liters of chromatography resin are necessary for the process scale-up 
studies and non-cGMP demonstration runs.  
 
Service Agreement and Maintenance Costs: The BioCads are on service/maintenance agreements. 
Resources are necessary to maintain the pilot-scale equipment, such as the K'40 chromatography skid and the 
Model 50 membrane system. Such equipment must be maintained on a regular basis with o-rings and critical 
parts being replaced on a regularly. 
 
 
cGMP Production UNL
Principal Investigator/Program Director (Last, first, middle): Velander, William H.
FROM THROUGH
1/1/2007 12/31/2007
Personnel (Applicant organization only) % DOLLAR AMOUNT REQUESTED (omit cents)
ROLE ON 
PROJECT
TYPE 
APPT.  
(months)
EFFORT 
ON 
PROJ.
INST. 
BASE 
SALARY
SALARY 
REQUESTED
FRINGE 
BENEFITS
TOTAL
cGMP 
Coordinator 12 50% 75,945 $37,973 $9,873 $47,845
Operator 12 40% 47,600 $19,040 $4,950 $23,990
Operator 12 40% 47,600 $19,040 $4,950 $23,990
Operator 12 40% 47,600 $19,040 $4,950 $23,990
Operator 12 40% 47,600 $19,040 $4,950 $23,990
Operator 12 40% 47,600 $19,040 $4,950 $23,990
Operator 12 40% 34,500 $13,800 $3,588 $17,388
$146,973 $38,213 $185,185
$0
$0
$82,700
0
$0
$267,885
$267,885
Page 13 Form Page 4
TOTAL DIRECT COSTS FOR INITIAL BUDGET PERIOD  (Item 7a, Face Page)
SBIR/STTR Only: FEE REQUESTED
PHS 398 (Rev. 05/01)
ALTERATIONS AND RENOVATIONS (Itemize by category)
SUBTOTAL DIRECT COST FOR INITIAL BUDGET PERIOD
DIRECT COSTS 
FACILITIES AND ADMINISTRATIVE COSTS
CONSORTIUM/CONTRACTUAL COSTS
TBN Research Tech I-FFP
TBN Research Tech I-FFP
Scott Johnson
TBN Research Tech I-FFP
NAME
DETAILED BUDGET FOR INITIAL BUDGET 
DIRECT COST ONLY
TBN Research Tech I-PPP
TBN Research Tech I-PPP
TBN Research Technician III
TRAVEL
OTHER EXPENSES (Itemize by category)
SUBTOTALS
SUPPLIES (Itemize by category)
PATIENT CARE COST INPATIENT
OUTPATIENT
EQUIPMENT (Itemize)
CONSULTANT COSTS   
Facility Change Over/Cleaning Supplies, 17,700
Membranes for Cross flow microfiltration and ultrafiltration studies (bench and pilot scale) 20,000
Chromatography Resins for pilot scale runs, 45,000
Disposables, 45,000 (purchased in year 1)
Principal Investigator/Program Director (Last, first, middle): Velander, William H.
cGMP Production (UNL)
INITIAL BUDGET
PERIOD
(from form Page 4) 2nd 3rd 4th 5th
PERSONNEL: Salary and
fringe benefits. Applicant
organization only. 0 0 0 185,185 190,741
CONSULTANT COSTS 0 0 0 0
EQUIPMENT 0 0 0 0 0
SUPPLIES 45,000 34,500 0 82,700 35,000
TRAVEL 0 0 0 0 0
INPATIENT
OUTPATIENT
ALTERATIONS AND
RENOVATIONS
OTHER EXPENSES 0 0 0 0 0
SUBTOTAL DIRECT COSTS 45,000 34,500 0 267,885 225,741
DIRECT
F&A
TOTAL DIRECT COSTS 45,000 34,500 0 267,885 225,741
TOTAL DIRECT COSTS FOR THE ENTIRE PROPOSED PROJECT PERIOD (Item 8A, Face Page) $573,126
SBIR/STTR Only
Fee Requested 0 0 0 0 0
SBIR/STTR Only: Total Fee Requested for Entire Propposed Project Preiod
$0
JUSTIFICATION. Follow the budget justification instructions exactly. Use continuation pages as needed.
PHS 398 (Rev. 05/01) Form Page 5Page ___14___
BUDGET CATEGORY
TOTALS
BUDGET FOR THE ENTIRE PROPOSED PROJECT PERIOD
DIRECT COSTS ONLY
ADDITIONAL YEARS OF SUPPORT REQUESTED
PATIENT
CARE
COSTS
CONSORTIUM/
CONTRACTUAL
COSTS
PERSONNEL
Scott Johnson, M.S., cGMP Production Coordinator
Mr. Johnson will spend 50% of his time on the project managing the cGMP production of Factor IX. 
Operation and management of a cGMP facility requires a significant amount of oversight just to maintain 
the facility and to continually upgrade GMPs. It is the c in cGMP (current) that makes operation of a 
facility so labor-intensive. Managing such a facility includes interacting with Ms. Barthuli, Quality 
Assurance Coordinator of the Biological Process Development Facility (BPDF) and the Quality Control 
Laboratory, which performs all of the testing of environmental and water samples. Mr. Johnson will also 
have primary responsibility for writing the Production Batch Records. Mr. Johnson will be responsible for 
scheduling the cGMP runs, staffing the production runs, first review of the completed Production Batch 
Records, and being on the floor during the runs.  
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cGMP Production, Budget Justification, continued 
 
Five Research Technologists I  
The research technologists (operators) will be responsible for running the cGMP production process. To meet 
cGMPs, two operators must be on the floor for all critical operations when verification is required. These 
technologists are also responsible for cleaning and maintaining the pilot plants. In the budget are listed 
Research Technologists for FPP and PPP. FPP stands for Fermentation Pilot Plant, which is where the initial 
recovery will be accomplished. The recovered Factor IX is then sterile-filtered into the Purification Pilot Plant 
(PPP) where the purification, polishing, and final formulation are completed.  
 
Research Technician III.  This individual’s primary responsibility is daily cleaning of the pilot plants and 
sampling of water and the environment. 
 
SUPPLIES COSTS 
 
Membranes: Membranes will be required for buffer exchange, concentration, and virus removal. Membranes 
maybe required for recovery, depending on the results from process development studies. Modules costs can 
vary from $2,000 to $10,000 per module depending on flux rate and type.  
 
Chromatography Resins: New chromatography resins (5 to 10 L) are necessary for cGMP production. It is 
our intent to reuse the resins for the second run based on studies during purification development. If not, 
resources will be needed to use fresh resins.  
 
Disposables: This budget is for disposables that are used in the cGMP pilot plants, such as dead end filters, 
plastic tank bag liners, final product storage containers, etc. This category also covers all of the testing (water 
and environment) supplies for maintaining the GMPs of the facility before, during, and after Factor IX 
processing. The pilot plants are monitored on a daily and weekly basis.  In order to balance the budget in 
accordance with the requirements of the RFA, disposable production supplies that would normally be 
purchased in years 4 and 5 will be purchased in years 1 and 2. 
 
  
Facility Change Over and Cleaning Supplies: The cGMP pilot plants are cleaned on a daily and weekly 
basis. Prior to the cGMP production, all elastomers are replaced. This process takes approximately 10 to 14 
working days to complete and requires that all elastomers be changed, such as o-rings and gaskets, including 
braided sanitary tubing. The average cost just for elastomers is approximately $10,000. 
 
 
Quality Assurance (UNL)
Principal Investigator/Program Director (Last, first, middle): Velander, William H.
FROM THROUGH
1/1/2005 12/31/2005
Personnel (Applicant organization only) % DOLLAR AMOUNT REQUESTED (omit cents)
ROLE ON 
PROJECT
TYPE 
APPT.  
(months)
EFFORT 
ON 
PROJ.
INST. 
BASE 
SALARY
SALARY 
REQUESTED
FRINGE 
BENEFITS
TOTAL
QA coord 12 40% 70,000 $28,000 $7,280 $35,280
Scientist 12 80% 48,000 $38,400 $9,984 $48,384
Scientist 12 80% 48,000 $38,400 $9,984 $48,384
$104,800 $27,248 $132,048
$0
$0
20,000
4000
0
$156,048
$156,048
Page 16 Form Page 4
TOTAL DIRECT COSTS FOR INITIAL BUDGET PERIOD  (Item 7a, Face Page)
SBIR/STTR Only: FEE REQUESTED
PHS 398 (Rev. 05/01)
ALTERATIONS AND RENOVATIONS (Itemize by category)
SUBTOTAL DIRECT COST FOR INITIAL BUDGET PERIOD
DIRECT COSTS 
FACILITIES AND ADMINISTRATIVE COSTS
CONSORTIUM/CONTRACTUAL COSTS
TBN QA Doc Specialist I
Ardis Barthuli
TBN QA Doc Specialist I
NAME
DETAILED BUDGET FOR INITIAL BUDGET 
DIRECT COST ONLY
TRAVEL 
OTHER EXPENSES (Itemize by category)
ACS or Pittcon Meeting--2 people
SUBTOTALS
SUPPLIES (Itemize by category)
PATIENT CARE COST INPATIENT
OUTPATIENT
EQUIPMENT (Itemize)
CONSULTANT COSTS   
Document Processing costs, 8,000
Equipment Calibration, 12,000
Principal Investigator/Program Director (Last, first, middle): Velander, William H.
Quality Assurance (UNL)
INITIAL BUDGET
PERIOD
(from form Page 4) 2nd 3rd 4th 5th
PERSONNEL: Salary and
fringe benefits. Applicant
organization only. 132,048 136,009 140,090 144,292 148,621
CONSULTANT COSTS 0 0 0 0
EQUIPMENT 0 0 0 0 0
SUPPLIES 20,000 20,600 21,218 21,855 22,510
TRAVEL 4,000 4,120 4,244 4,371 4,502
INPATIENT
OUTPATIENT
ALTERATIONS AND
RENOVATIONS
OTHER EXPENSES 0 0 0 0 0
SUBTOTAL DIRECT COSTS 156,048 160,729 165,551 170,518 175,633
DIRECT
F&A
TOTAL DIRECT COSTS 156,048 160,729 165,551 170,518 175,633
TOTAL DIRECT COSTS FOR THE ENTIRE PROPOSED PROJECT PERIOD (Item 8A, Face Page) $828,480
SBIR/STTR Only
Fee Requested 0 0 0 0 0
SBIR/STTR Only: Total Fee Requested for Entire Propposed Project Preiod
$0
JUSTIFICATION. Follow the budget justification instructions exactly. Use continuation pages as needed.
PHS 398 (Rev. 05/01) Form Page 5Page ___17__
BUDGET CATEGORY
TOTALS
BUDGET FOR THE ENTIRE PROPOSED PROJECT PERIOD
DIRECT COSTS ONLY
ADDITIONAL YEARS OF SUPPORT REQUESTED
PATIENT
CARE
COSTS
CONSORTIUM/
CONTRACTUAL
COSTS
PERSONNEL
Ardis Barthuli, Quality Assurance Coordinator 
Ms. Barthuli is responsible for the entire Quality Assurance program of the UNL Biological Process 
Development Facility and will dedicate 40% of her time to this project.  Ms. Barthuli will be responsible for 
overseeing the QA document specialists that will be writing and editing all of the Standard Operating 
Procedures (SOPs) that will be generated from Analytical Methods Development and the Production 
Batch Records.  Because this project will be utilizing the cGMP pilot plants and the Quality Control 
Laboratory, Ms. Barthuli’s time will also be required as regular oversight of all QA issues related to cGMP 
activities in the pilot plants and Quality Control Laboratory.  
Principal Investigator/Program Director (Last, First, Middle):    Velander, William H. 
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UNL Quality Assurance Program 
 
PERSONNEL 
Ardis Barthuli, Quality Assurance Coordinator  
Ms. Barthuli is responsible for the entire Quality Assurance program of the UNL Biological Process 
Development Facility and will dedicate 40% of her time to this project.  Ms. Barthuli will be responsible for 
overseeing the QA document specialists that will be writing and editing all of the Standard Operating 
Procedures (SOPs) that will be generated from Analytical Methods Development and the Production Batch 
Records.  Because this project will be utilizing the cGMP pilot plants and the Quality Control Laboratory, Ms. 
Barthuli’s time will also be required as regular oversight of all QA issues related to cGMP activities in the pilot 
plants and Quality Control Laboratory.   
 
TBN, Quality Assurance Document Specialists 
This project will require two QA Document Specialists with 80% effort for the entire project to assist in writing, 
editing, and tracking all cGMP documents and technology transfer documents related to this project.   
 
SUPPLIES COSTS 
Equipment Calibration: This is to cover the cost of supplies, outside contractors, and NIST traceable 
instruments to calibrate equipment used for this grant.   
 
Document Processing: This is to cover the cost of binders, paper, printing, copying, and document equipment 
supplies (scanner, copier, fax machine, and shredder). 
 
TRAVEL 
This is to cover the cost of two QA professionals to attend a national meeting. 
 
Quality Control (UNL)
Principal Investigator/Program Director (Last, first, middle): Velander, William H.
FROM THROUGH
1/1/2006 12/31/2006
Personnel (Applicant organization only) % DOLLAR AMOUNT REQUESTED (omit cents)
ROLE ON 
PROJECT
TYPE 
APPT.  
(months)
EFFORT 
ON 
PROJ.
INST. 
BASE 
SALARY
SALARY 
REQUESTED
FRINGE 
BENEFITS
TOTAL
co-PI 12 10% 71,585 $7,159 $1,861 $9,020
Scientist 12 90% 45,000 $40,500 $10,530 $51,030
Scientist 12 50% 45,000 $22,500 $5,850 $28,350
$70,159 $18,241 $88,400
$0
$0
105,248
2000
15,000
$210,648
$210,648
Page 19 Form Page 4
TOTAL DIRECT COSTS FOR INITIAL BUDGET PERIOD  (Item 7a, Face Page)
SBIR/STTR Only: FEE REQUESTED
PHS 398 (Rev. 05/01)
ALTERATIONS AND RENOVATIONS (Itemize by category)
Mass Spectrometry Contract Fees: $3,000; Cost of HPLC maintainence contracts: $12,000
SUBTOTAL DIRECT COST FOR INITIAL BUDGET PERIOD
DIRECT COSTS 
FACILITIES AND ADMINISTRATIVE COSTS
CONSORTIUM/CONTRACTUAL COSTS
TBN Research Tech I
S. Todd Swanson
TBN Research Tech I
NAME
DETAILED BUDGET FOR INITIAL BUDGET 
DIRECT COST ONLY
TRAVEL 
OTHER EXPENSES (Itemize by category)
ACS or Pittcon Meeting
SUBTOTALS
SUPPLIES (Itemize by category) Western and ELISA antibodies and reagents, 25091
PATIENT CARE COST INPATIENT
OUTPATIENT
HPLC Columns, 27,909
EQUIPMENT (Itemize)
CONSULTANT COSTS   
Electrophoresis supplies, 3,000
HPLC Solvents, 23,906
HPLC Supplies and Chemicals, 8,010
General Laboratory Chemicals, 8,395
General Laboratory Supplies, 8,937
Principal Investigator/Program Director (Last, first, middle): Velander, William H.
Quality Control (UNL)
INITIAL BUDGET
PERIOD
(from form Page 4) 2nd 3rd 4th 5th
PERSONNEL: Salary and
fringe benefits. Applicant
organization only. 88,400 198,483 150,299 154,808 159,452
CONSULTANT COSTS 0 0 0 0
EQUIPMENT 0 0 0 0 0
SUPPLIES 105,248 57,342 75,700 33,630 21,868
TRAVEL 2,000 2,060 2,122 2,185 2,251
INPATIENT
OUTPATIENT
ALTERATIONS AND
RENOVATIONS
OTHER EXPENSES 15,000 17,500 20,500 21,115 21,748
SUBTOTAL DIRECT COSTS 210,648 275,385 248,621 211,738 205,319
DIRECT
F&A
TOTAL DIRECT COSTS 210,648 275,385 248,621 211,738 205,319
TOTAL DIRECT COSTS FOR THE ENTIRE PROPOSED PROJECT PERIOD (Item 8A, Face Page) $1,151,711
SBIR/STTR Only
Fee Requested 0 0 0 0 0
SBIR/STTR Only: Total Fee Requested for Entire Propposed Project Preiod
$0
JUSTIFICATION. Follow the budget justification instructions exactly. Use continuation pages as needed.
PHS 398 (Rev. 05/01) Form Page 5Page ___20___
BUDGET CATEGORY
TOTALS
BUDGET FOR THE ENTIRE PROPOSED PROJECT PERIOD
DIRECT COSTS ONLY
ADDITIONAL YEARS OF SUPPORT REQUESTED
PATIENT
CARE
COSTS
CONSORTIUM/
CONTRACTUAL
COSTS
PERSONNEL
S. Todd Swanson, Ph.D., Key Person 
Dr. Swanson will devote 20% of his effort to this project as Co-Investigator and Key Person. He will have 
the overall responsibility for supervision of all aspects of Quality Control and will ensure that the needs of 
the project for Quality Control services are met. He will design and supervise the stability testing studies 
of bulk product and final formulations in conjunction with the Administrative, Quality Assurance, 
Production, and Formulation groups. He will supervise the research technologists and the research 
technicians, who will provide technical support. He will review all Quality Control data and approve or 
reject their release from the laboratory. He will also be responsible for facilitating communication of data 
and results from the Quality Control Laboratory among all interested parties. He will be responsible for 
resolving all issues of assay performance and reliability. Dr. Swanson has industrial experience in Quality 
Control and expertise in high-performance liquid chromatography of proteins. He will also be involved in 
review of technology transfer documents.
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UNL Quality Control Laboratory, Budget Justification, Continued 
 
 
TBN Research Technologist I #1, Quality Control Laboratory Factor IX team leader  
This individual will devote 90% of his/her effort to this project for all five years. She/he will act as the main 
repository of knowledge for Factor IX-related testing for the Quality Control Laboratory. In the first two years of 
the project, this person will focus on three major tasks: 1) technical transfer of assays created by the FIX 
Analytical Methods Group into the Quality Control Laboratory; 2) qualification of the transferred methods i.e., 
ensuring the transferred method functions as intended in the Quality Control Laboratory by actual testing; and 
3) training of other Quality Control Laboratory staff to perform these methods. These tasks will require the 
following: 1) authoring, editing, and reviewing of standard operating procedures; 2) specifying, ordering, 
installation, and testing of specific analytical systems; 3) implementing new testing procedures; and 4) training 
of other Quality Control staff to use these procedures. This person will be skilled with all instrumentation in the 
laboratory and capable of troubleshooting problems. In Years 3-5, he/she will also provide routine technical 
support and QC services to process development and manufacturing elements of this project. She/he will 
provide a first level of supervision for the Research Technicians (see below). She/he will also perform record 
keeping duties necessary for maintaining a laboratory in compliance with current Good Laboratory Practice. 
 
TBN Research Technologist I #2 
This individual will devote 50% of his/her effort to this project in the first year and 90% of his/her effort in the 
second year with his/her participation ending after Year 2. During the time of participation, she/he will assist the 
Quality Control Laboratory FIX team leader (Research Technologist I #1 above) with the technical transfer, 
qualifications, and training necessary to implement the new analytical procedures in the Quality Control 
Laboratory. She/he will assist the team leader with procedure testing and troubleshooting. The 40% increase in 
FTE on Year 2 will be used for training the Research Technicians (see below) who start in Year 2. 
 
TBN Research Technician III – 2 FTEs  
These individuals will devote 90% of their effort to this project. They will provide routine technical support to the 
process development and production efforts. This will be accomplished by using the transferred assays 
developed by the FIX analytical methods group. They will also perform record keeping duties necessary for 
maintaining a laboratory in compliance with current Good Laboratory Practice. 
 
Fringe benefits for permanent staff are calculated as 26% of salary. 
 
SUPPLIES COSTS 
($105,248 in Year 1; $57,342 in Year 2; $75,700 in year 3; $33,630 in year 4; and $21,868 in year 5) 
The following figures are derived through cost-accounting, i.e., using actual purchase orders written over the 
course of one year to purchase supplies for a similar project. In order to balance the budget in accordance with 
the requirements of the RFA, some supplies that would normally be to be purchased in years 4 and 5 will be 
purchased in years 1 and 3.The monies requested here will purchase the following items:  
 
HPLC: We expect that a minimum of 1,843 samples will be analyzed by a quantitative HPLC method per year 
during process development and production. This estimate is based on the use of more than one method being 
applied to the same sample, e.g., one sample evaluated by both size exclusion and reverse phase methods. 
This estimate also includes triplicate analysis of any sample that requires quantitation with an error estimate. 
Approximately 25% of these samples will be “dirty” (early stage purification from whole milk forward), and this 
type of sample substantially shortens column life. Note that HPLC costs are fixed except for adjustments for 
inflation in Year 2. Year 1 expenditures are less because routine technical support for process development 
and production does not begin until Year two. Year 1 costs cover the process of technical transfer, 
qualification, and training for analytical methods. 
 
Principal Investigator/Program Director (Last, First, Middle):    Velander, William H. 
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HPLC columns This category includes the following: size exclusion columns with guard columns; reverse 
phase columns (C4, C8, C18) with guard columns; cation exchange columns with guard columns; anion 
exchange columns with guard columns; and hydrophobic interaction chromatography columns. Also included 
in this category are coated and uncoated capillaries for the various modes of capillary electrophoresis. 
 
HPLC solvents High purity water (low UV contaminate low carbon load); Optima grade Acetonitrile; Optima 
grade Methanol; and HPLC grade Isopropanol. 
 
HPLC supplies and chemicals ($8,010): This category includes the following: Autosampler vials; tubing, 
fittings, inline filters; sample & solvent filtration, solid phase extraction for sample clean up, HPLC grade mobile 
phase chemicals, e.g., formic acid & trifluoroacetic acid for reverse phase chromatography, various salts for ion 
exchange and hydrophobic interaction chromatography. Also included in this category are the fluorescent 
labeling reagents for the LIF mode of detection for capillary electrophoresis. 
 
Limulus Amoebocyte Lysate (LAL) Assay for Pyrogens ($5,000, expenditure starts in Year 2): Costs 
include the following: Limulus amoebocyte lysate, Endotoxin free buffers, reference standard Endotoxin, and 
the shipping of these materials. This testing is critical during process development and production to ensure a 
very low to zero Endotoxin burden in the final product. This test will be used to monitor Endotoxin burden from 
the beginning of the process to the final product. 
 
Antibodies and Reagents for Western Blots and ELISA assays Costs include the following: Commercially 
available primary and secondary antibodies; cost of subcontracting for creation of non-commercially available 
primary antibodies; kits, reagents, and supplies necessary for detection of antibody binding; disposables 
associated with these techniques (e.g., 96 well plates and PVDF membranes); and the shipping of these 
materials. These techniques will be used to support of process development and production. 
 
Laboratory Chemicals ($8,395): This category includes the following: reagents for total protein assays, high 
purity buffers, salts, detergents, amino acids, non-HPLC solvents, and other general chemicals. Additionally, 
this includes reagents, media, and other chemicals needed for microbial testing in support of late stage 
process development and production. 
General Laboratory Supplies ($8,937): This category includes disposables (glass tubes, plastic ware, sterile 
filter apparatuses, 96 well microtiter plates, pipettes, pipettor tips, centrifuge ultrafiltration tubes, syringes, etc.), 
other consumables, and other general laboratory supplies. This includes the costs of labels, log books, 
notebooks, and other materials necessary to maintain the cGLP status of the Quality Control Laboratory. 
Included as well are the costs of spin desalting columns necessary for buffer exchange. Additionally, this 
includes disposables and other consumables needed for microbial testing in support of late stage process 
development and production. 
Electrophoresis Supplies ($3,000): To maintain consistent results with electrophoresis, we purchase pre-cast 
gels and pre-made buffers and stains. We do this because the manufacturers control variation between lots. It 
is critical to have gels with consistent analytical performance over time for the stability studies. We have 
standardized on Novex (Invitrogen) as an electrophoresis supplier. This category includes the following 
materials: Pre-cast SDS-PAGE gels, pre-cast IEF gels, IPG strips, electrolytes, electrophoretic standards, pre-
made buffers, pre-made stains, and materials for drying and archiving. 
 
TRAVEL 
($2,000) 
One trip per year for one person (the co-investigator or the scientists) is requested to attend a national 
scientific meeting (ACS or Pittcon: Registration: $300; Hotel: $1,000 {5 days}, Airfare: $600, ground 
transportation: $100). The purposes of this trip will be to present data acquired under this grant, confer with 
colleagues in the same field, and to learn about new technologies that may apply to future needs of the project. 
Principal Investigator/Program Director (Last, First, Middle):    Velander, William H. 
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OTHER 
($15,000 in Year 1, $17,500 in Year 2, $20,500 subsequent years) 
 
Analytical Services: All of these services require equipment and expertise that we do not possess. All of 
these services cannot be provided by us but are critical characterization and analysis that must be done in 
order to advance Factor IX to clinical trials. It is more cost- and time-effective to contract for these services 
than it is to acquire the equipment and expertise ourselves. 
 
Mass Spectrometry Services ($3,000 Years 1 & 2, $5,000 subsequent years): This covers the annual cost of 
analysis and characterization of purified Factor IX by various forms of mass spectrometry. Mass spectrometry 
is a key analytical technique that is critical for characterization of factor IX at all stages of development, 
production, and formulation.  
 
Protein Sequencing Services ($1,000 Year 1, $1,500 Year 2, and $2,500 subsequent years): This covers the 
annual cost of analysis and characterization of purified Factor IX by amino-terminal amino acid sequencing. 
Amino-terminal amino acid sequencing is a key analytical technique that is critical for characterization of Factor 
IX at all stages of development, production, and formulation.  
 
Amino Acid Analysis Services ($1,000): This covers the annual cost of analysis of purified Factor IX by 
amino acid analysis. Amino acid analysis is the most reliable, most direct method to quantitate a protein. 
Knowledge of exact protein concentrations is critical for characterization of Factor IX in the final stages of 
development, production, and formulation.  
Cost of HPLC maintenance and qualification contracts (prorated to 30%) $12,000: This service covers the 
annual preventive maintenance by the manufacturer’s field service engineer and guarantees the repair of any 
system that fails. This is provided at a cost that is slightly more than the cost of the preventive maintenance kits 
that can be purchased from the manufacturer. These costs also include the validation of the HPLC systems, 
the Client/Server database, and the data acquisition and instrument control software. This project will use 
HPLC as a primary analytical method in multiple types of assays.  
 
UNL Project Management
Principal Investigator/Program Director (Last, first, middle): Velander, William H.
FROM THROUGH
1/1/2005 12/31/2005
Personnel (Applicant organization only) % DOLLAR AMOUNT REQUESTED (omit cents)
ROLE ON 
PROJECT
TYPE 
APPT.  
(months)
EFFORT 
ON 
PROJ.
INST. 
BASE 
SALARY
SALARY 
REQUESTED
FRINGE 
BENEFITS
TOTAL
Principal 
Investigator 12 25% 146,000 $36,500 $9,490 $45,990
co-PI 12 20% 132,500 $26,500 $6,890 $33,390
Admin. 12 90% 51,000 $45,900 $11,934 $57,834
Maintenance 12 40% 46,000 $18,400 $4,784 $23,184
Info Tech 12 40% 59,000 $23,600 $6,136 $29,736
$150,900 $39,234 $190,134
$0
$0
$24,000
12000
$0
$226,134
$226,134
Page 24 Form Page 4
TOTAL DIRECT COSTS FOR INITIAL BUDGET PERIOD  (Item 7a, Face Page)
SBIR/STTR Only: FEE REQUESTED
PHS 398 (Rev. 05/01)
ALTERATIONS AND RENOVATIONS (Itemize by category)
SUBTOTAL DIRECT COST FOR INITIAL BUDGET PERIOD
DIRECT COSTS 
FACILITIES AND ADMINISTRATIVE COSTS
CONSORTIUM/CONTRACTUAL COSTS
Kevin McCulloch
TBN, Program Coordinator
William Velander
Michael Meagher
NAME
DETAILED BUDGET FOR INITIAL BUDGET 
DIRECT COST ONLY
William Heidal
TRAVEL
OTHER EXPENSES (Itemize by category)
SUBTOTALS
SUPPLIES (Itemize by category)
PATIENT CARE COST INPATIENT
OUTPATIENT
EQUIPMENT (Itemize)
CONSULTANT COSTS   
CyberLab Maintenance
Computer Supplies
Maintenance Supplies
Principal Investigator/Program Director (Last, first, middle): Velander, William H.
UNL Project Management
INITIAL BUDGET
PERIOD
(from form Page 4) 2nd 3rd 4th 5th
PERSONNEL: Salary and
fringe benefits. Applicant
organization only. 190,134 195,838 201,713 207,765 213,997
CONSULTANT COSTS 0 0 0 0
EQUIPMENT 0 0 0 0 0
SUPPLIES 24,000 24,720 25,462 26,225 27,012
TRAVEL 12,000 12,360 12,731 13,113 13,506
INPATIENT
OUTPATIENT
ALTERATIONS AND
RENOVATIONS
OTHER EXPENSES 0 0 0 0 0
SUBTOTAL DIRECT COSTS 226,134 232,918 239,906 247,103 254,516
DIRECT
F&A
TOTAL DIRECT COSTS 226,134 232,918 239,906 247,103 254,516
TOTAL DIRECT COSTS FOR THE ENTIRE PROPOSED PROJECT PERIOD (Item 8A, Face Page) $1,200,576
SBIR/STTR Only
Fee Requested 0 0 0 0 0
SBIR/STTR Only: Total Fee Requested for Entire Propposed Project Preiod
$0
JUSTIFICATION. Follow the budget justification instructions exactly. Use continuation pages as needed.
PHS 398 (Rev. 05/01) Form Page 5Page ___25___
BUDGET CATEGORY
TOTALS
BUDGET FOR THE ENTIRE PROPOSED PROJECT PERIOD
DIRECT COSTS ONLY
ADDITIONAL YEARS OF SUPPORT REQUESTED
PATIENT
CARE
COSTS
CONSORTIUM/
CONTRACTUAL
COSTS
PERSONNEL
William Velander, Ph.D., Principal Investigator
Dr. Velander is the Principal Investigator and will dedicate 25% of his time to the project. As Principal 
Investigator, Dr. Velander will be responsible for the development and supervision of the entire program 
including, but not limited to, providing technical oversight, designing experiments, interpreting data, and 
attending meetings. Dr. Velander will also serve as the project’s point of contact.
Principal Investigator/Program Director (Last, First, Middle):    Velander, William H. 
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Michael Meagher, Ph.D., Lead Scientist and Co-Investigator 
Dr. Meagher’s expertise is in process development and current Good Manufacturing Practice production of 
recombinant proteins. He is the Director of the University of Nebraska-Lincoln Biological Process Development 
Facility (BPDF). Dr. Meagher will oversee all aspects of process development and cGMP manufacturing of 
Factor IX. Dr. Meagher will have immediate responsibility for ensuring that Factor IX produced in the BPDF 
cGMP Facility meets final product specifications. Dr. Meagher will dedicate 20% of his time to this project. 
 
TBN: Program Coordinator 
This individual will be dedicated 90% of his/her time to the coordinating of non-scientific activities that will be 
ongoing primarily at the University of Nebraska-Lincoln, but also will interact with Lead Investigators at the 
University North Carolina and at Colorado State University. This person will oversee the administrative 
activities of the grant, in particular, all aspects of report submission, which includes reviewing all written 
reports, making sure reports meet NIH’s reporting requirements, and coordinating all reporting activity with 
each of the Lead Investigators.  This person will be responsible for scheduling weekly conference calls, 
participating in these weekly calls, and will be the lead person for making sure all action items from these 
meetings are addressed during that week. Other duties include scheduling, coordinating, and participating in 
quarterly face-to-face meetings, and monitoring progress of action items from these meetings.   
Kevin McCulloch, Maintenance 
Mr. McCulloch is responsible for maintaining equipment in the University of Nebraska-Lincoln Biological 
Process Development Facility (BPDF). This includes the Purification Development Laboratory (three BioCad 
chromatography systems, one pilot-scale chromatography system, and one membrane system), Analytical 
Development Laboratory, Quality Control Laboratory, and Media Prep Room (two autoclaves and a 
dishwasher). Because the BPDF operates under GLP, all of this equipment (and others not specifically listed) 
require routine maintenance and immediate repair. This project is programmed to use nearly one-third of the 
available resources at the BPDF. This individual is critical to keeping the facility running. 
 
William Heidal, Information Technology 
The UNL component of this project will be electronic with respect to data archiving and transfer of electronic 
information, and all critical equipment is interfaced with computers. The BPDF has more than 40 personal 
computers (equipment and personal), five servers, and a two-terabyte Storage Area Network (SAN) available 
to this project. Mr. Heidal has the responsible of maintaining and upgrading computer systems in the BPDF, of 
which a significant number will be serving this project.  
 
SUPPLIES COSTS 
CyberLab: This category covers the license fees for five project personnel to have simultaneous access to 
Cyber lab, the BPDF electronic notebook system. Additional costs include repair parts (hard drives, monitors, 
etc.) and software licensing fees for such programs as Microsoft Project, Adobe Acrobat, etc.  
 
Maintenance Supplies: This category covers the cost of general supply costs of maintenance and calibration 
of equipment. 
 
TRAVEL 
This category covers the cost of travel to NIH and one professional meeting for Dr. Velander, Dr. Meagher, and 
the program coordinator.  
CSU--Formulation Studies
Principal Investigator/Program Director (Last, first, middle): Velander, William H.
From Through
12/1/2005 12/31/2006
Personnel (Applicant organization only) % Dollar Amount Requested (omit cents)
ROLE ON 
PROJECT
TYPE 
APPT.  
(Months)
EFFORT 
ON 
PROJ.
INST. 
BASE 
SALARY
SALARY 
REQUESTED
FRINGE 
BENEFITS
TOTAL
co-PI 12 25% 103,000 $25,750 $6,695 $32,445
co-PI 12 10% 92,004 $9,200 $2,392 $11,592
Post Doc 12 100% 48,000 $48,000 $12,480 $60,480
$82,950 $21,567 $104,517
$0
$48,000
$7,200
$3,000
$0
$0
$0
$600
$163,317
$51,893
$215,210
Page 27 Form Page 4
COSTS
TRAVEL
OTHER EXPENSES (Itemize by category)
Travel to meet with collaborators
SUPPLIES (Itemize by category)  
PATIENT CARE COST INPATIENT
OUTPATIENT
Glassware and Chemicals
EQUIPMENT (Itemized) Agilent 8453 UV Spectrophotometer, 22,000 DynaPro DLS, 26,000
CONSULTANT COSTS
SUBTOTALS
DETAILED BUDGET FOR INITIAL BUDGET 
DIRECT COST ONLY
Patrick Miller
Mark Manning
William S. Dernell
NAME
TOTAL DIRECT COSTS FOR INITIAL BUDGET PERIOD  (Item 7a, Face Page)
SBIR/STTR Only:  FIXED FEE REQUESTED
PHS 398 (Rev. 05/01)
ALTERATIONS AND RENOVATIONS (Itemize by category)
SUBTOTAL DIRECT COST FOR INITIAL BUDGET PERIOD
DIRECT COSTS 
FACILITIES AND ADMINISTRATIVE COSTS @ 45.0%
CONSORTIUM/CONTRACTUAL
Principal Investigator/Program Director (Last, first, middle): Velander, William
CSU Formulation Studies
INITIAL BUDGET
PERIOD
(from form Page 4) 2nd 3rd 4th 5th
PERSONNEL: Salary and
fringe benefits. Applicant
organization only. 104,518 0 130,955 0 0
CONSULTANT COSTS 0 0 0 0
EQUIPMENT 48,000 0 0 0 0
SUPPLIES 7,200 0 11,160 0 0
TRAVEL 3,000 0 3,090 0 0
INPATIENT
OUTPATIENT
ALTERATIONS AND
RENOVATIONS
OTHER EXPENSES 600 0 33,000 0 0
SUBTOTAL DIRECT COSTS 163,318 0 178,205 0 0
DIRECT
F&A 51,893 0 80,192 0 0
TOTAL DIRECT COSTS 215,211 0 258,397 0 0
TOTAL DIRECT COSTS FOR THE ENTIRE PROPOSED PROJECT PERIOD (Item 8A, Face Page) $473,608
SBIR/STTR Only
Fee Requested 0 0 0 0 0
SBIR/STTR Only: Total Fee Requested for Entire Propposed Project Preiod
$0
JUSTIFICATION. Follow the budget justification instructions exactly. Use continuation pages as needed.
PHS 398 (Rev. 05/01) Form Page 5Page ___28___
BUDGET CATEGORY
TOTALS
BUDGET FOR THE ENTIRE PROPOSED PROJECT PERIOD
DIRECT COSTS ONLY
ADDITIONAL YEARS OF SUPPORT REQUESTED
PATIENT
CARE
COSTS
CONSORTIUM/
CONTRACTUAL
COSTS
Please see the following page:
 Principal Investigator/Program Director (Last, first, middle) Velander, William 
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Colorado State University – Formulation Studies 
 
PERSONNEL 
Mark Manning, Ph.D., Lead Investigator 
Dr. Manning will oversee the transgenic Factor IX formulation for intravenous and oral administration. He will 
direct protein structure and function studies that are used to evaluate the formulations. He will dedicate 25% of 
his time during the formulation experiments, and a salary is requested for his efforts. 
 
William Dernell, M.S., D.V.M., Key Person 
Dr. Dernell will oversee the evaluation of the IV and oral formulations in normal mouse and normal dog models. 
He will dedicate 10% of his time during the formulation experiments, and a salary is requested for his efforts. 
 
Patrick Miller, Ph.D., and Alexandra De Lille, Ph.D., Post-doctoral Fellows 
The post-doctoral fellows will be responsible for conducting the protein formulation experiments, analyzing the 
properties of the transgenic Factor IX formulations, and conducting the animal model treatments, sample 
collection, and sample analysis. Dr. Miller will be spending 100% of his time on this project, and Dr. De Lille will 
be spending 17% of her time on this project. Salaries are requested. 
 
Laura Chubb, Technician 
The technician will dedicate 25% of her time to this project and assist with the animal model experiments. 
 
EQUIPMENT 
Agilent 8453 UV Spectrophotometer: GLP diode array spectrophotometer needed for protein concentration 
and enzymatic assays. 
 
DynaPro DLS Instrument: For dynamic light-scattering experiments to measure the hydrodynamic radius of 
transgenic Factor IX molecules; used to determine if high molecular weight aggregates are present. 
 
SUPPLIES COSTS 
General Laboratory Supplies: This is to cover the costs of reagents such as chemicals, dry goods, 
electrophoresis gels and reagents, glassware, animal medical supplies (needles, syringes, plasma and serum 
collection tubes, etc.). 
 
OTHER 
Animal Costs: Procurement ($14.20/mouse; $400/dog), shipping ($54 for mice; $800 for dogs), housing 
($0.66/day/cage for mice; $3.38/day/dog), and histology ($20/mouse; $50/dog) for mice and dogs. It is 
estimated that at least 60 mice and 12 dogs will be needed for these studies.   
 
Drug Analysis: Laboratory evaluation for dog serum and urine samples are $45/sample; Factor IX analysis is 
estimated at $25/sample. 
 
Publication Costs: Publication and dissemination of data. 
 
 
UNC Chapel Hill--Mouse Model Experiments
Principal Investigator/Program Director (Last, first, middle): Velander, William
From Through
12/1/2005 12/31/2006
Personnel (Applicant organization only) % Dollar Amount Requested (omit cents)
ROLE ON 
PROJECT
TYPE 
APPT.  
(Months)
EFFORT 
ON 
PROJ.
INST. 
BASE 
SALARY
SALARY 
REQUESTED
FRINGE 
BENEFITS
TOTAL
P.I 12 10% 103,703 $10,370 $2,385 $12,755
post doc 12 50% 36,108 $18,054 $4,152 $22,206
technician 12 20% 22,660 $4,532 $1,042 $5,574
$32,956 $7,579 $40,535
$0
$0
$10,172
$800
$0
$0
$0
$0
$51,507
$23,693
$75,201
Page 30 Form Page 4
Commercial, plasma-derived, monoclonal antibody purified (Mononine) 
TOTAL DIRECT COSTS FOR INITIAL BUDGET PERIOD  (Item 7a, Face Page)
SBIR/STTR Only:  FIXED FEE REQUESTED
PHS 398 (Rev. 05/01)
ALTERATIONS AND RENOVATIONS (Itemize by category)
SUBTOTAL DIRECT COST FOR INITIAL BUDGET PERIOD
DIRECT COSTS 
FACILITIES AND ADMINISTRATIVE COSTS @ 46.0%
CONSORTIUM/CONTRACTUAL
Nathan LaBorde
Paul Monahan
Tai-ping Zhang
NAME
EQUIPMENT (Itemized)
CONSULTANT COSTS
SUBTOTALS
DETAILED BUDGET FOR INITIAL BUDGET 
DIRECT COST ONLY
SUPPLIES (Itemize by category)  Mice, Anesthesia/Vet supplies--Isofluorane Surgifoam 
PATIENT CARE COST INPATIENT
OUTPATIENT
 mouse immunoglobin standards, plasma-derived human factor IX control
Coagulometer supplies: Cuvettes: 3 boxes  Steel balls: 1  APTT reagent: 2  Buffers (2) 
Unicalibrator: 3  Thermal paper, CaCl, Finntipps:  Plastics, Disposables 
Assays: antibodies: anti-human F.IX, anti-mouse IgG1, IgG2a, IgG2b, IgG3, IgM, IgA 
 additional antibody supplies (colorigenic reagent), human plasma standards 
Coagulation factor IX: Commercial, Recombinant (Benefix) 
COSTS
TRAVEL
OTHER EXPENSES (Itemize by category)
Travel to meet with collaborators
Principal Investigator/Program Director (Last, first, middle): Velander, William
UNC Chapel Hill--Mouse Model Experiments
INITIAL BUDGET
PERIOD
(from form Page 4) 2nd 3rd 4th 5th
PERSONNEL: Salary and
fringe benefits. Applicant
organization only. 40,536 0 44,046 45,675 0
CONSULTANT COSTS 0 0 0 0
EQUIPMENT 0 0 0 0 0
SUPPLIES 10,171 0 10,244 10,321 0
TRAVEL 800 0 824 849 0
INPATIENT
OUTPATIENT
ALTERATIONS AND
RENOVATIONS
OTHER EXPENSES 0 0 0 0 0
SUBTOTAL DIRECT COSTS 51,507 0 55,114 56,845 0
DIRECT
F&A 23,693 0 25,352 26,149 0
TOTAL DIRECT COSTS 75,200 0 80,466 82,994 0
TOTAL DIRECT COSTS FOR THE ENTIRE PROPOSED PROJECT PERIOD (Item 8A, Face Page) $238,660
SBIR/STTR Only
Fee Requested 0 0 0 0 0
SBIR/STTR Only: Total Fee Requested for Entire Propposed Project Preiod
$0
JUSTIFICATION. Follow the budget justification instructions exactly. Use continuation pages as needed.
PHS 398 (Rev. 05/01) Form Page 5Page ___31___
BUDGET CATEGORY
TOTALS
BUDGET FOR THE ENTIRE PROPOSED PROJECT PERIOD
DIRECT COSTS ONLY
ADDITIONAL YEARS OF SUPPORT REQUESTED
PATIENT
CARE
COSTS
CONSORTIUM/
CONTRACTUAL
COSTS
Please see the following page:
Principal Investigator/Program Director (Last, first, middle): Velander, William H.  
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Budget Justification:  Hemophilia B Mouse Model Experiments (UNC-Chapel Hill) 
 
PERSONNEL 
 
Paul Monahan, M.D., Lead Investigator  
Dr. Monahan will spend 10% of his time directly conducting experiments with transgenic rhFIX 
in the murine hemophilia B model, and requests a salary.  Dr. Monahan will be responsible for 
supervising a post-doctoral fellow and a technician, overseeing the animal experiments to 
ensure compliance, designing the experiments, interpreting the results, and communicating the 
results to other Lead Investigators and project team members. A 3%/year increase is included. 
 
Tai-ping Zhang, MD., Post-doctoral Fellow 
Dr. Zhang will conduct the experiments for intravenous and oral dosage in the hemophilia B 
mouse model, and a salary is requested.  Dr. Zhang is a gastrointestinal surgeon who will be 
continuing a research sabbatical from the Surgery faculty of Peking Union Medical School. Dr. 
Zhang will spend 50% of his time on this project, and will be responsible for conducting 
experiments, animal procedures and post-procedural care, assisting with experimental design, 
assisting with interpretation of the results, and preparation of reports. A 3%/year increase is 
included. 
 
Nathan LaBorde, Research Technician 
Mr. LaBorde will assist in maintenance of the hemophilia B mouse colony that is used in this 
project, and a salary is requested.  He will spend 20% of his time on this project, and will be 
responsible maintaining hemostatically normal and hemostatically deficient mouse colonies, 
screening for genotype and for the bleeding phenotypes, and for feeding and care of the 
animals.  A 3%/year increase is included. 
 
SUPPLIES COSTS 
 Mouse cage costs:  Covers the animal facility per diem costs ($2.98/wk for mice in a 
hot washed cage).  A 4%/year increase is included for subsequent years. 
 
 Anesthesia and Vet Supplies:  Covers the costs of Isoflurane, Surgifoam, and the 
maintenance of inhalation anesthesia equipment and operative space. 
 
 Immunoassays: Covers costs for anti-human FIX antibodies, antibodies to mouse 
immunoglobulins (to determine if inhibiting antibodies are present), colorigenic reagents, human 
FIX standards, mouse immunoglobulin standards. 
 
 Coagulation assays: Covers costs for BeneFIX ($1600), Mononine ($1600), cuvettes 
($600), steel balls ($280), aPTT reagent, buffers (Owren’s buffer, calcium chloride), coagulation 
meter supplies (thermal paper, pipet tips). 
 
 General lab supplies: Covers costs of routine disposables (pipets, pipet tips, 
microcentrifuge tubes, etc.). 
 
TRAVEL 
$800/year is requested for travel to meet with Lead Investigators in Lincoln, NE. 
  
UNC Chapel Hill--Dog Trials
Principal Investigator/Program Director (Last, first, middle): Velander, William H.
From Through
12/1/2007 12/31/2008
Personnel (Applicant organization only) % Dollar Amount Requested (omit cents)
ROLE ON 
PROJECT
TYPE 
APPT.  
(Months)
EFFORT 
ON 
PROJ.
INST. 
BASE 
SALARY
SALARY 
REQUESTED
FRINGE 
BENEFITS
TOTAL
P.I 12 15% 170,625 $25,594 $5,349 $30,943
Res. 
Analyst 12 90% 54,434 $48,991 $12,409 $61,400
$0
$74,584 $17,758 $92,342
$0
$0
$33,116
$0
$0
$0
$0
$0
$125,458
$57,711
$183,169
Page 33 Form Page 4
Processing, preparing blood samples, anticoagulants, reagents for assaying FIX, 15,000
TOTAL DIRECT COSTS FOR INITIAL BUDGET PERIOD  (Item 7a, Face Page)
SBIR/STTR Only:  FIXED FEE REQUESTED
PHS 398 (Rev. 05/01)
ALTERATIONS AND RENOVATIONS (Itemize by category)
SUBTOTAL DIRECT COST FOR INITIAL BUDGET PERIOD
DIRECT COSTS 
FACILITIES AND ADMINISTRATIVE COSTS @ 46.0%
CONSORTIUM/CONTRACTUAL
Timothy Nichols
Elizabeth Merricks
NAME
EQUIPMENT (Itemized)
CONSULTANT COSTS
SUBTOTALS
DETAILED BUDGET FOR INITIAL BUDGET 
DIRECT COST ONLY
SUPPLIES (Itemize by category)  
PATIENT CARE COST INPATIENT
OUTPATIENT
Serum chemistries, shipping, plastics, etc., 9,000
4 hemophilia B dogs at $5.97/day x 365 days + classification charge /dog, 9,116
COSTS
TRAVEL
OTHER EXPENSES (Itemize by category)
Travel to meet with collaborators
Principal Investigator/Program Director (Last, first, middle): Velander, William
UNC Chapel Hill--Mouse Model Experiments
INITIAL BUDGET
PERIOD
(from form Page 4) 2nd 3rd 4th 5th
PERSONNEL: Salary and
fringe benefits. Applicant
organization only. 0 0 92,342 0 95,113
CONSULTANT COSTS 0 0 0 0
EQUIPMENT 0 0 0 0 0
SUPPLIES 0 0 33,116 0 68,881
TRAVEL 0 0 0 0 0
INPATIENT
OUTPATIENT
ALTERATIONS AND
RENOVATIONS
OTHER EXPENSES 0 0 0 0 0
SUBTOTAL DIRECT COSTS 0 0 125,458 0 163,994
DIRECT
F&A 0 0 57,711 0 75,437
TOTAL DIRECT COSTS 0 0 183,169 0 239,431
TOTAL DIRECT COSTS FOR THE ENTIRE PROPOSED PROJECT PERIOD (Item 8A, Face Page) $422,600
SBIR/STTR Only
Fee Requested 0 0 0 0 0
SBIR/STTR Only: Total Fee Requested for Entire Propposed Project Preiod
$0
JUSTIFICATION. Follow the budget justification instructions exactly. Use continuation pages as needed.
PHS 398 (Rev. 05/01) Form Page 5Page ___34___
BUDGET CATEGORY
TOTALS
BUDGET FOR THE ENTIRE PROPOSED PROJECT PERIOD
DIRECT COSTS ONLY
ADDITIONAL YEARS OF SUPPORT REQUESTED
PATIENT
CARE
COSTS
CONSORTIUM/
CONTRACTUAL
COSTS
Please see the following page:
Principal Investigator/Program Director (Last, first, middle): Velander, William H.  
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Budget Justification:  Hemophilia B Canine Model Experiments (UNC-Chapel Hill) 
 
PERSONNEL 
 
Timothy C. Nichols, M.D., Lead Investigator 
Professor of Medicine and Pathology and Laboratory Medicine, is the Lead Investigator.  He will 
plan and supervise all of the collaborative research activities and will spend 15% of his time 
conducting the experiments with transgenic rhFIX in the canine hemophilia B model, and 
requests salary support.  Dr. Nichols will be responsible for supervising Ms. Elizabeth Merrricks, 
overseeing the animal experiments to ensure compliance, designing the experiments, 
interpreting the results, and communicating the results to other Lead Investigators and project 
team members. He is the laboratory director of the Francis Owen Blood Research Laboratory 
(FOBRL).  He has worked with the bleeder animals at the FOBRL since 1982.  He maintains an 
office and laboratory at the FOBRL. A 3%/year increase is included. 
 
Elizabeth Merricks, B.S., Research Analyst 
Dr. Merricks will be responsible for the analysis of all samples obtained from the dogs for 
classification and before and after treatment of spontaneous bleeding episodes, dosing and 
administration of vectors and other test reagents and collaborative protocols.  Her 
responsibilities will include performing related clotting assays, electrophoretic procedures, 
ELISA quantitation of F.IX antigen, SDS-PAGE analysis of F.IX, and analysis of F.IX activity and 
Bethesda Inhibitors as needed..  She will maintain the scientific records of these results. She 
will spend 90% of their time on this project, and will be responsible for conducting experiments, 
assisting with experimental design, assisting with interpretation of the results, and preparation of 
reports. A 3%/year increase is included. 
 
SUPPLIES COSTS 
Animal costs: Covers the animal facility per diem costs ($5.97/day plus classification 
charge/dog).  A 4%/year increase is included for subsequent years. 
 
Coagulation assays:  Covers costs for processing and preparing blood samples, aPTT 
reagent, buffers, coagulation meter supplies, plastic ware, coagulation reagents, dry ice, liquid 
N2, catheters, histological processing of biopsies, CBC analyses, serum chemistry analyses for 
monitoring liver enzymes, serum electrolytes, and for evidence of a procoagulant effect.  
LifeSci Partners
Principal Investigator/Program Director (Last, first, middle): Velander, William
FROM THROUGH
1/1/2005 12/31/2005
Personnel (Applicant organization only) % Dollar Amount Requested (omit cents)
ROLE ON 
PROJECT
TYPE 
APPT.  
(Months)
EFFORT 
ON 
PROJ.
INST. 
BASE 
SALARY
SALARY 
REQUESTED
FRINGE 
BENEFITS
TOTAL
co-P.I 12 35% 150,000 $52,500 $13,650 $66,150
$52,500 $13,650 $66,150
$0
$0
$20,000
$0
$0
$0
$0
$86,150
$37,906
$124,056
Page 36 Form Page 4
COSTS
TRAVEL
OTHER EXPENSES (Itemize by category)
Tavel to project sites (10 trips/yr at 2,000/trip)
SUPPLIES 
PATIENT CARE COST INPATIENT
OUTPATIENT
EQUIPMENT (Itemized)
CONSULTANT COSTS
SUBTOTALS
DETAILED BUDGET FOR INITIAL BUDGET 
DIRECT COST ONLY
Stephen Abramson
NAME
TOTAL DIRECT COSTS FOR INITIAL BUDGET PERIOD  (Item 7a, Face Page)
SBIR/STTR Only:  FIXED FEE REQUESTED
PHS 398 (Rev. 05/01)
ALTERATIONS AND RENOVATIONS (Itemize by category)
SUBTOTAL DIRECT COST FOR INITIAL BUDGET PERIOD
DIRECT COSTS 
FACILITIES AND ADMINISTRATIVE COSTS @ 44.0%
CONSORTIUM/CONTRACTUAL
Principal Investigator/Program Director (Last, first, middle): Velander, William H.
LifeSci Partners
INITIAL BUDGET
PERIOD
(from form Page 4) 2nd 3rd 4th 5th
PERSONNEL: Salary and
fringe benefits. Applicant
organization only. 66,150 68,135 70,179 72,284 74,452
CONSULTANT COSTS 0 0 0 0
EQUIPMENT 0 0 0 0 0
SUPPLIES 0 0 0 0 0
TRAVEL 20,000 20,600 21,218 21,855 22,510
INPATIENT
OUTPATIENT
ALTERATIONS AND
RENOVATIONS
OTHER EXPENSES 0 0 0 0 0
SUBTOTAL DIRECT COSTS 86,150 88,735 91,397 94,138 96,963
DIRECT 86,150 88,735 91,397 94,138 96,963
F&A 37,906 39,043 40,214 41,421 42,664
TOTAL DIRECT COSTS 124,056 127,778 131,611 135,559 139,626
TOTAL DIRECT COSTS FOR THE ENTIRE PROPOSED PROJECT PERIOD (Item 8A, Face Page) $658,630
SBIR/STTR Only
Fee Requested 0 0 0 0 0
SBIR/STTR Only: Total Fee Requested for Entire Propposed Project Preiod
$0
JUSTIFICATION. Follow the budget justification instructions exactly. Use continuation pages as needed.
PHS 398 (Rev. 05/01) Form Page 5Page ___37___
BUDGET CATEGORY
TOTALS
BUDGET FOR THE ENTIRE PROPOSED PROJECT PERIOD
DIRECT COSTS ONLY
ADDITIONAL YEARS OF SUPPORT REQUESTED
PATIENT
CARE
COSTS
CONSORTIUM/
CONTRACTUAL
COSTS
  PERSONNEL
Stephen Abramson, Ph.D., Lead Investigator 
Dr. Abramson will dedicate 35% of his effort to this project. Dr. Abramson has a tremendous amount of 
experience in the biopharmaceutical industry and was instrumental in bringing plasma-derived Factor IX
to commercial production. Dr. Abramson will assist Dr. Velander in all aspects of the project, especially 
issues related to bring transgenic human Factor IX to clinical trials.  
TRAVEL COSTS
Dr. Abramson will be traveling to Nebraska, North Carolina, Colorado, and NIH during the project. Dr. 
Abramson is located in California and will be making 10 trips per year to the different sites as needed.   
Pro Genetics, LLC
Principal Investigator/Program Director (Last, first, middle): Velander, William
From Through
1/1/2005 12/31/2005
Personnel (Applicant organization only) % Dollar Amount Requested (omit cents)
ROLE ON 
PROJECT
TYPE 
APPT.  
(Months)
EFFORT 
ON 
PROJ.
INST. 
BASE 
SALARY
SALARY 
REQUESTED
FRINGE 
BENEFITS
TOTAL
co-P.I 12 0% 0 $0 $0 $0
$0 $0 $0
$0
$0
$62,000
$0
$0
$0
$0
$0
$62,000
$27,900
$89,900
Page 38 Form Page 4
COSTS
TRAVEL
OTHER EXPENSES (Itemize by category)
SUPPLIES 
PATIENT CARE COST INPATIENT
OUTPATIENT
 (Cost to Maintain and Supply Transgenic Milk from 5 Female Lactating Pigs)
EQUIPMENT (Itemized)
CONSULTANT COSTS
SUBTOTALS
DETAILED BUDGET FOR INITIAL BUDGET 
DIRECT COST ONLY
Julian Cooper
NAME
TOTAL DIRECT COSTS FOR INITIAL BUDGET PERIOD  (Item 7a, Face Page)
SBIR/STTR Only:  FIXED FEE REQUESTED
PHS 398 (Rev. 05/01)
ALTERATIONS AND RENOVATIONS (Itemize by category)
SUBTOTAL DIRECT COST FOR INITIAL BUDGET PERIOD
DIRECT COSTS 
FACILITIES AND ADMINISTRATIVE COSTS 
CONSORTIUM/CONTRACTUAL
Principal Investigator/Program Director (Last, first, middle): Velander, William H.
ProGenetics LLC
INITIAL BUDGET
PERIOD
(from form Page 4) 2nd 3rd 4th 5th
PERSONNEL: Salary and
fringe benefits. Applicant
organization only. 0 0 0 0 0
CONSULTANT COSTS 0 0 0 0
EQUIPMENT 0 0 0 0 0
SUPPLIES 62,000 63,860 65,776 67,749 69,782
TRAVEL 0 0 0 0 0
INPATIENT
OUTPATIENT
ALTERATIONS AND
RENOVATIONS
OTHER EXPENSES 0 0 0 0 0
SUBTOTAL DIRECT COSTS 62,000 63,860 65,776 67,749 69,782
DIRECT 62,000 63,860 65,776 67,749 69,782
F&A 27,900 28,737 29,599 30,487 31,402
TOTAL DIRECT COSTS 89,900 92,597 95,375 98,236 101,183
TOTAL DIRECT COSTS FOR THE ENTIRE PROPOSED PROJECT PERIOD (Item 8A, Face Page) $477,291
SBIR/STTR Only
Fee Requested 0 0 0 0 0
SBIR/STTR Only: Total Fee Requested for Entire Propposed Project Preiod
$0
JUSTIFICATION. Follow the budget justification instructions exactly. Use continuation pages as needed.
PHS 398 (Rev. 05/01) Form Page 5Page ___39___
BUDGET CATEGORY
TOTALS
BUDGET FOR THE ENTIRE PROPOSED PROJECT PERIOD
DIRECT COSTS ONLY
ADDITIONAL YEARS OF SUPPORT REQUESTED
PATIENT
CARE
COSTS
CONSORTIUM/
CONTRACTUAL
COSTS
  
PERSONNEL
Julian Cooper, Ph.D., CEO of ProGenetics LLC
Dr. Cooper is CEO of ProGenetics LLC and is providing his time to the project at no cost.  
SUPPLIES COSTS
Milking: This is to cover part of the cost of maintaining and milking five lactating pigs. This cost also 
includes shipping the fresh frozen milk to the University of Nebraska-Lincoln. ProGenetics is providing 
a majority of the cost for the milk as an in-kind contribution to the project.   
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h Principal Investigator/Program Director (Last, first, middle): Velander, William H. 
 
BIOGRAPHICAL SKETCH 
Provide the following information for the key personnel in the order listed for Form Page 2. 
Follow the sample format on preceding page for each person. DO NOT EXCEED FOUR PAGES. 
 
NAME 
William H. Velander, Ph.D. 
POSITION TITLE 
Chair, Department of Chemical Engineering 
EDUCATION/TRAINING  (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.) 
INSTITUTION AND LOCATION DEGREE 
(if applicable) 
YEAR(s) FIELD OF STUDY 
Illinois Benedictine College, Lisle, IL B.S. 1977 Biochemistry 
Illinois Institute of Technology, Chicago, IL M.ChE 1980 Chemical Engineering 
The Pennsylvania State University, State College, PA Ph.D. 1987 Chemical Engineering 
 
A. POSITIONS AND HONORS  
 
Positions and Employment 
1976-1977 Clinical Chemistry Technologist, Northwest Suburban Hospital, Arlington Heights, IL 
1980-1982 Research Engineer (Drug Synthesis and Scale-up), Merck, Sharp and Dohme Research 
Laboratories, Merck and Co. Rahway, NJ 
1986-1992 Assistant Professor, Department Chemical Engineering, Virginia Polytechnic Institute and State 
University (VPISU) 
1992-1996 Associate Professor, Department Chemical Engineering, VPISU 
1994  Visiting Scientist (Calcium-dependent Monoclonal Antibody-Protein C Interactions using 
Biacore), Pharmacia Biotechnology AB, Uppsala, Sweden 
1997  Full Professor, Department Chemical Engineering, VPISU 
1998  W. Martin Johnson Professor of Engineering, VPISU 
2001  Chief Technology Officer of ProGenetics-HemoCare LLC 
2002  Distinguished Lecturer, University of Mayaguez, Puerto Rico, Merck Sharp & Dohme Lecture 
Series 
2002  Faculty Member, School of Medical and Bioengineering, VPISU 
2003-present Chair, Department of Chemical Engineering, University of Nebraska-Lincoln, Lincoln, NE 
 
Other Experience and Professional Memberships 
1994-1994 Consultant, USFDA for formulation of federal regulatory guidelines for human therapeutics 
derived from transgenic animals 
1996-2002 Co-inventor of several U.S. patents concerning gene transfer and the production of recombinant 
proteins of haemostatsis; all have been licensed and are in process of commercialization 
2003  Advisory Board Member, Centre for Blood Research, University of British Columbia   
2000-present Elected Fellow, American Institute of Medical and Bioengineering 
1995-present Member, American Chemical Society 
 
Honors 
1994  Virginia Technological Institute Alumni Award for Excellence in Research 
2000  Elected Fellow of the American Institute for Medical and Bioengineering 
 
B. SELECTED PEER-REVIEWED PUBLICATIONS (in chronological order) 
W.N. Drohan, D.-W. Zhang, R.K. Paleyanda, R. Chang, M. Wroble, W. Velander and H.K. Lubon, Inefficient 
Processing of Human Protein C in the Mouse Mammary Gland, Transgenic Research, 3:355-364, 1994. 
W.L. Fodor, B.L. Williams, L.A. Matis, J.A. Madri, S.A. Rollins, J.W. Knight, W. Velander and S.P. Squinto, 
Expression of a Functional Human Complement Inhibitor in a Transgenic Pig as a Model for the 
Prevention of Xenogeneic Hyperacute Organ Rejection, Proc. Natl. Acad. Sci. USA, 91:11153-11157, 
1994. 
Principal Investigator/Program Director (Last, first, middle): Velander, William H.  
 
 PHS 398/2590 (Rev. 05/01) Page ___41____ Biographical Sketch Format Page  
Number pages consecutively at the bottom throughout the application. Do not use suffixes such as 3a, 3b. 
T. Morcol, R.M. Akers, J.L. Johnson, B.L. Williams, F.C. Gwazdauskas, J.W. Knight, H. Lubon, R.K. 
Paleyanda, W.N. Drohan and W.H. Velander, The Porcine Mammary Gland as a Bioreactor for Complex 
Proteins, The Annals of the New York Academy of Sciences, 721, 218-233, 1994. 
R.L. Page, S.P. Butler, A. Subramanian, F.C. Gwazdauskas, J.L. Johnson, and W.H. Velander, Transgenesis 
in Mice by Cytoplasmic Injection of Polylysine/DNA Mixtures, Transgenic Research, 4:353-360, 1995. 
H. Lubon, R. K. Paleyanda, W. H. Velander and W. N. Drohan, Blood Proteins from Transgenic Animal 
Bioreactors, Transfusion Medicine Reviews, 10:131-143, 1996. 
T. K. Lee, N. Bangalore, W. Velander, W. N. Drohan and H. Lubon, Activation of Recombinant Human Protein 
C, Thrombosis Research, 82:225-234, 1996. 
A. Subramanian, R. K. Paleyanda, H. Lubon, B. L. Williams, F. C. Gwazdauskas, J. W. Knight, W. N. Drohan 
and W. H. Velander, Rate Limitations in Posttranslational Processing by the Mammary Gland of 
Transgenic Animals, The Annals of the New York Academy of Sciences, 782, 87-96, 1996. 
S. P. Butler, K. Van Cott, A. Subramanian, F.C. Gwazdauskas and W. H. Velander, Current Progress in the 
Production of Recombinant Human Fibrinogen in the Milk of Transgenic Animals, Thrombosis and 
Haemostasis, 78, 1:537-542, 1997.  
R. K. Paleyanda, W. H. Velander, T. K. Lee, D. H. Scandella, F. C. Gwazdauskas, J. W. Knight, L. W. Hoyer, 
W. N. Drohan and H. Lubon, Transgenic Pigs Produce Functional Human Factor VIII in Milk, Nature 
Biotechnology, 15:971-975, 1997. 
K. E. Van Cott, H. Lubon, C. G. Russell, S. P. Butler, F. C. Gwazdauskas, J. Knight, W. N. Drohan and W. H. 
Velander, Phenotypic and Genotypic Stability of Multiple Lines of Transgenic Pigs Expressing 
Recombinant Human Protein C, Transgenic Research, 6:1-10, 1997. 
K. E. Van Cott, B. L. Williams, F. Gwazdauskas, T. Lee, H. Lubon, W. N. Drohan and W. H. Velander, Affinity 
Purification of Biologically Active and Inactive Forms of Recombinant Human Protein C Produced in the 
Porcine Mammary Gland, Journal of Molecular Recognition, 9:407-414, 1997. 
W. H. Velander, H. Lubon, and W. Drohan, Transgenic Livestock as Drug Factories, Scientific American, 
276:54-58, 1997. 
A. Degener, M. Belew and W. H. Velander, AZn2+-selective Purification of Recombinant Proteins from the Milk 
of Transgenic Animals, Journal of Chromatography A, 799:125-137, 1998. 
K. Van Cott, and W. H. Velander, Transgenic Animals as Drug Factories: A New Source of Recombinant 
Protein Therapeutics. Expert Opinion on Investigational Drugs, 7:1683-1690, 1998. 
K. Van Cott, S. P. Butler, C. G. Russell, A. Subramanian, H. Lubon, F. C. Gwazdauskas, J. Knight, W. N. 
Drohan, and W. H. Velander. Transgenic Pigs as Bioreactors: A Comparison of Gamma-carboxylation of 
Glutamic Acid in Recombinant Human Protein C and Factor IX by the Mammary Gland. Genet Anal, 
15:15560, 1999. 
K. E. Van Cott, H. Lubon, F. C. Gwazdauskas, J. Knight, W. N. Drohan, W. H. Velander, Recombinant Human 
Protein C Expression in the Milk of Transgenic Pigs and the Effect on Endogenous Milk Immunoglobulin 
and Transferrin Levels. Transgenic Research, 10:43-51, 2001.  
W. Velander and K. Van Cott, Protein Expression Using Transgenic Animals: in Handbook of Industrial Cell 
Culture Mammalian, Microbial, and Plant Cells,  eds. Vinci, Victor A. and Parekh, Sarad R. , Human Press, 
Totawa, NJ, 2002. 
L. C. Bolling, R. S. Pleasant, S. P. Butler, W. H. Velander, and F. C. Gwazdauskas. An Evaluation of Sperm 
Mediated Gene Transfer, Transgenics 4:77-86, 2003. 
M. Lindsay, G. C. Gil, A. Cadiz, C. Zhang, W. H. Velander, K. E. Van Cott. Purification of Recombinant  DNA-
derived Factor IX and Fractionation of Active and Inactive Subpopulations.  Journal of Chromatography, 
1026:149-157, 2004. 
 
C. RESEARCH SUPPORT  
Dr. Velander has more than 17 years experience and cumulatively more than $6 million of research support in 
directing transgenic animal engineering research and plasma protein purification research. 
 
Ongoing Research Support 
None.  
 
Principal Investigator/Program Director (Last, first, middle): Velander, William H.  
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Completed Research Support 
         12/31/99-12/31/00 
American Red Cross.  
Production of  Recombinant Fibrinogen in the Milk of Transgenic Animals 
Overall project goal: Produce recombinant fibrinogen and Factor VIII in the milk of transgenic animals. 
Role: Principal Investigator 
Principal Investigator/Program Director (Last, first, middle): Velander, William H.  
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BIOGRAPHICAL SKETCH 
Provide the following information for the key personnel in the order listed for Form Page 2. 
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NAME 
Stephan B. Abramson, Ph.D. 
POSITION TITLE 
Principal, LifeSci Partners 
EDUCATION/TRAINING  (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.) 
INSTITUTION AND LOCATION DEGREE 
(if applicable) 
YEAR(s) FIELD OF STUDY 
California Institute of Technology B.S. 1967 Chemistry 
Harvard University Ph.D. 1975 Biochemistry 
University of California, Los Angeles Post-doc 1975-1977 Protein Biochemistry 
University of Southern California Post-doc 1977-1981 Protein Biochemistry 
 
A. POSITIONS AND HONORS  
Positions and Employment 
1981-1986 Investigator (Biochemistry and Cell Biology), Huntington Medical Research Institutes, 
Pasadena, CA 
1986  Clinical Research Associate, Alpha Therapeutic Corporation, Los Angeles, CA 
1986-1989 Clinical Project Manager, Alpha Therapeutic Corporation, Los Angeles, CA 
1989-1992 Associate Director, Clinical Research, Alpha Therapeutic Corporation, Los Angeles, CA 
1991-2002 Associate Director, Business Development, Alpha Therapeutic Corporation, Los Angeles, CA 
2001-2002 Associate Director, Clinical Affairs, Alpha Therapeutic Corporation, Los Angeles, CA 
2002-2003 Director, Corporate and Business Development, Alpha Therapeutic Corporation, Los Angeles, 
CA 
2002-2003 Director, Clinical Affairs, Alpha Therapeutic Corporation, Los Angeles, CA 
2003-present Principal, LifeSci Partners, Altadena, CA 
 
Other Experience and Professional Memberships 
Professional Experience:  
• Extensive industrial experience in clinical development, business development, and corporate project 
management in the development and commercialization of plasma-derived protein therapeutics, including 
especially coagulation factors (one of them a high-purity Factor IX) and intravenous immune globulin (IgG).   
• Preparation and submission of 18 IND submissions, with more than 25 clinical protocols and more than 20 
final clinical reports, along with other submissions that led to 5 new product approvals and 4 license 
amendments.  
• Extensive experience in product licensing and the development and management of corporate alliances. 
• Internal consulting at Alpha Therapeutic Corporation and with corporate partners in a variety of areas, 
including, quality systems development, regulatory strategy, and the design and implementation of 
preclinical development programs. 
 
Other Related Experience: 
In Vivo Recovery, Half-Life, Safety and Hemostatic Efficacy of Affinity Purified Factor VIII (Antihemophilic 
Factor).  J. M. Goldsmith, C. K. Kasper, S. B. Abramson, P. Battacharya and P. Novak, presented at the 
1991 Annual Meeting of the National Hemophilia Foundation. 
In Vivo Recovery, Half-Life and Safety of Affinity Purified Solvent-Detergent Coagulation Factor IX.  C. K. 
Kasper, S. B. Abramson, J. C. Goldsmith and S. Herring, presented at the 1992 Annual Meeting of the 
American Society for Hematology. 
Safety, in Vivo Recovery and Half-Life of Alpha-8® HP an Affinity Chromatography Purified, Solvent/ Detergent 
Treated Factor VIII Concentrate.  Y. Arkel, S. Abramson, P. Bhattacharya, C. K. Kasper and A. D. 
Retzios, presented, XXth International Congress, World Federation of Hemophilia, 1992. 
Principal Investigator/Program Director (Last, first, middle): Velander, William H.  
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In Vivo Recovery, Half-Life, Thrombogenic Potential and Safety of Affinity Purified Solvent-Detergent Treated 
Coagulation Factor IX.  C. K. Kasper, S. B. Abramson, J. C. Goldsmith and S. Herring, presented at the 
XXth International Congress of the World Federation of Hemophilia, 1992. 
 
Memberships:  
American Association for Advancement of Sciences, American Chemical Society, American Society for Cell 
Biology, American Society for Microbiology, Association of University Technology Managers, Licensing 
Executives Society (USA and Canada), New York Academy of Sciences, Society of Sigma Xi. 
 
Reviewer:  
Biochemical Pharmacology, Blood, Clinical Immunology and Immunopathology, Experimental Cell Research, 
European Journal of Cell Biology, Journal of Clinical Investigation, Journal of Immunology and the Journal of 
Leukocyte Biology. 
 
Honors 
Listed in American Men and Women in Science. 
 
B. SELECTED PEER-REVIEWED PUBLICATIONS (In chronological order) 
I. G. Renner, S. B. Abramson and A. P. Douglas. Alpha-Amylase of Human Pure Pancreatic Juice: Effects of 
Pancreatic Disease and the Occurrence of Variant Forms in Pancreatic Juice from Healthy Volunteers.  
Clin Chim Acta 99:259-266, 1979. 
H. Rinderknecht, N. F. Adham, I. G. Renner and S. B. Abramson. Diagnosis of Pancreatic Disease by 
Fluorometric Determination of Plasma Trypsinogen.  Prog Clin Enzymol 2, 1981. 
S. B. Abramson, H. Rinderknecht and I. G. Renner. Ribonuclease C and Pancreatic Secretory Proteins in the 
Peripheral Circulation before and after Pancreatectomy for Pancreatic Cancer. Digest Dis Sci 27:889-896, 
1982. 
R. Carmel, S. B. Abramson and I. G. Renner. Characterization of Human Pure Pancreatic Juice: Cobalamin 
Content, Cobalamin-Binding Proteins and Activity against Human R Binders of Various Secretions.  Clin 
Sci 64:193-205, 1983. 
J. L. Pantoja, I. G. Renner, S. B. Abramson and H. A. Edmundson. Production of Acute Hemorrhagic 
Pancreatitis in the Dog using Venom of the Scorpion Buthus Quinquestriatus. Digest Dis Sci 28:429-439, 
1983. 
I. G. Renner, J. L. Pantoja, S. B. Abramson, F. E. Russell and M. M. Koch. Effects of Scorpion and 
Rattlesnake Venoms on the Canine Pancreas Following Pancreaticoduodenal Arterial Injections. Toxicon 
21:405-420, 1983. 
H. Rinderknecht, I. G. Renner, S. B. Abramson and C. Carmack. Mesotrypsin: A New Inhibitor-Resistant 
Protease from a Zymogen in Human Pure Pancreatic Juice. Gastroenterology 86:681-692, 1984. 
W. F. Agnew, R. B. Alvarez, T. G. H. Yuen, S. B. Abramson and D. Kirk. A Serum-Free Culture System for 
Studying Solute Exchanges in the Choroid Plexus. In Vitro 20:712-722, 1985. 
R. Carmel, D. Hollander, H. M. Gergely, I. G. Renner and S. B. Abramson. Pure Human Pancreatic Juice 
Directly Enhances Uptake of Cobalamin by Guinea Pig Ileum in Vivo. Proc Soc Exp Biol Med Sci 178:143-
150, 1985. 
R. T. Chlebowski, S. B. Abramson, J. R. Bateman, J. M. Weiner and I. G. Renner. Influence of Nutritional 
Status on Circulatory Ribonuclease C Levels in Patients with Cancer.  Cancer 55:427-431, 1985. 
A. Khwaja, B. Johnson, I. E. Addison, S. B. Abramson, K. Ruthven, K. Yong and D. C. Linch. In Vivo Effects 
of Macrophage Colony-Simulating Factor on Human Monocyte Function. Br J Haematol 77:25-31, 1991. 
A. Khwaja, K. Yong, H. M. Jones, R. Chopra, A. K. McMillan, A. H. Goldstone, K. G. Patterson, C. Matheson, 
K. Ruthven, S. B. Abramson and D. C. Linch. The Effect of Macrophage Colony-Stimulating Factor on 
Haemopoietic Recovery after Autologous Bone Marrow Transplantation.  Br J Haematol  81:288-295, 
1992. 
 
Principal Investigator/Program Director (Last, first, middle): Velander, William H.  
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C. RESEARCH SUPPORT 
Ongoing Research Support 
Not Applicable 
 
Completed Research Support  
Not Applicable 
 
Principal Investigator/Program Director (Last, first, middle): Velander, William H.  
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BIOGRAPHICAL SKETCH 
Provide the following information for the key personnel in the order listed for Form Page 2. 
Follow the sample format on preceding page for each person. DO NOT EXCEED FOUR PAGES. 
 
NAME 
Julian D. Cooper, Ph.D. 
POSITION TITLE 
President and Chief Executive Officer 
EDUCATION/TRAINING  (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.) 
INSTITUTION AND LOCATION DEGREE 
(if applicable) 
YEAR(s) FIELD OF STUDY 
Bradford University, UK B.Tech 1979 Medical Sciences 
Birmingham University, UK M.Sc 1982 Biotechnology 
Birmingham University, UK Ph.D. 1985 Chemical Engineering 
Reading University, UK Post-Doc 1986-1989 Microbiology 
     
A. POSITIONS AND HONORS  
Positions and Employment 
1979-1981 Research Technician, Interferon Laboratory, Warwick University, Coventry, England 
1989-1992 Molecular Biologist, PPL Therapeutics LTD., Roslin, Scotland 
1992-1994 Team Leader and Project Manager, PPL Therapeutics LTD., Roslin, Scotland 
1995-1996 General Manager, PPL Therapeutics Inc., Blacksburg, VA 
1997  Vice President and General Manager, PPL Therapeutics Inc., Blacksburg, VA 
1997-1999 Chief Operating Officer, PPL Therapeutics Inc., Blacksburg, VA 
2000-present President and Chief Executive Officer, ProGenetics LLC, Blacksburg, VA 
 
Other Experience and Professional Memberships 
None 
 
Honors 
None 
 
B. SELECTED PEER-REVIEWED PUBLICATIONS (in chronological order)
M. Skinner, V. R. Racaniello, G. Dunn, J. Cooper, P.D. Minor, and J. W. Almond. New Model for the 
Secondary Structure of the 5’ Non-coding RNA of Poliovirus is Supported by Biochemical and Genetic 
Data that also Show that RNA Secondary Structure is Important in Neurovirulence. J. Mol. Biol., 
207(2):379-392, 1989. 
T. Urakawa, M. Ferguson, P. D. Minor, J. Cooper, M. Sullivan, J. W. Almond, and D. H. L. Bishop. Synthesis 
of Immunogenic but Non-infectious Poliovirus Particles in Insect Cells by a Baculovirus Expression Vector. 
J. Gen. Virol. 70(6):1453-1464, 1989. 
A. Carver, G. Wright, D. Cottom, J. Cooper, M. Dalrymple, S. Temperley, M. Udell, D. Reeves, J. Percy, and 
A. Scott. Expression of Human Alpha 1 Antitrypsin in Transgenic Sheep. Cytotechnology, 1(3):77-84, 
1992.  
A. Stacey, A. Schnieke, J. McWhir, J. Cooper, A. Colman, and D. W. Melton. Use of Double-replacement 
Gene Targeting to Replace the Murine Alpha-lactalbumin Gene with its Human Counterpart in Embryonic 
Stem Cells and Mice. Mol. Cell Biol., 14:1009-1016, 1994. 
J. D. Cooper, and M. A. Dalrymple. The Use of Transgenic Sheep as Bioreactors. Experimental Medicine, 
Developmental Biotechnology Suppl., 12(2):124-132, 1994. 
J. Cooper. Protein Production in Transgenic Animals. NABC report, 8:137-144, 1996. 
J. D. Cooper, and A. E. Schnieke. Alpha-lactalbumin Gene Constructs. US patent US5852224, 1998. 
W. H. Eyestone, M. Gowallis, J. Monohan, T. Sink, S. F. Ball, and J. D. Cooper. Production of Transgenic 
Cattle Expressing Human Alpha-lactalbumin in Milk. Theriogenology, 49(1):386, 1998. 
Principal Investigator/Program Director (Last, first, middle): Velander, William H.  
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J. D. Cooper, W. H. Velander, and T. K. O’Sickey. Production of High Levels of Transgenic Factor IX without 
Gene Rescue, and its Therapeutic Uses. Patent application PCT/US02/07532. 
J. D. Cooper, T. K. O’Sickey, and S. B. Butler. Transgenic Proteins from Multi-gene Systems, Methods, 
Compositions, Uses and the like Relating Thereto. Patent application PCT/02/07540. 
J. D. Cooper, W. H. Velander, and S. P. Butler. Production of High Levels of Transgenic Factor VIII with 
Engineered Stability, and its therapeutic uses. Patent application PCT/US02/07530. 
 
C. RESEARCH SUPPORT  
 
Ongoing Research Support 
None 
 
Completed Research Support  
None 
 
Principal Investigator/Program Director (Last, first, middle): Velander, William H.  
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BIOGRAPHICAL SKETCH 
Provide the following information for the key personnel in the order listed for Form Page 2. 
Follow the sample format on preceding page for each person. DO NOT EXCEED FOUR PAGES. 
 
NAME 
William S. Dernell, D.V.M. 
POSITION TITLE 
Associate Professor 
EDUCATION/TRAINING  (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.) 
INSTITUTION AND LOCATION DEGREE 
(if applicable) 
YEAR(s) FIELD OF STUDY 
Harper College, Palatine, IL  1977-1978 General Science 
Utah State University, Logan, UT B.S 1978-1981 Animal Science 
University of Illinois, Urbana, IL B.S., D.V.M. 1981-1985 Veterinary Science 
Washington State University, Pullman, WA M.S. 1990-1993 Veterinary Science 
 
A. POSITIONS AND HONORS  
Positions and Employment 
1986-1988 Relief State Veterinarian, Colorado Racing Commission, Denver, CO 
1985-1990 Associate Veterinarian, Rio Cucharas Veterinary Clinic, Walsenburg, CO 
1987-1990 Associate Veterinarian, Allpets Clinic, Boulder, CO 
1990-1993 Small Animal Surgical Resident, Washington State University, Pullman, WA 
1993-1994 Surgical Oncology Fellowship, Colorado State University, Ft Collins, CO 
1994-1995 Oncology Research Fellowship, Colorado State University, Ft Collins, CO 
1995-2001 Assistant Professor, Surgical Oncology, Colorado State University, Ft Collins, CO 
2001-present Associate Professor, Surgical Oncology, Colorado State University, Ft. Collins, CO 
2002-present Chief, Clinical Oncology Service, Colorado State University, Ft. Collins, CO 
 
Other Experience and Professional Memberships 
American College of Veterinary Surgeons (Diplomate Status since 1994); American Veterinary Medical 
Association, American Animal Hospital Association; Veterinary Cancer Society, Veterinary Orthopedic Society 
Veterinary Comparative Oncology Group; Phi Zeta Honor Society, American Association of Veterinary 
Clinicians, Colorado Veterinary Medical Association. 
 
Honors 
2001 Phi Zeta Research Day First Place Faculty Poster Presentation, Colorado State University 
1998 Pfizer Animal Health Award for Research Excellence, Colorado State University 
1996 Member of a Program of Research and Scholarly Excellence, Colorado State University, Fort Collins, 
CO 
1993 Surgery Scholarship, Washington State University, College of Veterinary Medicine 
1993 Phi Zeta Honor Society Member 
1992 Washington State University, Travel Grant Award 
1991 Dr. Ivor H. Evans Scholarship, Washington State University 
 
B. SELECTED PEER-REVIEWED PUBLICATIONS (in chronological order)
(Publications since 1998) 
S. A. Mendoza, T. Konishi, W. S. Dernell, S. J. Withrow and C. W. Miller. Status of the P53, Rb and Mdm2 
Genes in Canine Osteosarcoma, Anticancer Res, 18:4449-4454, 1998. 
W. S. Dernell. Treatment of Severe Orthopedic Infections, Vet Clin North Am: Small Anim Pract, 29:1261-
1274, 1999. 
N. Ehrhart, W. S. Dernell, E. J. Ehrhart, J. M. Hutchison, E. B. Douple, J. H. Brekke, R. C. Straw and S. J. 
Withrow. The Effects of a Controlled-Release Cisplatin Delivery System after Marginal Resection of Breast 
Carcinoma, Am J Vet Res, 60(11):1347-1351, 1999.  
Principal Investigator/Program Director (Last, first, middle): Velander, William H.  
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M. J. Thomson, S. J. Withrow, W. S. Dernell and B. E. Powers. Intermuscular Lipomas of the Thigh Region in 
Dogs: 11 Cases, J Am Hosp Assoc, 35:165-167, 1999. 
V. S. Bregazzi, W. S. Dernell, D. J. Huber, R. Schochet, M. Lafferty, B. E. Powers, G. K. Ogilvie, S. J. Withrow 
and M. C. Manning. Intracavitary Slow Release Paclitaxel Polymer in a Rodent Model of Mammary 
Carcinoma, J Bioact Compat Polymer, 15:85-88, 2000. 
W. S. Dernell, B. J. Van Vechten, R. C. Straw, S. M. LaRue, B. E. Powers and S. J. Withrow. Outcome 
Following Treatment of Vertebral Tumors in 20 Dogs (1986-1995), J Am Anim Hosp Assoc, 36:245-251, 
2000. 
S. E. Lana, G. K. Ogilvie, R. A. Hansen, B. E. Powers, W. S. Dernell and S. J. Withrow. Identification of Matrix 
Metalloproteinases in Canine Neoplastic Tissue, Am J Vet Res, 61(2):111-114, 2000. 
W. S. Dernell, C. Gentry-Weeks, M. C. Manning, B. E. Powers, R. D. Park, M. Lafferty, C. A. Kuntz, J. E. 
Shively, R. F. Falk, J. D. Meyer, T. W. Randolph and S. J. Withrow. In Vivo Evaluation of Antibiotic 
Impregnated Beads in a Rat Osteomyelitis Model, J Bioact Compat Polymer, 16:235-250, 2001. 
W. S. Dernell, S. J. Withrow, C. A. Kuntz, R. Dewell, F. B. Garry, B. E. Powers, J. E. Shively, R. F. Falk, J. D. 
Meyer, M. C. Manning and T. W. Randolph. In Vivo Evaluation of Gentamicin Impregnated Polylactic Acid 
Beads Implanted in Sheep, J Bioact Compat Polymer, 16:119-135, 2001. 
S. D. Ferreira, W. S. Dernell, B. E. Powers, R. A. Schochet, D. J. Huber, C. A. Kuntz, S. J. Withrow, R. M. 
Wilkins and M. Jackson. Effects of gas plasma sterilization on demineralized bone matrix, Clin Orthop Rel 
Res, 388:233-239, 2001. 
N. Leibman, C. Kuntz, P. Steyn, M. Fettman, B. Powers, S. Withrow and W. Dernell. The Measurement of the 
Proximal Extent of Canine Osteosarcoma of the Distal Radius Using Radiography, Nuclear Scintigraphy, 
and Histopathology, Vet Surg, 30:240-245, 2001. 
V. S. Bregazzi, S. M. LaRue, E. McNiel, D. W. Macy, W. S. Dernell, B. E. Powers and S. J. Withrow. 
Treatment with a Combination of Doxorubicin, Surgery and Radiation Versus Surgery and Radiation Alone 
for Cats with Vaccine-Associated Sarcomas: 25 Cases (1995-2000), J Am Vet Med Assoc., 218(4):547-
550, 2001. 
M. L. Mehl, S. J. Withrow, B. Seguin, B. E. Powers, W. S. Dernell, A. D. Pardo, R. C. Rosenthal, S. Z. 
Dolginow and R. D. Park. Spontaneous Regression of Osteosarcoma in Four Dogs. J Am Vet Med Assoc, 
219(5):614-617, 2001. 
B. Seguin, N. F. Leibman, V. S. Bregazzi, G. K. Ogilvie, B. E. Powers, W. S. Dernell, M . J. Fettman and S. J. 
Withrow. Clinical Outcome of Grade II Mast Cell Tumors Treated with Surgery Alone in Dogs: 55 Cases 
(1996-1999), J Am Vet Med Assoc, 218(7):1120-1123, 2001.  
W. S. Dernell, B. E. Powers, D. J. Taatjes, P. Cogan, G. Gaudiano and T. H. Koch. Evaluation of 
Epidoxorubicin-formaldehyde Conjugate, Epidoxoform in a Mouse Mammary Carcinoma Model, Cancer 
Invest, 20:713-724, 2002. 
E. Morello, W. S. Dernell, C. A. Kuntz, S. M. LaRue, M. Lafferty, A. Nelson, J. H. Brekke, C. H. Mallinckrodt, S. 
J. Withrow and M. C. Manning. Evaluation of Cisplatin in Combination with a Biologic Response Modifier 
in a Murine Mammary Carcinoma Model, Cancer Invest, 204(4):480-489, 2002. 
B. D. X. Lascelles, E. Monnet, J. M. Liptak, J. Johnson and W. S. Dernell. Surgical Treatment of Right-sided 
Renal Lymphoma with Invasion of the Vena Cava, J Sm Anim Pract, 44:1-4, 2003. 
B. C. X. Lacelles, M. J. Thomson, W. S. Dernell, R. C. Straw, M. Lafferty and S. J. Withrow. Combined 
Dorsolateral and Intraoral Approach for the Resection of Tumors of the Maxilla in the Dog, J Am Anim 
Hosp Assoc, 39:294-305, 2003. 
B. Seguin, P. J. Walsh, D. R. Mason, E. R. Wiser, J. L. Parmenter and W. S. Dernell. Use of an Ipsilateral 
Vascularized Ulnar Transposition Autograft for Limb Sparing Surgery of the Distal Radius in Dogs: An 
Anatomic and Clinical Study, Vet Surg, 32:69-79, 2003. 
Principal Investigator/Program Director (Last, first, middle): Velander, William H.  
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C. RESEARCH SUPPORT 
 
Ongoing Research Support 
DAMD17-02-1-0348 and DAMD17-02-1-0347    05/14/02-06/13/05 
U.S. Army Medical Research and Material Command     
Evaluation of Intracavitary Chemotherapy Delivery for Treatment of Mammary Carcinoma 
Overall project goals: The major goals of this clinical bridge and career enhancement grant are to evaluate 
local delivery of taxol chemotherapy to control human breast tumor in nude mice. 
Role: PI 
 
1-49103         07/01/03-06/30/04 
College Research Council 
Antitumor Effect of a Novel Controlled Release Cisplatin Delivery System to Human Ovarian Xenografted Nude 
Mice 
Overall project goal: The major goal of this project is to evaluate a unique chemotherapy delivery system in a 
rodent model of ovarian cancer. 
Role: PI  
 
RO1 CA 092107-03        06/01/01-05/31/04 
NIH (subcontract) 
New Drugs Targeted to Metastatic Cancer and Angiogenesis 
Overall project goals: The major goals of this project are to evaluate a novel, targeted antimetastatic drug in a 
mouse mammary carcinoma model. 
Role: PI (subcontract) 
 
Completed Research Support 
IR43CA88585-01A2        09/01/02-08/31/03 
NIH (Subcontract) 
Development of a Multidepot Polymer Drug Delivery System 
Overall project goals: The major goals of this project are to evaluate tolerability and pharmacokinetics of a 
polymer system loaded with two chemotherapy drugs in small and large animal systems. 
Role: PI (subcontract) 
 
1-49113         07/01/02-07/01/03 
College Research Council 
Evaluation of an Active Silver Antisepsis Device in a Rodent Infection Model 
Overall project goal: The major goal of this project was to evaluate a novel activated silver device for it’s 
efficacy in treating a rat model of osteomyelitis. 
Role: PI 
 
5-35559         06/02/00-12/01/02 
AlloSource 
Quantification of Bone Induction by Porous and Dense Hydroxyapatite Beads in Combination with 
Demineralized Bone Matrix 
Overall project goal: The major goal of this project was to evaluate bone induction properties of two types of 
hydroxyapatite beads mixed with demineralized bone matrix in a rat osteoinduction model. 
Role: PI 
 
5-35167         12/01/01-11/30/02 
Irish Wolfhound Club of America 
Bisphosphonate Treatment for Osteosarcoma 
Overall project goal: The major goal of this study is to evaluate the efficacy of aledronate (an oral 
bisphosphonate) against canine osteosarcoma. 
Role: PI 
 
Principal Investigator/Program Director (Last, first, middle): Velander, William H.  
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DAMD17-01-1-0046        04/01/01-6/30/02 
U.S. Army Medical Research and Materiel Command (subcontract) 
Design, Synthesis and Evaluation of Activated Doxorubicin Targeted to Advanced Prostate Cancer 
Overall project goals: The major goals of this project are to evaluate activated doxorubicin targeted to 
advanced prostate cancer in a mouse model. 
Role: PI (subcontract) 
 
5-30149         07/01/00-6/30/01 
CIRB  
Evaluation of Slow Release Taxol Chemotherapy in a Rodent Model for Mammary Carcinoma 
Overall project goal: The major goal of this project was to evaluate the local and systemic toxicity as well as 
anti-tumor efficacy of a locally delivered taxol/polymer system in mice. 
Role: PI 
 
Principal Investigator/Program Director (Last, first, middle): Velander, William H.  
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BIOGRAPHICAL SKETCH 
Provide the following information for the key personnel in the order listed for Form Page 2. 
Follow this format for each person. DO NOT EXCEED FOUR PAGES. 
 
NAME 
Mark C. Manning, Ph.D. 
POSITION TITLE 
Chief Technical Officer, HTD BioSystems 
Associate Professor, Colorado State University 
EDUCATION/TRAINING  (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.) 
INSTITUTION AND LOCATION DEGREE 
(if applicable) 
YEAR(s) FIELD OF STUDY 
Hope College, Holland, MI A.B. 1978 Chemistry 
Northwestern University, Evanston, IL Ph.D. 1983 Inorganic Chemistry 
Colorado St. Univ., Ft. Collins, CO Postdoc 1982-1984 Organometallic 
Chemistry 
Colorado St. Univ., Ft. Collins, CO Postdoc 1984-1988 Biophysical Chemistry 
 
 
A. POSITIONS AND HONORS 
 
Positions and Employment 
1988-1990 Assistant Professor of Pharmaceutical Chemistry, University of Kansas   
1988-1990 Courtesy Assistant Professor of Biochemistry, University of Kansas    
1989  Summer Visiting Professor, Abbott Laboratories, N. Chicago, IL    
1990-1997 Assistant Professor of Pharmaceutics, University of Colorado    
1997-2003  Associate Professor of Pharmaceutics, University of Colorado    
1997-2003 Co-Director, Center for Pharmaceutical Biotechnology, University of Colorado 
2003-present Chief Technical Officer, HTD BioSystems 
2003-present Special Associate Professor, Colorado State University Animal Cancer Center  
 
Other Experience and Professional Memberships 
Editorial Board for Current Pharmaceutical Biotechnology and Journal of Pharmaceutical and Biomedical 
Analysis; Co-organizer of the Colorado Protein Stability Conferences and the Colorado Macromolecular Delivery 
Conferences. 
 
Honors 
1997 Research Achievement Award in Biotechnology from the American Association of Pharmaceutical 
Scientists 
1997 Invited Guest, Novo Nordisk Technology Conference on Protein Stability, Hvidøre, Denmark (one 
of only five outside scientists invited) 
 
B. SELECTED PEER-REVIEWED PUBLICATIONS (in chronological order) 
(70 publications before 2000) 
S.D. Allison, A. Williams, K. Middleton, T.W. Randolph, M.C. Manning and J.F. Carpenter. Optimizing Storage 
Stability of Lyophilized Actin with Dextran/Disaccharide Mixtures, J. Pharm. Sci., 89:199-214, 2000. 
D. J. Claffey, J. D. Meyer, R. Beauvais, T. Brandt, E. Shefter, D. J. Kroll, J. A. Ruth, and M. C. Manning. Long 
Chain Arginine Esters: A New Class of Biocompatible Cationic Detergents, Biochem. Cell Biol. 78:59-65, 
2000. 
Y-S. Kim, J. S. Wall, J. Meyer, C. Murphy, T. W. Randolph, M. C. Manning, and J. F. Carpenter. Thermodynamic 
Modulation of Light Chain Amyloid Fibril Formation, J. Biol. Chem., 275:1570-1573, 2000. 
V.S. Bregazzi, W.S. Dernell, D.J. Huber, R. Schochet, M. Lafferty, G.K. Oglivie, S.J. Withrow, B.E. Powers, and 
M. Manning. Intracavitary Slow Release Paclitaxel Polymer in a Rodent Model of Mammary Carcinoma, J. 
Bioactive Compatible Polym. 15:85-88, 2000. 
J-J. Lin, J. D. Meyer, J. F. Carpenter, and M. C. Manning. Stability of Human Serum Albumin during 
Bioprocessing. Denaturation and Aggregation during Processing of Albumin Paste, Pharmaceutical Res. 
17:391-386, 2000. 
h Principal Investigator/Program Director (Last, first, middle): Velander, William H. 
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T-H. Yang, J. L. Cleland, J. D. Meyer, L. S. Jones, T. W. Randolph, M. C. Manning, and J. F. Carpenter. Effect of 
Zinc-Binding and Precipitation on Structures of Recombinant Human Growth Hormone and Nerve Growth 
Factor, J. Pharm. Sci. 89:1480-1485, 2000. 
A. Dong, J. D. Meyer, M. C. Manning, J. L. Brown, and J. F. Carpenter. Comparative FT-IR and CD 
Spectroscopic Analysis of ∀1-Proteinase Inhibitor and Ovalbumin in Aqueous Solution, Arch. Biochem. 
Biophys. 383:148-155, 2000. 
W.S. Dernell, S.J. Withrow, M.C. Manning, C.A. Kuntz, R. Dewell, F.B. Garry, B.E. Powers, J.E. Shively, R.F. 
Falk, and T.W. Randolph. In Vivo Evaluation of Gentamicin-Impregnated Polylactic Acid Beads Implanted in 
Sheep, J. Bioactive Compatible Polym 16:119-135, 2001. 
Y-S. Kim, S. P. Cape, E. Chi, R. Raffen, P. Wilkins-Stevens, F. J. Stevens, M. C. Manning, T. W. Randolph, A. 
Solomon, and J. F. Carpenter. Counteracting Effects of Renal Solutes in Amyloid Fibril Formation by 
Immunoglobulin Light Chains, J. Biol. Chem. 276:1626-1633, 2001. 
E. Morello, W. S. Dernell, C. A. Kuntz, M. Lafferty, A. Nelson, J. H. Brekke, C. H. Mallinckrodt, S. J. Withrow, and 
M. C. Manning. Evaluation of Cisplatin in Combination with a Biological Response Modifier in a Murine 
Mammary Carcinoma Model, Cancer Investigations 20:480-489, 2002. 
 R. Nayar and M. C. Manning. High Throughput Development: Meeting the Coming Challenges, BioPharm  Feb, 
25-32, 2002. 
H. Zhou, C. S. Lengsfeld, D. J. Claffey, J. A. Ruth, B. A. Hybertson, T. W. Randolph, K-Y. Ng, and M. C. 
Manning. Ion Pairing of Isoniazid Using a Prodrug Approach, J. Pharm. Sci. 91:1502-1511, 2002. 
S. Krishnan, E. Y. Chi, J. N. Webb, B. S. Chang, D. Shan, M. Goldenberg, M. C. Manning, T. W. Randolph, and 
J. F. Carpenter. Aggregation of Granulocyte Colony Stimulating Factor under Physiological Conditions: 
Characterization and Thermodynamic Inhibition, Biochemistry 41:6422-6431, 2002. 
C. S. Lengsfeld, M. C. Manning, and T. W. Randolph. Encapsulating DNA within Biodegradable Polymeric 
Microspheres, Curr. Pharm. Biotechnol. 3:227-235, 2002. 
D. Pitera, C. S. Lengsfeld, M. C. Manning, and T. W. Randolph. Dissolution and Partitioning Behavior of 
Hydrophobic Ion Paired Complexes, Pharm. Res. 19:1572-1576, 2002. 
J. D. Meyer, M. C. Manning, and D. G. Vander Velde. Characterization of the Solution Conformations of 
Leuprolide Acetate, J. Peptide Res. 60:159-168,  2002. 
 R. Krishnamurthy and M. C. Manning. The Stability Factor: Importance in Formulation Development, Curr. 
Pharm. Biotechnol. 3:361-371, 2002. 
M. M. Tomczak, L. Vigh, J. D. Meyer, M. C. Manning, D. K. Hincha, and J. H. Crowe. Lipid Unsaturation 
Determines the Interaction of AFP Type I with Model Membranes during Thermotropic Phase Transitions, 
Cryobiology 45:135-142, 2002. 
Y.-S. Kim, T. W. Randolph, M. C. Manning, F. J. Stevens, and J. F. Carpenter. Congo Red Populates Partially 
Unfolded States of an Amyloidogenic Protein to Enhance Aggregation and Amyloid Fibril Formation, J. Biol. 
Chem. 278:10842-10850, 2003. 
Y. Zhang, W. Garzon-Rodriguez, M. C. Manning, and T. J. Anchordoquy. The Use of Fluorescence Resonance 
Energy Transfer to Monitor Dynamic Changes of Lipid-DNA Interactions during Lipoplex Formation Biochim. 
Biophys. Acta 1614:182-192, 2003. 
 
C. RESEARCH SUPPORT  
 
Ongoing Research Support 
T32 CA79446          07/01-06/06 
NIH 
Leadership Training in Pharmaceutical Biotechnology  
Overall project goal: This grant provides graduate student support for the Center’s training programs 
Role: Co-PI (T. Randolph, PI)  
 
h Principal Investigator/Program Director (Last, first, middle): Velander, William H. 
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Completed Research Support 
R01 AI47446          04/99-03/03 
NIH 
Aerosol-Based Nanoparticle Drug Delivery System for Tuberculosis       
Overall project goal: This grants supports work on the development of inhaled controlled release treatments for 
TB 
Role: Collaborator (PI Lawrence Ng) 
 
           03/02-02/03 
HTD Biosystems 
Studies on Novel Protein Formulations 
Overall project goal: This contract supported studies on the stability of novel protein formulations 
Role: PI 
 
           02/02-01/03 
Human Genome Sciences 
Characterization of Novel Protein Hormone 
Overall project goal: This grant supports work on the interaction of a novel cytokine with excipients. 
Role: PI 
 
          08/01-07/02 
GonexPets 
Preformulation of Toxin-Gonadotropin Conjugate 
Overall project goal: This grant covers studies on the stability and structure of a toxin-gonadotropin conjugate 
Role: PI  
 
 
h Principal Investigator/Program Director (Last, first, middle): Velander, William H. 
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BIOGRAPHICAL SKETCH 
Provide the following information for the key personnel in the order listed for Form Page 2. 
Follow this format for each person. DO NOT EXCEED FOUR PAGES. 
 
NAME 
Michael M. Meagher, Ph.D. 
POSITION TITLE 
Professor and Director of the UNL Biological Process 
Development Facility 
EDUCATION/TRAINING  (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.) 
INSTITUTION AND LOCATION DEGREE 
(if applicable) 
YEAR(s) FIELD OF STUDY 
Colorado State University, Fort Collins, CO B.S. 1981 Engineering Science 
Iowa State University, Ames, IA M.S. 1984 Chemical Engineering 
Iowa State University, Ames, IA Ph.D. 1987 Chemical Engineering 
 
C. POSITIONS AND HONORS 
 
Positions and Employment 
1981–1987 Graduate Research Assistant, Iowa State University 
1987–1989 Senior Scientist/Biochemical Engineer, Hoffmann-LaRoche 
1989–1995 Assistant Professor, University of Nebraska-Lincoln 
1995–2003 Associate Professor, University of Nebraska-Lincoln 
2003–present Professor, Donald and Mildred Othmer Endowed Chair, University of Nebraska-Lincoln 
 
Other Experience and Professional Memberships 
Member, American Institute of Chemical Engineering and American Chemical Society 
 
D. SELECTED PEER-REVIEWED PUBLICATIONS (in chronological order)  
V. Chiruvolu, J. M. Cregg, and M. M. Meagher. Recombinant Protein Production in an Alcohol Oxidase-
defective Strain of Pichia pastoris in Fed-batch Fermentations.  Enzyme Microbiol. Technol. 21:277-283, 
1997. 
V. Chiruvolu, K. Eskridge, J. Cregg, and M. Meagher. Effects of Glycerol Concentration and pH on Growth of 
Recombinant Pichia pastoris Yeast.  Appl. Biochem. Biotechnol.  75:163-173, 1998. 
K.J. Potter, M. A. Bevins, E. V. Vassilieva, V. J. Chiruvolu, T. Smith, L. A. Smith, M. M. Meagher.  Production 
and Purification of the Heavy-chain Fragment C of Botulinum Neurotoxin, Serotype B, Expressed in the 
Methylotropic Yeast  Pichia pastoris.  Protein Express. Purif. 13:357-365, 1998. 
K.J. Potter, W. Zhang, L.A. Smith, and M.M. Meagher.  Production and Purification of the Heavy Chain 
Fragment C of Botulinum Neurotoxin, Serotype A, Expressed in the Methylotropic Yeast Pichia pastoris. 
Protein Express. Purif. 19:393-402, 2000. 
W. Zhang, M.A. Bevins, B.A. Plantz, L.A. Smith, and M.M. Meagher. Modeling Pichia pastoris Growth on 
Methanol and Optimizing the Production of a Recombinant Protein, the Heavy-Chain Fragment C of 
Botulinum Neurotoxin, Serotype A. Biotechnol. Bioeng. 70(1):1-8, 2000. 
W. Zhang, M. Inan and M. M. Meagher. Fermentation Strategies for Recombinant Protein Expression in the 
Methylotrophic Yeast Pichia pastoris. Biotechnol. Bioprocess Eng. 5(4):275-287, 2000. 
M. Inan and M. Meagher. Non-Repressing Carbon Sources for Alcohol Oxidase (AOX1) Promoter of Pichia 
pastoris.  J. Biosci. Bioeng. 92:585-589, 2001. 
M. Inan and M. Meagher. The Effect of Ethanol and Acetate on Protein Expression in Pichia pastoris.  J. 
Biosci. Bioeng. 92:337-341, 2001. 
W. Zhang, L. A. Smith, B. A. Plantz, V. L. Schlegel, and M. Meagher. Design of Methanol Feed Control in 
Pichia pastoris Fermentation Based Upon a Growth Model. Biotechnol. Prog. 18(6):1392-1399, 2002.  
B. A. Plantz, J. Andersen, L. A. Smith, M. M. Meagher, V. L. Schlegel.  Detection of Non-Host Viable  
Contaminants in Pichia pastoris Cultures and Fermentation Broths.  J. Indust. Microbiol. Biotechnol.  
30(11):643-650, 2003. 
h Principal Investigator/Program Director (Last, first, middle): Velander, William H. 
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S. K. Johnson, W. Zhang, L. A. Smith, K. J. Hywood-Potter, T. S. Swanson, V. L. Schlegel, M. Meagher.  
Scale-up of the Fermentation and Purification of the Recombinant Heavy Chain Fragment C of Botulinum 
Neurotoxin Serotype F Expressed in Pichia pastoris.  Protein Express. Purif.  32(1):1-9, 2003. 
W. Zhang, K. J. Hywood Potter, B. A. Plantz, V. L. Schlegel, L. A. Smith, M. Meagher. Pichia pastoris 
Fermentation with Mixed-Feeds of Glycerol and Methanol: Growth Kinetics and Production Improvement.    
J. Industr.. Microbiol. Biotechnol.  30(4):210-215, 2003.  
J. Sinha, B. A. Plantz, W. Zhang, M. Gouthro, V.  L. Schlegel, C.-P. Liu, M. Meagher. Improved Production of 
Recombinant Ovine Interferon-τ by Mut+ Strain of Pichia pastoris Using an Optimized Methanol Feed 
Profile. Biotechnol. Prog. 19(3):794-802, 2003. 
 
C. RESEARCH SUPPORT 
Ongoing Research Support 
U01-AI056514-01         09/02/03 – 09/01/07 
NIH 
Fast Track Development of a Heptavalent Vaccine Against the Botulinum Neurotoxin 
Overall project goal:  The goal of this project is to complete all aspects of process development for a 
recombinant vaccine against the botulinum neurotoxin. This includes molecular biology, fermentation, 
purification, analytical methods development, and technology transfer for cGMP production of serotypes C, D, 
E, F, and G of the botulinum neurotoxin. 
Role: Co-PI 
 
DAMD17-02-1-0659         03/15/02-03/14/05 
UAMRMC 
Process Research and Development of Antibodies as Countermeasures for C. botulinum 
Overall Project Goal:  The goal of this project is to express and optimize expression in CHO cells of human 
antibodies against the the botulinum neurotoxin.  The goal of the this project is to fill out laboratory space on 
third floor of Othmer Hall, new home for the UNL Biological Process Development Facility 
Role: PI 
 
DAMD17-02-C-0107         01/01/02 – 01/01/05 
USAMRMC           
Process Research and Development for Therapeutic Agents and Vaccines as Countermeasures Against 
Biological Warfare Agents 
Overall project goal: The goal of this project is the research and development of processes to produce 
vaccines and therapeutic agents against biological threats. The Army needs countermeasures to protect 
combat and non-combat personnel against biological threats.  
Role: PI 
 
Completed Research Support 
DAMD17-98-C8034        01/01/98 – 12/30/01 
USAMRMC 
Fermentation Process Development for the Production of the Hc Fragment of the Botulinum Neurotoxin  
Serotype A      
Overall project goal: This is part of the project “Fermentation, Recovery, and Purification of the Hc Fragment of 
the Botulinum Neurotoxin from Pichia pastoris” contracted with USAMRMC. The goal is to develop a workable 
and scalable fermentation and purification process research and development of botulinum vaccine 
candidates. 
Role: PI  
 
 
 
Principal Investigator/Program Director (Last, first, middle): Velander, William H.  
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BIOGRAPHICAL SKETCH 
Provide the following information for the key personnel in the order listed for Form Page 2. 
Follow the sample format on preceding page for each person. DO NOT EXCEED FOUR PAGES. 
 
NAME 
Paul E. Monahan, M.D. 
POSITION TITLE 
Assistant Professor, Pediatric Hematology/Oncology 
EDUCATION/TRAINING  (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.) 
INSTITUTION AND LOCATION DEGREE 
(if applicable) 
YEAR(s) FIELD OF STUDY 
Princeton University, Princeton, NJ B.A. 1986 English 
University of Virginia School of Medicine, 
Charlottesville, VA 
M.D. 1990 Medicine 
University of North Carolina, Chapel Hill, NC Internship/ 
Residency 
1990-1993 Pediatrics 
University of North Carolina, Chapel Hill, NC Fellow 1993-1998 Pediatric Hematology 
and Oncology 
University of North Carolina School of Medicine Post-doc 1994-1998 Adeno-associated virus 
(AAV) delivery of factor 
IX gene therapy 
National Hemophilia Foundation Postgraduate 
Research 
Fellow 
1998-2000 AAV factor IX gene 
delivery to muscle 
 
A. POSITIONS AND HONORS  
Positions and Employment 
1981-1982 Nursing Assistant, General Medicine and Post-anesthesia Care units, Winchester Medical Center, 
Winchester, VA  
1982-1983 Psychiatric Technician, Winchester Medical Center, Winchester, VA 
1998-2000  Research Assistant Professor, Department of Pediatrics, Division of Hematology/Oncology, 
University of North Carolina, Chapel Hill, NC 
2001-present Assistant Professor, Department of Pediatrics, Division of Hematology/Oncology, 
Attending Physician, Comprehensive Hemophilia Diagnostic and Treatment Center,       
University of North Carolina, Chapel Hill, NC 
 
Other Experience and Professional Memberships 
1997-present American Society of Hematology: Member 
1998-present Children's Oncology Group: Member 
1999-present International Society of Thrombosis and Hemostasis: Member 
1999-present Hemophilia Research Society: Member 
2001-present American Society of Gene Therapy: Member 
1994-2000 American Academy of Pediatrics: Member 
2003-present Editorial Board, Hematology Section, The Annals of Pharmacotherapy 
Specialty Certification 
October 1995  American Board of Pediatrics: Board Certified in General Pediatrics 
November 1996;  
Renewed July 2002 American Board of Pediatrics: Board Certified in Pediatric Hematology and Oncology 
Medical Licensure 
1996-present North Carolina Medical Board 
 
Principal Investigator/Program Director (Last, first, middle): Velander, William H.  
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Honors 
July 1996-1998 NIH NIDDK Individual National Research Service Award (NRSA), Packaging Cell Lines 
for Adeno-associated Virus Vectors. Mentor: R. Jude Samulski, Ph.D. 
July 1998-July 2000 National Hemophilia Foundation Judith Graham Pool Postgraduate Research Fellowship 
Award, AAV Hemophilia Gene Therapy Vectors 
 
B. SELECTED PEER-REVIEWED PUBLICATIONS (in chronological order) 
J. R. Kerrigan, P. M. Martha Jr., R. J. Krieg Jr., T. A.Queen, P. E. Monahan, and A. D. Rogol.  Augmented 
Hypothalamic Proopiomelanocortin Gene Expression with Pubertal Development in the Male Rat: 
Evidence for an Androgen Receptor-Independent Action.  Endocrinology, 128:1029-103, 1991. 
P. E. Monahan, R. J. Samulski, J. Tazelaar, X. Xiao, T. C. Nichols, D. A. Bellinger, M. S. Read, and C. E. 
Walsh. Direct Intramuscular Injection with Recombinant AAV Vectors Results in Sustained Expression in a 
Dog Model of Hemophilia. Gene Therapy, 5(1):40-49, 1998. 
H. J. Chao, R. J. Samulski, D. Bellinger, P. E. Monahan, T. Nichols, and C. E. Walsh. Persistent Expression of 
Canine Factor IX in Hemophilia B Canines. Gene Therapy, 6(10):1695-1704, 1999. 
A. K. Malik, P. E. Monahan, D. L. Allen, B-G Chen, R. J. Samulski, and K. Kurachi. Kinetics of Recombinant 
Adeno-associated Virus (AAV)-mediated Gene Transfer.  J Virology, 74(8):3555-3565, 2000. 
P. E. Monahan and R. J. Samulski. AAV Vectors: Is Clinical Success on the Horizon? Gene Therapy, 7(1): 24-
30, 2000. 
P. E. Monahan and R. J. Samulski. Adeno-associated Virus Vectors for Gene Therapy: More Pros than Cons? 
Molecular Medicine Today, 6:433-440, 2000. 
J. Blatt, S. H. Gold, J. M. Wiley, P. E. Monahan, H. C. Cooper, and D. Harvey. Off-label Use of Recombinant 
Factor VIIa in Patients Following Bone Marrow Transplantation. Bone Marrow Transplantation, 28(4):405-
407, 2001. 
H. Chao*, P. E. Monahan*, Y. Liu, R. J. Samulski, and C. E. Walsh. Sustained and Complete Phenotype 
Correction of Hemophilia B Mice Following Intramuscular Injection of AAV1 Serotype Vectors. Molecular 
Therapy, 4(3):217-222, 2001. *contributed equally. 
D. M. McCarty, P. E. Monahan, and R. J. Samulski. Self-complementary Adeno-associated Virus (scAAV) 
Vectors Promote Efficient Transduction Independently of DNA Synthesis. Gene Therapy, 8(16):1248-
1253, 2001. 
P. E. Monahan, K. Jooss, and M. S. Sands. Safety of Adeno-associated Virus Gene Therapy Vectors: A 
Current Evaluation. Expert Opinions in Drug Safety, 1(1):79-91, 2002. 
M. Richardson, G. Allen, and P. Monahan. Thromboembolism in Childhood. Current Perspective and Distinct 
Challenges. Thrombosis and Haemostasis, 88(6):900-911, 2002. 
D. M. McCarty, H. Fu, P. E. Monahan, C. E. Toulson, and R. J. Samulski. Adeno-associated Virus Terminal 
Repeat (TR) Mutant Generates Double-strand Vectors to Overcome Rate-limiting Step in Transduction in 
Vivo. Gene Therapy, 10:2112-2118, 2003. 
M. G. Douvas and P. E.  Monahan. Life-threatening Thrombosis Complicating the Management of Hepatic 
Hemorrhage: Anticoagulant Treatment in a Newborn with Hemophilia B. Journal of Pediatric 
Hematology/Oncology, 2004 (In press). 
 
C. RESEARCH SUPPORT 
 
Ongoing Research Support 
P01-HL66973       09/01/2000 – 07/31/2004 
Factor IX Mouse Models for Hemophilia B Gene Therapy 
NIH/NHLBI 
Overall project goal: This work generates several strains of mice expressing human factor IX molecules, for 
investigation of the role of human factor IX/collagen interaction in hemostasis and to serve as models for factor IX 
gene therapy safety and efficacy studies. 
Role: Co-Investigator 
 
Principal Investigator/Program Director (Last, first, middle): Velander, William H.  
 PHS 398/2590 (Rev. 05/01) Page ___59____ Biographical Sketch Format Page  
Number pages consecutively at the bottom throughout the application. Do not use suffixes such as 3a, 3b. 
        07/03-(renewable thru 2006) 
Double-stranded Adeno-associated Virus (AAV) Vectors to Improve Efficacy and to Evaluate Safety of Factor IX 
Gene Therapy  
National Hemophilia Foundation, Career Development Award 
Overall project goal: This study investigates the potential of double-stranded AAV vectors to achieve tolerance of 
factor IX and therapeutic expression in the context of liver-targeted gene therapy. 
Role: PI 
 
        07/03-(renewable thru 2008) 
Overcoming Limited Clotting Factor Gene Transfer to the Liver Using Adeno-associated Virus (AAV) Vectors 
Presenting a More Active Molecular Form 
Hemophilia of Georgia Clinical Scientist Development Grant 
Overall project goal: This study investigates the use of self-complementary vector sequences to result in early 
and widespread liver transduction in available animal models of hemophilia B. 
Role: PI 
 
Completed Research Support (Recent) 
K08 HL03960       02/99-11/03   
AAV-Directed Muscle Gene Therapy for Hemophilia B 
NIH/NHLBI Mentored Clinical Scientist Development Award 
Overall project goal: This study investigated AAV-directed expression of factor IX in the muscle, examining rate-
limiting factors in the kinetics of expression of factor IX from this tissue.  
Role: PI (Sponsor: R. Jude Samulski, PhD. Co-sponsor: Gilbert White, II, MD) 
 
 
Principal Investigator/Program Director (Last, first, middle): Velander, William H.  
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BIOGRAPHICAL SKETCH 
Provide the following information for the key personnel in the order listed for Form Page 2. 
Follow the sample format on preceding page for each person. DO NOT EXCEED FOUR PAGES. 
 
NAME 
Timothy C. Nichols, M.D. 
POSITION TITLE 
Professor of Medicine, Pathology and Lab Medicine 
EDUCATION/TRAINING  (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.) 
INSTITUTION AND LOCATION DEGREE 
(if applicable) 
YEAR(s) FIELD OF STUDY 
Stanford University, Stanford, CA B.S. 1974 Biology 
Medical College of Virginia, Richmond, VA M.D. 1978 Medicine 
North Carolina Memorial Hospital Intern, Resident, 
Chief Resident 
1978-1982 Internal Medicine 
North Carolina Memorial Hospital Fellow 1982-1985 Cardiology 
 
A. POSITIONS AND HONORS  
 
Positions and Employment 
1981-1985  Clinical Instructor, Department of Internal Medicine, North Carolina Memorial Hospital 
1985-1986  Instructor in Medicine, Department of Internal Medicine, North Carolina Memorial Hospital 
1986-1993  Assistant Professor of Medicine, North Carolina Memorial Hospital 
1991-1993  Assistant Professor of Pathology, University of North Carolina, Chapel Hill 
1993-1999  Associate Professor of Medicine and Pathology, University of North Carolina, Chapel Hill 
1999-present Professor of Medicine and Pathology, University of North Carolina, Chapel Hill 
 
Other Experience and Professional Memberships (in past 3 years) 
NIH Study Section: NHLBI Program Project Grant Reviewer 2003 
 
Honors 
1974  Graduated with Department Honors in Biology, Stanford University 
1975  Summer Research Award, Richmond Chapter, American Psoriasis Association 
1982  NRSA Training Grant in Experimental Cardiology 
1987 Recipient of Young Investigator Award, International Society for Thrombosis and Hemostasis, XI 
Congress, Brussels 
1988  James W. Woods Faculty Award 
1992-1993 Kenan Fellowship  
 
B. SELECTED PEER-REVIEWED PUBLICATIONS (in chronological order, selected from 52)  
T. C. Nichols, J. Roussi, D. A. Bellinger, C. M. Samama, R. L. Reddick, M. Bonneau, M. S. Read, O. Bailliart, G. 
G. Koch, M. Vaiman, J. L. Sigman, G. A. Pignaud, K. M. Brinkhous, T. R. Griggs and L. Drouet. Function of von 
Willebrand Factor After Crossed Bone Marrow Transplantation Between Normal and von Willebrand Disease 
Pigs: Effect on Arterial Thrombosis in Chimeras, Proc. Natl. Acad. Sci. USA, 92:2455-2459, 1995. 
M. S. Read, R. L. Reddick, A. P. Bode, D. A. Bellinger, T. C. Nichols, K. Taylor, S. V. Smith, D. K. McMahon, T. 
R. Griggs and K. M. Brinkhous. Preservation of Hemostatic and Structural Properties of Rehydrated Lyophilized 
Platelets: Potential for Long-term Storage of Dried Platelets for Transfusion, Proc. Natl. Acad. Sci. USA, 
92:391-401, 1995.  
P. E. Monahan, J. Tazelaar, T. C. Nichols, D. A. Bellinger, M. S. Read, C. E. Walsh and R. J. Samulski. 
Sustained Expression of Human Factor IX in a Hemophilia B Canine Following Intramuscular Recombinant 
AAV Gene Transfer, Human Gene Therapy, 5:40-49 1998. 
H. Chao, R. Samulski, D. Bellinger, P. Monahan, T. C. Nichols and C. Walsh. Persistent Expression of Canine 
Factor IX in Hemophilia B Canines, Gene Ther, 6:1695-704, 1999. 
R. W. Herzog, E. Y. Yang, L. B. Couto, J. N. Hagstrom, D. Elwell, P. A. Fields, M. Burton, D. A. Bellinger, M. S. 
Read, K. M. Brinkhous, G. M. Podsakoff, T. C. Nichols, G. J. Kurtzman and K. A. High, Long-term Correction 
Principal Investigator/Program Director (Last, first, middle): Velander, William H.  
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of Canine Hemophilia B by Gene Transfer of Blood Coagulation Factor IX Mediated by Adeno-Associated Viral 
Vector, Nature Medicine, 5:56-63, 1999. 
R. O. Snyder, C. Miao, L. Meuse, B. A. Donahue, H-F Lin, D. W. Stafford, S. Patel, A. Thompson, T. C. Nichols, 
D. Bellinger, M. Read, K. M. Brinkhous and M. A. Kay. Correction of the Bleeding Disorder in Canine and 
Murine Models of Hemophilia B Using Recombinant Adeno-Associated Viral Vectors, Nature Medicine, 5:64-70, 
1999. 
R. Herzog, V.R. Arruda, T.H. Fischer, M.S. Read, T.C. Nichols and K.A. High. Absence of Circulating Factor IX 
Antigen in Hemophilia B Dogs of the UNC-Chapel Hill Colony, Thromb Haemost, 84:352-354, 2000. 
L. Wang, T. C. Nichols, M .S. Read, D. A. Bellinger and I. M. Verma. Sustained Expression of Therapeutic Level 
of Factor IX in Hemohilia B Dogs by AAV-Mediated Gene Therapy in Liver, Molecular Therapy, 1:154-158, 
2000. 
V. R. Arruda, P. A. Fields, R. Milner, L. Wainwright, P. De Miguel, P. J. Donavan, R. W. Herzog, T. C. Nichols, J. 
A. Biegel, M. Razavi, M. Dake, D. Huff, A. W. Flake, L. Couto, M. Kay and K. A. High. Lack of Germline 
Transmission of Vector Sequences Following Systemic Administration of Recombinant AAV-2 Vectors in 
Males, Molecular Therapy, 4:586-592, 2001. 
K. E. Russell, M. S. Read, D. A. Bellinger, K. Leitermann, B. J. Rup, K. P. McCarthy, J. C. Keith, R. G. Schaub, S. 
P. Khor and T. C. Nichols. Intratracheal Administration of Recombinant Human Factor IX (Benefixtm) Achieves 
Therapeutic Levels in Hemophilia B Dogs, Thromb Haemost, 85:445-9, 2001. 
K. M. Brinkhous, H. Sandberg, L. Widlund, M. Read, T. Nichols, J. Sigman, U. Oswaldsson, R. G. Schaub and M. 
Mikaelsson. Preclinical Pharmacology of Albumin-Free B-Domain Deleted Recombinant Factor VIII, Seminars 
in Thromb and Haemost, 28:269-272, 2002. 
R. W. Herzog, P. A. Fields, V. R. Arruda, J. Brewbaker, E. Armstrong, D. McClintock, D. A. Bellinger, L. B. Couto, 
T. C. Nichols and K. A. High. Influence of Vector Dose on Factor IX-Specific T and B Cell Responses in 
Muscle-Directed Gene Therapy for Canine Hemophilia B, Human Gene Therapy, 13:1281-1291, 2002. 
J. N. Lozier, A. Dutra, E. Pak, N. Zhou, Z. Zheng, T. C. Nichols, D. A. Bellinger, M. Read and R. A. Morgan. The 
Chapel Hill Hemophilia: A Dog Colony Exhibits a Factor VIII Gene Inversion, Proc Natl Acad Sci, 99:12991-
12996, 2002. 
J. D. Mount, R. W. Herzog, D. M. Tillson, S. A. Goodman, N. Robinson, M. L. McCleland, D. A. Bellinger, T. C. 
Nichols, V. R. Arruda, C. D. Lothrop Jr. and K .A. High. Sustained Phenotypic Correction of Hemophilia B 
Dogs with a Factor IX Null Mutation by Liver-Directed Gene Therapy, Blood, 99:2670-2676, 2002. 
E. H. N. Olsen, A. S. McCain, E. P. Merricks, T. H. Fischer, I. M. Dillon, R. A. Raymer, D. A. Bellinger, S. A. Fahs, 
R. R. Montgomery, J. C. Keith Jr, R. G. Schaub and T. C. Nichols. Comparative Response of Plasma VWF in 
Dogs to Up-Regulation of VWF Mrna by Interleukin-11 Versus Weibel-Palade Body Release by Desmopressin 
(DDAVP), Blood, 102:436-441, 2003. 
L. Xu, C. Gao, M. S. Sands, S. R. Cai, T. C. Nichols, D. A. Bellinger, R. A. Raymer, S. McCorquodale and K. P. 
Ponder. Neonatal or Hepatocyte Growth Factor-Potentiated Adult Gene Therapy with a Retroviral Vector 
Results in Therapeutic Levels of Canine Factor IX for Hemophilia B, Blood, 101:3924-3932, 2003. 
A. Ehrhardt, H. Xu, A. M. Dillow, D. A. Bellinger, T. C. Nichols and M. A. Kay. A Gene Deleted Adenoviral Vector 
Results in Phenotypic Correction of Canine Hemophilia B without Liver Toxicity or Thrombocytopenia, Blood, 
102:2403-11, 2003. 
K. E. Russell, E. H. N. Olsen, R. A. Raymer, E. P. Merricks, D. A. Bellinger, M. S. Read, B. J. Rup, J. C. Keith Jr, 
K. P. McCarthy, R. G. Schaub and T. C. Nichols. Reduced Bleeding Events with Subcutaneous Administration 
of Recombinant Human Factor IX (Benefixtm) in Immune Tolerant Hemophilia B Dogs, Blood, 102:4393-4398, 
2003 
 
C. RESEARCH SUPPORT 
Ongoing Research Support 
2 R24-HL63098 05 (Nichols TC) 07/01/03-06/30/08  
NIH/NHLBI 
Maintenance of Animal Models of Human Hemophilia and vWD 
Overall project goal: Production and maintenance of the hemophilic and von Willebrand disease animals for 
performing collaborative research studies. 
Role: PI 
 
R01 HL69364 (Clemmons DR) 09/30/01-08/31/06 
NIH/NHLBI 
Atherosclerosis in Insulin-Resistant, Hyperlipidemic Pigs 
Principal Investigator/Program Director (Last, first, middle): Velander, William H.  
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Overall project goal: Development and characterization of insulin resistant atherosclerotic pigs. 
Role: Co-PI 
 
P01 HL66973-01A1 (Samulski RJ) 09/30/01-07/31/06 
NIH/NHLBL 
Gene Therapy Pulmonary & Hematologic Disorders 
Overall project goal: Studies to optimize gene therapy of hemophilia. 
Role: Co-Investigator on sub-project. 
 
R01 (Ponder K, Washington Univ) 02/01/02 – 01/31/06 
NIH/NHLBI  
Gene Therapy Blood Protein Deficiencies 
Overall project goal: Studies of gene therapy for blood protein deficiencies. 
Role: PI on subcontract at UNC 
 
PPG (Steer C, Univ of Minnesota) 09/14/01-06/30/05 
NIH/NHLBI  
Chimeroplasty for Factor IX and VIII Gene Expression 
Overall project goal: Studies of chimeroplasty for Factor IX and VIII gene expression. 
Role: PI for subcontract at UNC 
 
P01-HL64190 (High K, Univ. of Penn.) (Nichols, T.C.) 12/01/99-11/30/04 
NIH/NHLBI  
Gene Therapy for Hemophilia 
Overall project goal: Studies to optimize gene therapy of hemophilia utilizing muscle and liver as target organs; 
emphasis is placed on the immune response of the host. 
Role: PI on subcontract at UNC 
 
P-60-DE13079 (Flood P)  08/01/99-07/30/04  
NIH/NIDCR  
Activation of NF-kappa B and Oral Inflammation in Atherogenesis 
Overall project goal: Studies focused on activation of NF-kappa B and oral inflammation in atherogenesis. 
Role: PI for Project 4 
 
U01DE13940 (Offenbacher S) 07/15/01-07/14/04 
NIH 
A Periodontal Program to Prevent Cardiovascular Events  
Overall project goal: A pilot clinical trial to determine the role of periodontitis on cardiovascular events. 
Role: Co –PI 
 
Completed Research Support (past 3 years)  
1R01 HL52706-01A2 (Lord, Susan)   04/01/98 - 03/31/03 
NIH/NHLBI  
Fibrinogen As A Determinant In Cardiovascular Disease 
Overall project goal: Studies focused on the role of fibrinogen in atherogenesis using a newly created 
hyperfibrinogenemic mouse. 
Role: Co-Investigator 
 
R01-HL61921 (Katherine High, Univ. of Penn) (Nichols, T.C.) 09/30/98 – 09/29/02 
NIH/NHLBI  
Inhibitor Formation in Gene Therapy for Hemophilia 
Overall project goal: Studies on the mechanisms of inhibitor formation during gene therapy for hemophilia. 
Role: PI on subcontract at UNC and director of gene therapy studies in hemophilic dogs. 
 
P50-HL54500 (Bennett/ High, Univ. of Penn.)(Nichols, T.C.)  06/01/97–01/31/02 
NIH/NHLBI  
Intramuscular Injection of AAV-F.IX to Treat Canine Hemophilia B 
Principal Investigator/Program Director (Last, first, middle): Velander, William H.  
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Overall project goal: Studies to optimize safety and efficacy of skeletal muscle based gene therapy for  hemophilia 
Role: PI on subcontract at UNC and director of gene therapy studies in hemophilic dogs 
 
ONR  N00014-97-1-0891  (Read, M.S.)   06/14/97 - 05/31/01 
Office of Naval Research  
Studies to Evaluate Efficacy and Safety of Infusable Rehydrated Platelets in Animal Models 
Overall project goal: Studies to evaluate efficacy and safety of infusable rehydrated platelets. 
Role: Co-Investigator  
 
ONR  N00014-97-1-0867 (Read, M.S.)   06/14/97 - 04/30/01 
Office of Naval Research  
Lyophilized Red Blood Cells and Platelets: Preservation of Oxygen Delivery Capabilities of RBCs and Hemostatic  
Properties of Platelets  
Overall project goal: Studies of preservation of oxygen delivery capabilities of RBCs and hemostatic  properties of 
rehydrated platelets. 
Role: Co-Investigator 
 
                                                                         Principal Investigator/Program Director (Last, first, middle):   Velander, William H.       
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BIOGRAPHICAL SKETCH 
Provide the following information for the key personnel in the order listed for Form Page 2. 
Follow the sample format for each person. DO NOT EXCEED FOUR PAGES. 
 
NAME 
S. Todd Swanson, Ph.D. 
POSITION TITLE 
Research Assistant Professor 
Department of Chemical Engineering 
EDUCATION/TRAINING  (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.) 
INSTITUTION AND LOCATION DEGREE 
(if applicable) 
YEAR(s) FIELD OF STUDY 
Lewis and Clark College, Portland, OR B.S. (w/honors) 1985 Chemistry 
University of California, San Diego M.S. 1992 Chemistry 
University of California, San Diego Ph.D. 1993 Chemistry 
 
A. POSITIONS AND HONORS 
 
Positions and Employment 
1986-1987 Quality Control Chemist, Hall Laboratories, Portland, Oregon 
1988-1992 Teaching Assistant, Dept of Chemistry, University of California, San Diego 
1996 Instructor, Dept of Biochemistry, University of Nebraska-Lincoln 
1993-1997 Post-doctoral Researcher, University of Nebraska-Lincoln 
1997-2000 Chilton Foundation Fellow, U.T. Southwestern Medical Center at Dallas (TX) 
2000-2002 Supervisor, Analytical Development Laboratory, University of Nebraska-Lincoln 
2002-present Research Assistant Professor, Dept of Chemical Engineering, University of Nebraska-Lincoln 
 
B. SELECTED PEER-REVIEWED PUBLICATIONS (in chronological order) 
S. T. Swanson and D. Roise. Protein Import into Mitochondria. Biophysical Journal, 57(2):A198, part 2, 1990. 
S. T. Swanson and D. Roise. Binding of a Mitochondrial Presequence to Natural and Artificial Membranes: 
Role of the Surface Potential. Biochemistry, 31:5746-5751, 1992. 
S. T. Swanson, H. Fang, and M. H. O’Leary. Are All Ribulose 1,5-bisphosphate carboxylase/oxygenases the 
Same?” FASEB Journal, 9(6):A1481, 1995. 
S. Madhavan, S. T. Swanson, T. M. Blackmer, T. S. Pinkerton, and M. H. O’Leary, M. H. Relationship 
between Nitrogen Nutrition and Photosynthetic Carbon Isotope Fractionation in Corn. Plant Physiology, 
111(2):336, Supplement S, 1996. 
T. Swanson, H.B. Brooks, A. L. Osterman, M. H. O’Leary, and M. A. Phillips. Carbon-13 Isotope Effect Studies 
of Trypanosoma brucei Ornithine Decarboxylase. Biochemistry, 37:14943-14947, 1998.  
S. T. Swanson, D. W. Foster, J. D. McGarry, and N. F. Brown. Roles of the N- and C-terminal Domains of 
Carnitine Palmitoyltransferase I Isoforms in Malonyl-CoA Sensitivity of the Enzymes: Insights from 
Expression of Chimaeric Proteins and Mutation of Conserved Histidine Residues. Biochemical Journal, 
335:513-519, 1998. 
S. T. Swanson, J. Rudzinski, P. Paneth, and M. H. O’Leary. Carbon and Chlorine Kinetic Isotope Effects and 
Solvent Effects on the Hydrolysis of Chloroformates. Polish Journal of Chemistry, 76:1721–1731, 2002. 
J. J. Robinson, K. M. Scott, S. T. Swanson, M. H. O’Leary, K. Horken, F. R. Tabita, and C. M. Cavanaugh. 
Kinetic Isotope Effect and Characterization of Form II RubisCO from the Chemoautotrophic 
Endosymbionts of the Hydrothermal Vent Tubeworm, Riftia pachyptila. Limnology and Oceanography 
48(1):48-54, 2003. 
S. K. Johnson, W. Zhang, L. A. Smith, K. J. Hywood-Potter, S. T. Swanson, V. L. Schlegel, and M. M. 
Meagher. Scale up of the Fermentation and Purification of the Recombinant Heavy Chain C of Botulism 
nNurotoxin Serotype F, Expressed in Pichia pastoris. Protein Expression and Purification, 32(1):1-9, 2003. 
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C. RESEARCH SUPPORT 
 
Ongoing Research Support 
U01-AI056514-01         09/02/03 – 09/01/07 
NIH 
Fast Track Development of a Heptavalent Vaccine Against the Botulinum Neurotoxin 
Overall project goal:  The goal of this project is to complete all aspects of process development for a 
recombinant vaccine against the botulinum neurotoxin. This includes molecular biology, fermentation, 
purification, analytical methods development, and technology transfer for cGMP production of serotypes C, D, 
E, F, and G of the botulinum neurotoxin. 
Role: Co-PI: Manage Quality Control Laboratory and manage Analytical Methods Laboratory. 
 
DAMD17-02-1-0659         03/15/02-03/14/05 
UAMRMC 
Process Research and Development of Antibodies as Countermeasures for C. botulinum 
Overall Project Goal:  The goal of this project is to express and optimize expression in CHO cells of human 
antibodies against the the botulinum neurotoxin.  The goal of the this project is to fill out laboratory space on 
third floor of Othmer Hall, new home for the UNL Biological Process Development Facility 
Role: Key Person:  Provide analytical and quality control support for cell culture experiments. 
 
DAMD17-02-C-0107         01/01/02 – 01/01/05 
USAMRMC           
Process Research and Development for Therapeutic Agents and Vaccines as Countermeasures Against 
Biological Warfare Agents 
Overall project goal: The goal of this project is the research and development of processes to produce 
vaccines and therapeutic agents against biological threats. The Army needs countermeasures to protect 
combat and non-combat personnel against biological threats.  
Role: Key Person:  Provide analytical methods development and quality control for process development. 
 
 
Completed Research Support 
DAMD17-98-C8034        01/01/98 – 12/30/01 
USAMRMC 
Fermentation Process Development for the Production of the Hc Fragment of the Botulinum Neurotoxin  
Serotype A      
Overall project goal: This is part of the project “Fermentation, Recovery, and Purification of the Hc Fragment of 
the Botulinum Neurotoxin from Pichia pastoris” contracted with USAMRMC. The goal is to develop a workable 
and scalable fermentation and purification process research and development of botulinum vaccine 
candidates. 
Role: Key Person:  Quality control and analysis of in-process samples.  
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BIOGRAPHICAL SKETCH 
Provide the following information for the key personnel in the order listed for Form Page 2. 
Follow the sample format on preceding page for each person. DO NOT EXCEED FOUR PAGES. 
 
NAME 
Kevin E. Van Cott, Ph.D. 
POSITION TITLE 
Assistant Professor, Department of Chemical 
Engineering 
EDUCATION/TRAINING  (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.) 
INSTITUTION AND LOCATION DEGREE 
(if applicable) 
YEAR(s) FIELD OF STUDY 
Purdue University B.S. 1991 Chemical Engineering 
Virginia Technological Institute Ph.D. 1996 Chemical Engineering 
Virginia Technological Institute Post-doc 1996 Chemical Engineering 
 
A. POSITIONS AND HONORS  
 
Positions and Employment 
1991 Exxon Production Research, Houston, TX (engineering internship) 
1996-1998   Research Scientist, F&S Inc., Blacksburg, VA (now Luna Innovations Inc.) 
1998-present Assistant Professor, Virginia Technological Institute 
 
Other Experience and Professional Memberships 
ProGenetics LLC (Blacksburg, VA) Animal Care Committee; Founding member of the Center for Self-
Assembled Nanostructures and Devices at Virginia Tech; Faculty Advisor: Omega Chi Epsilon (Chemical 
Engineering Honor Society); Undergraduate Curriculum Committee, Department of Chemical Engineering; 
Referee:  Journal of Dairy Science, Biotechnology Progress, Sensors and Materials, Biotechnology and 
Bioengineering 
 
Honors 
1996 Paul Torgersen Excellence in Research Award – 1st Place for best Ph.D. Dissertation in the College of 
Engineering at Virginia Tech 
 
B. SELECTED PEER-REVIEWED PUBLICATIONS (in chronological order)
K. E. Van Cott, R. D. Whitley, N. H. L. Wang. Effects of Temperature and Flow Rate on Frontal and Elution 
Chromatography of Aggregating Systems. Separations Technology, 1:142-152, 1991. 
R. D. Whitley, K. E. Van Cott, J. A. Berninger, N. H. L. Wang. Effects of Protein Aggregation in Isocratic 
Nonlinear Chromatography. AIChE J., 37(4):555-568, 1991. 
R. D. Whitley, K. E. Van Cott, N. H. L. Wang. Analysis of Non-equilibrium Adsorption/Desorption Kinetics and 
Implications for Analytical and Preparative Chromatography.  Ind. Eng. Chem. Res., 32:149-159, 1993. 
A. Subramanian, K. E. Van Cott, D. S. Milbrath, W. H. Velander. Role of Local Antibody Density Effects on 
Immunosorbent Efficiency. Journal of Chromatography, 672:11-24, 1994. 
S. P. Butler, K. Van Cott, A. Subramanian, F. C. Gwazdauskas, W. H. Velander. Current Progress in the 
Production of Recombinant Human Fibrinogen in the Milk of Transgenic Animals. Thrombosis and 
Haemostasis, 78(1):537-542, 1997. 
K. E. Van Cott,  H. Lubon, C. G. Russell, S. P. Butler,  F. C. Gwazdauskas, J. Knight, W. N. Drohan,  W. H. 
Velander. Phenotypic and Genotypic Stability of Multiple Lines of Transgenic Pigs Expressing of 
Recombinant Human Protein C. Transgenic Research, 6:203-212, 1997. 
K. E. Van Cott, B. L. Williams, F. C. Gwazdauskas, H. Lubon,  T. Lee,  W. N. Drohan, W. H. Velander. Affinity 
Purification of Biologically Active  and Inactive Forms of Recombinant Human Protein C Produced in the 
Porcine Mammary Gland. Journal of Molecular Recognition, 9:407-414, 1997. 
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C. RESEARCH SUPPORT 
 
Ongoing Research Support 
ARM-2T-1026/488-VT        08/18/03-08/17/05 
DOD-STTR Phase II   
Fluorescent, Polymerized, Affinity Liposomes for the Detection of Bacterial Toxins 
Overall project goal: Produce, purify, and characterize stable liposomes that can be used for new specific and 
sensitive assays for bacterial toxins (cholera toxin, anthrax lethal factor).   
Role: PI 
 
ARM-2T-1027/489-VT        08/18/03-08/17/05 
DOD-STTR Phase II 
Viability Assays for Monitoring Decontamination of Pathogenic Bacteria 
Overall project goal: Determine how new decontamination agents the U.S. Army is developing affects bacterial 
toxin structure and function. 
Role: PI 
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Completed Research Support 
ARM-1S-1026/286-VT        09/15/02- 01/15/03 
DOD-STTR Phase I   
Fluorescent, Polymerized, Affinity Liposomes for the Detection of Bacterial Toxins 
Overall project goal: Produce, purify, and characterize stable liposomes that can be used for new specific and 
sensitive assays for bacterial toxins (cholera toxin, anthrax lethal factor). 
Role: PI 
 
BES-0086876          09/1/00-08/31/02 
NSF 
Monodisperse Block Copolymers for Environmentally-Friendly Processing of Aqueous Metal Oxide 
Suspensions 
Overall project goal: Develop new cloning strategies to produce synthetic protein polymers.  
Role: Co-PI 
 
NSF-2T-7002          11/15/01-07/15/02 
NSF-STTR Phase I   
Optic Fiber Sensors for the Detection of Pathogenic Microorganisms 
Overall project goal: Determine if Long Period Grating fiber optics can be used to detect the presence of 
pathogenic bacteria or bacterial toxins. 
Role: PI 
 
BES-0103037          06/15/01-05/31/02 
NSF 
Detecting Specific Biomolecule Adsoprtion in Ionically Self-assembled Monolayers via Second Harmonic 
Generation 
Overall project goal: Exploratory grant to see if second harmonic generation can be used to specifically detect 
the adsorption of a biomolecule (protein or DNA) to a surface.   
Role: Co-PI 
 
ECS-9907747          09/01/99-08/31/01 
NSF 
Supramolecular Self-assembly of Second Order Nonlinear Optical Materials for Electro-optic Devices 
Overall project goal: Design new materials and strategies for making nonlinear optical materials (materials that 
have a high degree of polar ordering of the constituents. 
Role: Co-PI 
 
NSF (REU Supplement)        07/15/00-03/15/01 
Supramolecular Self-Assembly of Second Order Nonlinear Optical Materials for Electro-optic Devices  
Overall project goal: Undergraduate research project. 
Role: Co-PI 
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 Principal Investigator/Program Director (Last, first, middle): Velander, William H. 
 
RESOURCES 
FACILITIES:  Specify the facilities to be used for the conduct of the proposed research. Indicate the performance sites and describe capacities, 
pertinent capabilities, relative proximity, and extent of availability to the project.  Under “Other,” identify support services such as machine shop, 
electronics shop, and specify the extent to which they will be available to the project.  Use continuation pages if necessary. 
 
William H, Velander, Ph.D., Principal Investigator – University of Nebraska-Lincoln 
 
Laboratory:  
Not Applicable 
 
Clinical:  
Not Applicable 
 
Animal:  
Not Applicable 
 
Computer:  
Dr. Velander has a Sony Viao 1.7 GHz laptop computer with full access to the internet, network color laser 
printer, and the Biological Process Development Facility (BPDF) local area network with access to the Storage 
Area Network.   
 
Office:  
Dr. Velander has a separate, private office, approximately 160 square feet with full access to the Department 
of Chemical Engineering office equipment, fax and copier. In addition, Dr. Velander has full access to the 
BPDF’s computer support staff and systems. 
  
Other:  
Access to fax and scanners for document processing. 
 
 
 MAJOR EQUIPMENT:  List the most important equipment items already available for this project, noting the location and pertinent capabilities of each. 
 
Not Applicable
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Analytical Methods Laboratory – University of Nebraska-Lincoln  
 
Laboratory:  
The Analytical Method Development Laboratory is co-located with the Quality Control Laboratory in a combined 
biochemistry and chemistry laboratory with approximately 900 square feet of space is located in Room 310. The 
room is equipped with an eight-foot chemical fume hood and secured cold storage for short-term samples. In the 
service corridor is secured long-term cold storage for 4 °C, -20 °C, and –80 °C samples. 
 
Clinical: 
Not Applicable  
 
Animal:  
Not Applicable 
 
Computer: 
The laboratory is equipped with several computer systems as listed in the major equipment section below. The 
minimum instrument workstation is a Pentium II with 128 Mb of Ram, a 20 Gb hard drive, NIC, and color monitor 
running a Windows 2000 workstation. Each laboratory has at least two computer workstations that are similarly 
equipped. Of major note is the client/server system for high performance liquid chromatography instrument 
control, data acquisition, data analysis, and data reporting. This system consists of two Waters Lac/e32 
Acquisition servers (Pentium III with 512 Mb Ram and 40 Gb running Windows 2000 workstation SP4 operating 
system) and a Dell PowerEdge 2500 server (1.3 GHz Pentium III, 1 Gb RAM, 4 x 36 Gb Hard drives set up in two 
raid 1 (mirrored) arrays, one for operating and programs system and another for the Empower Oracle database) 
running a Windows 2000 server SP4 operating system. The clients, acquisition servers, and the database server 
run Waters Empower software, version 5.0. The client/server system is accessed by software clients, which are 
installed on several workstations in the laboratory and the computers in Dr. Swanson’s and Analytical Methods 
laboratory personnel offices. The current office computer in service is a Latitude 840C laptop, 2.2 GHz Pentium 
III, 512 Mb RAM, 40 Gb hard drive, CD-R/RW/DVD, interchangeable 250 Mb ZIP drive or 1.44 Mb floppy disk 
drive, two batteries (six hours time on batteries), fax/modem, Ethernet NIC, two USB ports, external mouse, and 
keyboard or equivalent. The computers are pre-loaded with Microsoft Office suite, Waters Millennium 32 software, 
and ancillary software programs. All computers are interconnected via the University of Nebraska LAN system 
and protected from external tampering by a Biological Process Development Facility (BPDF) controlled firewall. 
 
Office: 
A separate, private office, approximately 120 square feet, is available to Dr. Todd Swanson, Manager of both the 
Analytical Methods Laboratory and the Quality Control Laboratory. The technologists will each have a desk area. 
Technicians are provided locker storage for personal items.  
 
Other:  
The Analytical Methods Development Laboratory will request amino acid analysis and amino terminal amino acid 
sequencing from two contract facilities: 1) The Protein Structure Core Facility of the University of Nebraska 
Medical Center in Omaha  is equipped with and is capable of performing cGLP amino terminal amino acid 
sequencing. The equipment includes an Applied Biosystems Procise protein sequencer and an Applied 
Biosystems 477 protein sequencer. 2) AAA Service Laboratory, Boring, OR, uses a Beckman 6300 Amino Acid 
Analyzer for performing cGLP compliant amino acid analysis. We have existing working relationships with both 
facilities. 
 
Mass Spectrometry services will be acquired on a fee-for-service basis from contract service laboratories 
depending on our needs. Locally, the University of Nebraska-Lincoln’s Nebraska Center for Mass Spectrometry 
offers some of the services needed. The University of California, Davis’ Molecular Structure Facility offers an 
extensive list of mass spectrometry services at attractive non-profit rates. 
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• 3 HPLC systems:  
1) Waters HPLC 2695 Alliance System with a 2996 photodiode array absorbance detector and a 2420 
evaporative light scattering detector; 2) Waters 600 Modular HPLC System with a 717+ autosampler and a 
2487 dual wavelength absorbance detector; and 3) Waters 600 Modular HPLC System with manual 
injector and a 2487 dual wavelength absorbance detector. System control, data acquisition, data analysis, 
and data reporting are accomplished by using a Waters Lac/E32 acquisition server and a Database server 
both running the Empower software package for HPLC systems (see computer section above).The 
database server with Empower software package for HPLC systems is operated by the Quality Control 
Laboratory but shared with the Analytical Methods Laboratory (see computer section above). Capabilities: 
1) Solvent delivery – modular systems can deliver flow rates for analytical and semi-preparative HPLC 
columns; Alliance system can deliver flow rates for capillary to semi-preparative columns. All systems are 
capable of generating quaternary gradients with a 1% composition accuracy. 2) Detection – all 
absorbance detectors have wavelength range of 190 nm to 800 nm and are equipped with 10 microliter 
analytical flow cell with a 1 cm path length. Data can be acquired up to a rate of 10 per second for a single 
wavelength and 1 per second for dual wavelength acquisition (10 spectra per second for the photodiode 
array detector). 3) Autosamplers – both 48 and 96 sample carousels are available for the 717+ 
autosamplers. The 2695 Alliance systems have five carousel, turntable autosamplers built-in with the 
capacity for 120 vials. Sample compartments are temperature controlled 0°C to 40°C. Currently all these 
systems are validated. 
• Beckman MDQ capillary electrophoresis system with a filter-based UV-visible absorbance detector and a 
photodiode array detector (attached to a computer) instrument operation, data acquisition, and data 
analysis are controlled by 32 Karat software. Capabilities: 96 well plates with robotics system; internal 
liquid cooling system for the capillary, 30,000 kV maximum voltage, ability to perform capillary zone 
electrophoresis, capillary gel electrophoresis, capillary isoelectric focusing, and capillary 
electrochromatography. This system can be validated. 
• Dynex MRX filter based, UV-visible absorbance microplate reader and computer software for data 
acquisition and analysis. Capabilities: multiwell plates up to 96 wells; equipped with filters for 215 nm, 405 
nm, 450 nm, and 590 nm. 
• Multiwell plate washer system 
• The equipment of the Quality Control Laboratory will be accessible to the Analytical Methods Laboratory 
on a need and availability basis. This is a reciprocal agreement requiring both parties to adhere to the 
highest quality standards required, e.g., cGLP or cGMP. 
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Analytical Methods and Characterization, Kevin E. Van Cott, Ph.D. – University of Nebraska-Lincoln 
 
Laboratory:  
Dr. Van Cott will be moving to UNL in May 2004. He will have 700 sq ft of laboratory space in 330 Othmer Hall, 
adjacent to the Biological Process Development Facility (BPDF) laboratories. His laboratory at UNL will be 
similar to what he currently has at Virginia Tech (as of January 2004). 
 
Clinical:  
Not applicable 
 
Animal:  
Not applicable 
 
Computer:  
Dr. Van Cott will have one desktop office computer and one notebook computer. The laboratory will be equipped 
with dedicated computers and printers for each HPLC, FPLC, and Capillary electrophoresis unit. 
 
Office:  
An office space in Othmer Hall has been assigned to Van Cott. 
 
Other:  
Dr. Van Cott will have a close association with the UNL BPDF especially the Analytical Methods Laboratory 
and the Quality Control Laboratory.   
Mass Spectrometry services will be acquired on a fee-for-service basis from contract service laboratories 
depending on our needs. Locally, the University of Nebraska-Lincoln’s Nebraska Center for Mass 
Spectrometry offers some of the services needed. The University of California, Davis’ Molecular Structure 
Facility offers an extensive list of mass spectrometry services at attractive non-profit rates. 
 
 MAJOR EQUIPMENT:  List the most important equipment items already available for this project, noting the location and pertinent capabilities of each. 
 
The following items are in the process of being installed in Van Cott’s new laboratory 
¾ Beckman System Gold 32Karat HPLC system with diode array UV/Vis detector and fluorescent 
detector and fraction collector (330 Othmer): for analysis of rhFIX samples and glycan analysis. 
¾ Beckman System Gold 32Karat HPLC system with diode array UV/Vis detector and fraction collector 
(330 Othmer):  for analysis of samples; high resolution purification.  
¾ Beckman PACE MDQ Glycoprotein Capillary electrophoresis system with UV/Vis and LIF detectors 
(330 Othmer):  for cIEF analysis of rhFIX samples; monosaccharide and oligosaccharide analysis. 
¾ Akta Explorer 100 chromatography system (330 Othmer):  chromatography process development; flow 
rates of up to 100 ml/minute.   
¾ Other related protein characterization equipment in 330 Othmer:  Novex SDS PAGE; BioRad Protean 
IIxi SDS PAGE; Beckman DU-600 UV/Vis spectrophotometer; refrigerated centrifuges (table top and 
desktop); HPLC columns; lab-scale FPLC columns (up to 5 cm ID); coagulation meter; automated 
microtiter plate reader; Savant speed-vac system; walk-in cold rooms; -80 freezers; laminar flow hood; 
fume hood. 
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Purification – University of Nebraska-Lincoln  
 
Laboratory:  
The Purification Development Laboratory is located on the third floor of Othmer Hall on the University of 
Nebraska-Lincoln campus. The Purification Development Laboratory is a 1,500 square foot newly constructed 
laboratory with a 150 square foot cold room, dark room (80 square feet), electrophoresis station (SDS-PAGE, 
IEF, Western blot), and a 200-foot pilot-scale purification area. Also available is a 600 square foot media 
preparation room. The entire facility and all of its resources will be available for this project. 
 
Clinical:  
Not applicable 
 
Animal:  
Not applicable 
 
Computer:   
Two computer workstations are in the Purification Development Laboratory. Dr. Meagher and the research 
scientist working on purification have personal computers in their offices.  
 
Office:  
Office space is provided on the third floor of Othmer Hall across from the laboratory. The research scientist has 
an 80 square foot cubical, and Dr. Meagher has a standard single-occupancy office. Research technicians 
have computer access in the laboratory. There is a locker area for storage of personal items. 
 
Other  
There are no other facilities that the purification group will require for this project. If there is a need to            
fabricate anything (unforeseen at this point), the University of Nebraska-Lincoln Department of Chemistry 
Machine Shop is available on the first floor of Othmer Hall. 
 
 
 MAJOR EQUIPMENT:  List the most important equipment items already available for this project, noting the location and pertinent capabilities of each. 
In the Purification Development Laboratory and under the direct control of the purification group: 
2 Perseptive Biosystems Biocad process chromatography workstation and one Perseptive Biosystems Biocad 
Vision chromatography workstation – attached robot. Systems have UV, conductivity, and pH monitoring on-
line, computer controlled for unattended operation and capable of running multiple columns/buffers systems. 
Flow rates up to 100 ml/min, and the Vision is equipped with a robot for automated sample analysis; 1 EH-110 
Microfluidizer – Capable of cell disruption up to 25,000 psig and a flow rate of 400 ml/min; 1 Amicon K’40 
Process chromatography skid – Capable of gradient, online pH, conducitivity, UV 280, and a flow rate up to 
500ml/min; 1 bench-top ultrafiltration system – Capable of 8 L/min recirculation rate and a minimum volume of 
300 mL and maximum of 3,500 mL. Upper pressure limit of the pump is 100 psig; 1 NCSRT Model 50 
ultrafiltration system – Capable of 100 L/min recirculation rate and a minimum volume of 3,500 mL. Upper 
pressure limit of the pump is 100 psig; 2 floor model Sorval Evolution centrifuges – Capable of 30,000 x g with 
a volume capacity of 6 L (8,000 x g); 1 Beckman J2-21 floor model centrifuge – Capable of 21,000 x g, upper 
volume limit 3 L; 1 Alpha Innotech gel scanning and documentation system – Capable of complete 
documentation and scanning including chemillumensence;  2-by-20 L stainless steel processing tanks – 
Capable of mixing and are jacketed. 
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cGMP Production – University of Nebraska-Lincoln  
 
Process area:  
The GMP pilot plants consist of a Fermentation Pilot Plant (FPP) and a Purification Pilot Plant (PPP) and are 
located on the first floor of Filley Hall on the University of Nebraska-Lincoln campus. The FPP is a 700 square foot 
room consisting of a 60 square foot centrifuge room. The PPP is a 600 square foot Class 100,000 room with a 
220 square foot cold room and a 40 square foot curtained, clean air area containing a clean workstation.  Also 
available is a 150 square foot clean room for inocculum preparation and a 100 square foot chemical weight room. 
The entire facility and its resources will be available for this project. 
 
Clinical: Not applicable 
 
Animal: Not applicable 
 
Computer:   
One computer workstation is located in each of the pilot plants. Managers working on this project have personal 
computers in their offices, and an operator office is used that contains two computers.  
 
Office:  
Office space is provided on the second floor of Filley Hall. A 60 square foot office is used by the GMP pilot plant 
coordinator, and a 100 square foot office is used by operators of the GMP pilot plants. 
 
Other  
The BPDF also has a Quality Control laboratory located on the third floor of Othmer Hall that will perform analysis 
of cleaning samples and any in-process testing that may be required. If there is a need to fabricate anything 
(unforeseen at this point), the University of Nebraska-Lincoln Department of Chemistry Machine Shop is available 
on the first floor of Othmer Hall. 
 
 MAJOR EQUIPMENT:  List the most important equipment items already available for this project, noting the location and pertinent capabilities of each. 
In the GMP pilot plants and under the direct control of the GMP pilot plant group: 
Located in FPP:  1 ABEC 500 L Fermentor.  Capable of high cell density fermentations of Pichia pastoris and 
Escherichia coli with programmed fixed, ramped or exponential feed profiles.  System has control and on-line 
monitoring of pH, DO, temperature, three different nutrient addition lines, acid/base addition and agitation;  1 
CSC8 Westfalia disk separator.  Capable of 4 lpm flow rates and separating at a maximum of 12 % solid;  2 
NCSRT Model 50 Cross flow filtration systems.  Bleed and fed systems with in-line pH, temperature, conductivity, 
permeate flow rate monitoring and capable of 800 lpm recirculation rates and operating up to 100 psi;  1 APV 
Gaulin 30-3000 Homogenizer.  Capable of cell disruption up to 18,000 psi and a flow rate of 4 lpm;  1 x 250 L, 1 x 
125 L, 1 x 150 L stainless steel mixing/holding tanks.  Jacketed tanks capable of CIP.     
Located in PPP:  1 NCSRT Chromatography skid.  System has in-line UV, pH, temperature, conductivity 
monitoring with 2 sets of dual metering pumps capable of flow rates ranging from 50 to 700 mL/min and 500 to 
7,000 mL/min isocratic.  Able to perform linear gradients with five outlets for fractionation if necessary;  1 NCSRT 
Model 10 Cross flow filtration skid.  Capable of 80 lpm and a minimum volume of 3 liters with on-line pH, 
temperature, conductivity and flow rate monitoring;  1 NCSRT Model 5 Cross flow filtration skid.  Capable of 17 
lpm and a minimum volume of 500 mL;.  1 AirClean Class 100 workstation.  4’x 2’x 3.5’ HEPA filtered workstation 
for use during aseptic manipulation of product and bulking of final product;  2 x 100/500 BPG column, 2 x 200/500 
BPG columns, 1 x 200/1000 BPG column, 1 x 300/500 BPG column, 1 x 450/500 BPG column, 1 x 450/1000 
BPG column.  Sanitary borosilicate glass columns commonly used in GMP bioprocessing capable of column 
volumes ranging from 0.5 to 116 L and pressure limits ranging from 36 to 116 psi. 
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Quality Assurance – University of Nebraska-Lincoln 
 
Laboratory:  
Not Applicable 
 
Clinical:  
Not Applicable 
 
Animal:  
Not Applicable 
 
Computer:  
All individuals have Dell Latitude D800 Laptop Pentium M computers with 1.7 Ghz processors, 15.4” WUXGA 
monitors, 60 GB Hard Drive and 1025 MB RAM. Operating System is Windows XP Professional. Computers 
are connected to the internet, network color laser printer, and the Biological Process Development Facility 
(BPDF)  local area network with access to the Storage Area Network.   
 
Office:  
A separate, private office, approximately 130 square feet, is available to Ms. Ardis Barthuli, Quality Assurance 
Coordinator for the BPDF.  QA Document Specialists are provided a general office area with approximately 90 
square feet of office area. There is a separate 1,500 square feet controlled access room with lockable lateral 
filing cabinets for document storage. 
 
Other:  
Access to fax and scanners for document processing. 
 
 
 MAJOR EQUIPMENT:  List the most important equipment items already available for this project, noting the location and pertinent capabilities of each. 
 
Not Applicable 
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Quality Control – University of Nebraska-Lincoln  
 
Laboratory:  
The Quality Control Laboratory is located in several rooms on the third floor of Othmer Hall: Rooms 310, 321, 
and 334. A combined biochemistry and chemistry laboratory with approximately 900 square feet of space is 
located in Room 310. The room is equipped with an eight-foot chemical fume hood and secured cold storage 
for short-term samples. In the service corridor is secured long-term cold storage for 4 °C, -20 °C, and –80 °C 
samples. A temporary microbiology laboratory consisting of approximately 64 square feet is located in Room 
321. This space contains a four-foot biological safety cabinet. The main Quality Control Microbiology 
Laboratory, Room 334, is currently under design and construction. Current construction time lines suggest that 
this facility will be built and partially validated by 2005. This facility will consist of two functional spaces: 1) a 
microbiology laboratory with a class 100,000 environment and 2) a class 10,000 clean room environment with 
two sequential ante rooms. The class 100,000 laboratory space, approximately 645 square feet, will contain a 
cGMP autoclave, a four-foot biological safety cabinet, a five-foot biological safety isolator, and a pass-through 
glove box for transfer of materials from the laboratory to the clean room space. The class 10,000 clean room 
will be accessed by passage from the hallway into a 120 square foot ante room and gowning area and then 
into a secondary class 10,000 ante room prior to entry into the clean room. The clean room will contain a 10-
foot biological safety isolator. The clean room and all isolators will be sterilized by a hydrogen peroxide vapor 
generation system.  
The Quality Control Laboratories are adjacent to the fermentation, mammalian cell culture, molecular biology, 
and protein purification laboratories of the Biological Process Development Facility (BPDF). The Nebraska 
Center for Mass Spectrometry is five minutes walking distance from the laboratory. 
Clinical:  
Not Applicable 
 
Animal: 
Not Applicable  
 
Computer: 
The laboratory is equipped with several computer systems as listed in the major equipment section below. The 
minimum instrument workstation is a Pentium II with 128 Mb of Ram, a 20 Gb hard drive, NIC, and color 
monitor running Window 2000 workstation. Each laboratory has at least two computer workstations that are 
similarly equipped. Of major note is the client/server system for high performance liquid chromatography 
instrument control, data acquisition, data analysis, and data reporting. This system consists of two Waters 
Lac/e32 Acquisition servers (Pentium III with 512 Mb Ram and 40 Gb running Windows 2000 workstation SP4 
operating system) and a Dell PowerEdge 2500 server (1.3 GHz Pentium III, 1 Gb RAM, 4 x 36 Gb Hard drives 
set up in two raid 1 (mirrored) arrays, one for operating and programs system and another for the Empower 
Oracle database) running a Windows 2000 server SP4 operating system. The clients, acquisition servers, and 
the database server run Waters Empower software, version 5.0. The client/server system is accessed by 
software clients, which are installed on several workstations in the laboratory and the computers in Dr. 
Swanson’s and QC laboratory personnel offices. The current office computer in service is a Latitude 840C 
laptop, 2.2 GHz Pentium III, 512 Mb RAM, 40 Gb hard drive, CD-R/RW/DVD, interchangeable 250 Mb ZIP 
drive or 1.44 Mb floppy disk drive, two batteries (six hours time on batteries), fax/modem, Ethernet NIC, two 
USB ports, external mouse, and keyboard or equivalent. The computers are pre-loaded with Microsoft Office 
suite, Waters Millennium 32 software, and ancillary software programs. All computers are interconnected via 
the University of Nebraska LAN system and protected from external tampering by a BPDF controlled firewall.  
 
 
 
 
Office:  
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A separate, private office, approximately 120 square feet, is available to Dr. Todd Swanson, Manager of both 
the Analytical Methods Laboratory and the Quality Control Laboratory. The technologists will each have a desk 
area. Technicians are provided locker storage for personal items.  
 
Other: 
The Quality Control Laboratory will request amino acid analysis and amino terminal amino acid sequencing 
from two contract facilities: 1) The Protein Structure Core Facility of the University of Nebraska Medical Center 
in Omaha is equipped with and is capable of performing cGLP amino terminal amino acid sequencing. The 
equipment includes an Applied Biosystems Procise protein sequencer, and an Applied Biosystems 477 protein 
sequencer. 2) AAA Service Laboratory, Boring, OR, uses a Beckman 6300 Amino Acid Analyzer for performing 
cGLP compliant amino acid analysis. We have existing working relationships with both facilities. 
 
Mass Spectrometry services will be acquired on a fee-for-service basis from contract service laboratories 
depending on our needs. Locally, the University of Nebraska-Lincoln’s Nebraska Center for Mass 
Spectrometry offers some of the services needed. The University of California, Davis’ Molecular Structure 
Facility offers an extensive list of mass spectrometry services at attractive non-profit rates. 
 
 
 MAJOR EQUIPMENT:  List the most important equipment items already available for this project, noting the location and pertinent capabilities of each. 
Biochemistry and Chemistry Laboratory, Othmer 310 
• Associates of Cape Cod Pyrokinetics turbidometric system for endotoxin determination (attached to a 
computer and printer). Capabilities: this system has been validated and is capable of simultaneously 
assaying 96 samples 
• Two HPLC systems: 1) Waters HPLC 2695 Alliance System with a 2487 dual wavelength absorbance 
detector, 2) Waters 600 Modular HPLC System with a 717+ autosampler and a 486 single wavelength 
absorbance detector. System control, data acquisition, data analysis, and data reporting are 
accomplished by using a Waters Lac/E32 acquisition server and a Database server both running the 
Empower software package for HPLC systems (see computer section above). Capabilities: 1) Solvent 
delivery – modular systems can deliver flow rates for analytical and semi-preparative HPLC columns; 
Alliance system can deliver flow rates for capillary to semi-preparative columns. All systems are 
capable of generating quaternary gradients with a 1% composition accuracy; 2) Detection – all 
absorbance detectors have a wavelength range of 190 nm to 800 nm and are equipped with a 10 
microliter analytical flow cell with a 1 cm path length. Data can be acquired up to a rate of 10 per 
second for a single wavelength and 1 per second for dual wavelength acquisition; 3) Autosamplers – 
both 48 and 96 sample carousels are available for the 717+ autosamplers. The 2695 Alliance systems 
have five carousel, turntable autosamplers built-in with the capacity for 120 vials. Sample 
compartments are temperature controlled 0°C to 40°C. Currently all these systems are validated. 
• Gas Chromatography system. This system consists of a Shimadzu GC17A (containing capillary and 
wide-bore injectors and a flame ionization detector) equipped with an AOC-20 I autosampler and an 
AOC 20s sample carousel. The system is controlled by Class VP 7 software using a computer similar to 
those listed above. This system has been validated. 
• Bruker Tensor 37 Fourier Transform Infrared spectrophotometer with Near IR and Mid IR spectral 
ranges, diffuse reflectance sample accessory, and internal sample compartment attenuated total 
reflectance sample accessory. Instrument operation, data acquisition, and data analysis are controlled 
by OPUS software. The attached computer is a Pentium 4 1.7 GHz with 256 MB RAM, 20 Gb hard 
drive with a Windows 2000 operating system. Capabilities: Near- and Mid-infrared scanning from any 
sample accessory, software for spectrum library matching. 
• Varian Cary 50 UV/VIS spectrophotometer with temperature control and 18 cell thermostated cell 
holder (attached to a computer and printer) instrument operation, data acquisition, and data analysis 
are controlled by Cary WinUV software. Capabilities: wavelength range 190-1100 nm; data collection 
rate 80 points per second. This system is validated of IQ/OQ. 
• Beckman Microfuge 22R refrigerated microcentrifuge. Capabilities: 24 1.5 to 2.0 mL tube capacity; 
temperature control from –10 C to 40 C; maximum RCF 18,000 x g with current rotor. 
• Anatel Anatoc wide range total organic carbon analyzer (accompanied by an autosampler, attached to 
a computer and printer). Capabilities: The detection range is from 10 parts per thousand to 50 parts per 
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billion of organic carbon. This system has been validated; autosampler holds up to 63 samples; data 
are acquired and analyzed by computer. 
• The equipment of the Analytical Development Laboratory will be accessible to the Quality Control 
Laboratory on a need and availability basis. This is a reciprocal agreement requiring both parties to 
adhere to the highest quality standards required, e.g. cGLP or cGMP. 
 
Microbiology Laboratory, Othmer 321 
• Dupont Qualicon Riboprinter automated microbial analyzer is a computer-controlled, DNA 
electrophoresis-based system that finger prints microorganisms. This system will be used for rapid 
identification of microbial contaminants. The system can analyze eight samples in eight hours, and 
additional eight samples sets can be added every three hours.  
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Formulation Studies – Mark Manning, Ph.D. and William S. Dernell, D.V.M. – Colorado State University 
Animal Cancer Center  
 
Laboratory:  
We have two laboratories within the Animal Cancer Center (ACC), at our disposal. One is an 
oncology/osteology lab (room 244) and the other a pharmacology lab (room 238). Each lab is approximately 
1,200 square feet of space and contains equipment and supplies for tissue culture, drug analysis, formulation 
work as well as handling and processing blood and tissue samples. 
 
Clinical:  
Colorado State University Veterinary Teaching Hospital is one of the premier veterinary clinical sites in the 
country, with a full range of hospital capabilities.  Future directions in our bone research include continuation 
and expansion of our present work and investigation of additional limb sparing techniques such as isolated 
limb perfusion and intraoperative radiation.  
 
Animal:  
A full-service AAALAC-approved animal facility is available on campus in the Painter Center. This facility has a 
dedicated surgical suite as well as housing animal care facilities suitable for immunoincompetent animals. 
Future plans include expansion of the rodent care facilities within the Veterinary Teaching Hospital (close 
proximity to the ACC) to include immunoincompetent strains.  
 
Computer:  
Each member of the Animal Cancer Center has his/her own Pentium-based personal computers with 
networking capabilities. Laser printers, zip drives, and writable CD drives are available for all key personnel. 
Computer services within the Clinical Science department maintains and repairs all computer equipment. 
 
Office:  
All personnel have either separate or shared office space. The oncology service has a dedicated fax machine 
as well as a dedicated copy machine. Additional facilities are available through the clinical sciences 
department. 
 
Other:  
The Animal Cancer Center has various meeting rooms for informal lab meetings and seminars, including 
capability for videoconferencing. 
 
 MAJOR EQUIPMENT:  List the most important equipment items already available for this project, noting the location and pertinent capabilities of each. 
 
We have 2 dedicated -80º freezers for long-term storage of tissue and serum samples. These freezers are 
located in a separate room from our laboratory. Our osteology and pharmacology laboratories have a 
centrifuge, 2 refrigerators, 2 -20º freezers, a dedicated liquid nitrogen tank for flash freezing and storage, a 
microscope, an HPLC analyzer, 2 incubators (one CO2 incubator), 2 water baths, heat block, tissue culture 
hood, pipets, and glassware. The laboratories are equipped with fume hoods and for chemical storage. The 
Veterinary Teaching Hospital has histology services available in house through the Veterinary Diagnostic 
Laboratory. 
 
In addition, Dr. Manning and Dr. Dernell have access to a wide variety of equipment in the Department of 
Chemistry and the Department of Biochemistry and Molecule Biology for biophysical characterization. This 
includes mass spectrometry, as well as circular dichroism, infrared, fluorescence spectrometers. 
Principal Investigator/Program Director (Last, first, middle): Velander, William H. 
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Mouse Assay – Paul E. Monahan, M.D. – University of North Carolina at Chapel Hill School of Medicine, 
Chapel Hill, NC     
 
Laboratory:  
Dr. Monahan has approximately 500 sq ft of laboratory space in Thurston Bowles Hall. This space is a part of the 
Department of Pediatrics and is located immediately adjacent to the University of North Carolina Gene Therapy 
Center. This space is equipped with fume hood, thermal cyclers for PCR and for quantitative (real-time) PCR, 
lyophilizer, Start4 Coagulation Analyzer, Image analysis camera/hardware/software, freezers, clinical centrifuge, 
water baths, and small equipment for general molecular biology. 
 
Dr. Monahan is an Investigator in the UNC Gene Therapy Center, with total laboratory space approximately 2,300 
sq ft, equipped with chemical hoods, super speed centrifuges, cryostat, thermal cycler for PCR, incubators, 
freezers, and various small equipment for general molecular biology. Also available is a P3 containment facility, 
500 sq ft tissue culture facility with four TC hoods, dual stack incubators, a Centra-08R tabletop centrifuge, and 
microscopes.  We also have access to all common equipment in the Gene Therapy Center Viral Vector Core 
facility, including: controlled temperature rooms (37 degree, 4 degree), dark room, scintillation counter, sonicator, 
tissue culture room, ultraspeed centrifuge, and glassware facility.  
 
Clinical:  
No human subjects work is included in this project. The investigator directs Pediatric Coagulation at UNC-Chapel 
Hill and is an attending physician at the UNC-CH Comprehensive Hemophilia Treatment Center and the UNC-CH 
Children’s Hospital Pediatric Hematology-Oncology service. He serves or has served as a clinical consultant for 
Bayer Biologicals and Aventis-Behring in regards to hemophilia clinical care and is/has been an educational 
consultant for Bayer Biologicals, Baxter Healthcare, and Novo-Nordisk.   
 
Animal:  
A virus-free animal facility is located on the first floor of our building. The facility is equipped with a fume and 
tissue culture hoods, areas for inhaled or injected general anesthesia delivery and care, and procedure/surgery 
rooms. Basic animal care is provided by qualified animal technicians and a certified veterinarian is available at all 
times. As an investigator in the NHLBI-sponsored Programs in Excellence in Gene Therapy program, additional 
care in the selective breeding and screening and generation of novel hemophilia mouse models is assisted 
through the Transgenic Mouse Core Facility directed by Dr. Randy Thrasher and Dr. Terry Van Dyke.  
 
Computer:  
There is access to departmental IBM and Macintosh computers and printers. There is access to the UNC Chapel 
Hill mainframe, which includes access to Duke University, NC State, and Wake Forest libraries and databases. 
 
Office:  
Personal office space is available to the investigator along with administrative, accounting, and secretarial support 
through both the Gene Therapy Center and the Division of Pediatric Hematology.  
 
Other:  
The investigator is a member of the UNC Center for Thrombosis and Hemostasis and the Lineberger 
Comprehensive Cancer Center. Resources available through the Cancer Center include Oligonucleotide Core 
Facility, Tissue Culture Core Facility, and DNA Sequencing Core. Resources at UNC-CH available through the 
investigator’s role in the NHLBI-sponsored Programs in Excellence in Gene Therapy program include a 
Histology/Morphology Core Facility and a Transgenic Mouse Core Facility. Dr. Monahan has long-standing 
collaborative relationships with Dr. Darrel Stafford, Dr. Timothy Nichols, Dr. Harold Roberts and Dr. Gilbert White 
and Dr. R. Jude Samulski, who are consulted frequently. 
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 MAJOR EQUIPMENT:  List the most important equipment items already available for this project, noting the location and pertinent capabilities of each. 
Investigator’s laboratory:   Gene Therapy Center: 
Start4 coagulation analyzer     Spectrophotometer   
Fibrometer     Microtiter platereader 
Microtiter plate reader    Tissue culture hoods and incubators 
Electrophoresis setups    High and low speed centrifuges 
Lyophilizer      
Thermal cycler     
Quantitative (real-time) PCR
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Dog Trials – Timothy C. Nichols, M.D. – University of North Carolina at Chapel Hill 
 
Laboratory:  The Francis Owen Blood Research Laboratories (FOBRL) was built in 1960 with money from an NIH 
facilities grant plus matching support from private donors and from the University of North Carolina. The 
FOBRL is located at University Lake on approximately five acres of University property. The location is four 
miles from the Medical Center. The property is on a 600+ acre parcel of land that is part of the local water 
supply. The location is convenient to the medical center, yet relatively isolated from current or potential 
development of the adjacent private land. The two research laboratories indicated on the attached FOBRL site 
plan contain 2,400 sq. ft. These laboratories are equipped to perform molecular biology, tissue culture, 
biochemical studies, protein purification, immunoassays, bioassays, coagulation assays, electrophoresis, and 
immunohistochemistry. A dark room for film processing and a constant temperature room (i.e., “cold room”) are 
also located within these laboratories. Laboratory bench space is reserved for visiting collaborators to perform 
bench work on site as needed on a pre-arranged basis.  
 
Clinical:  Not applicable.  
 
Animal:  
 
 
 
  PHS 398 (Rev. 05/01) Page ___83____ Resources Format Page  
Use ½-inch MARGINS. Number pages consecutively at the bottom throughout the application. Do not use suffixes such as 3a, 3b. 
 Principal Investigator/Program Director (Last, first, middle): Velander, William H. 
 
Animal Facilities at the Francis Owen Blood Research Laboratory (FOBRL). The FOBRL has specialized 
animal housing that meets or exceeds US Department of Agriculture and NIH requirements and AAALAC 
recommendations. The facility houses strains of dogs with hemophilia B, hemophilia A, von Willebrand disease 
(VWD), combined hemophilia A/VWD and normal blood donor dogs. The two Dog Runways house the majority 
of these dogs in indoor/outdoor runs (~5,400 sq ft). Heating and cooling are provided for all animals. In 
addition, the dogs are allowed into the fenced in area. Special whelping (temperature and humidity controlled) 
and isolation facilities are available. Pigs with inherited bleeding and metabolic disorders are also housed on 
site. Normal dogs and pigs with compatible blood types are maintained as a “walking blood bank” from which 
same-species replacement products are produced. More than 600 transfusions are performed in the animals 
each year. There is also a support laboratory in the Animal Treatment Area and a diagnostic clinical laboratory 
located at the FOBRL dedicated to the treatment of these animals.  
 
Computer:  Several computer systems are in the laboratories and animal care areas. These computers have 
comprehensive software for word processing, database management, computer graphics, and internet access 
via T1 lines to onsite and University servers for all high speed communication and bioinformatics. The 
University has a dedicated center with equipment and personnel available for microcomputing support. 
 
Office:  A 28 x 66-ft modular office building is also located on the grounds of the FOBRL. The building contains 
office space for the investigators including Dr. Nichols (200 sq. ft), administrative support (200 sq. ft), library, 
conference room, and a break room for all employees. 
 
Other: The UNC Department of Laboratory Animal Medicine (DLAM) provides all professional veterinary 
requirements and services. Anatomic pathology laboratories are utilized within DLAM. A suite for performing 
survival surgery on laboratory animals is located in Berryhill Hall, School of Medicine, Division of Laboratory 
Animal Medicine. A radiology research laboratory with dedicated X-ray facilities and fluoroscopy is also located 
in Berryhill Hall. These facilities are available as needed for experiments in the hemophilic dogs.  
 
 
 MAJOR EQUIPMENT:  List the most important equipment items already available for this project, noting the location and pertinent capabilities of each. 
 
The following equipment is contained within the laboratories at the FOBRL: immunohistochemistry equipment, 
Perkin Elmer and Beckman spectrophotometers, HPLC, Packard Gamma counter, Molecular Devices Vmax 
microplate reader, cell counter with emphasis on dog and pig blood analysis (Heska), Thermovac lyophilizer, 
fraction collectors, absorbance monitors, recorders, pumps, electrophoresis chambers and power supplies, 
analytical balances, ultra-low freezers, refrigerators, gel dryers, ovens, chemical hood, electrocauterization 
equipment, Leitz Orthoplan fluorescence microscope, 8 channel physiologic model 7 recorder, Doppler flow 
crystal and calibration equipment, Sorval JB-4 microtome, micro and high speed centrifuges, incubators for 
bacteria and tissue culture, 6-foot laminar flow tissue culture hood, PCR machine, water baths, several sizes of 
electrophoresis systems, PAP-4C Biodata platelet aggregometer, comprehensive gel electrophoresis systems 
for protein analyses, and ST4 coagulation units
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Stephan B. Abramson, Ph.D. – LifeSci Partners, Altadena, California 
 
Laboratory:  
Not Applicable 
 
Clinical:  
Not Applicable 
 
Animal:  
Not Applicable 
 
Computer:  
Pentium 4 PC with 384 MB RAM, 34 GB hard drive storage, CD-RW and DVD-ROM drives, color inkjet, and 600 
dpi resolution laser printers. 
 
Office:  
Full communication capability, including dedicated phone lines, fax, high-speed internet access. 
 
Other:  
Ready access to literature search utilities, several university technical and medical school libraries. 
 
 
 MAJOR EQUIPMENT:  List the most important equipment items already available for this project, noting the location and pertinent capabilities of each. 
 
Not Applicable 
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Julian Cooper, Ph.D. – ProGenetics LLC 
 
Laboratory:  
Laboratory at Ripplemead, Virginia:  200 sq. ft. located adjacent to the Swine Research and Housing unit used for 
preparing the collected milk for storage. Contains wash area, prep area, and milk cooling equipment. Fully 
accessible for the project.   
 
Laboratory at Blacksburg, Virginia: 1,900 sq. ft. located in Blacksburg, Virginia. Fully functional molecular biology 
and protein chemistry laboratory, capable of performing standard protocols in DNA manipulation and general 
protein work. Fully accessible for the project. 
 
Clinical:  
Not applicable 
 
Animal:  
Swine Research and Housing unit at Ripplemead, Virginia:  900 sq.ft. modular unit with a capacity to hold up to 
18 adult animals. Capacity to perform swine milking in a controlled environment. Facility will be fully accessible to 
the project. 
 
Computer:  
One desktop Pentium III computer with ethernet located in the Blacksburg laboratory with full project access, and one 
desktop Pentium IV computer with DSL located at the Ripplemead laboratory with full project access. 
 
Office:  
800 sq. ft. of total office space. 500 sq.ft. available for the project including desk areas, break area, and large 
conference room. 
 
Other:  
 
 
 MAJOR EQUIPMENT:  List the most important equipment items already available for this project, noting the location and pertinent capabilities of each. 
 
Milking crate 
Two 30 cu.ft. –40 freezers 
Water purification system 
Large capacity centrifuge 
Microcentrifuge 
Spectrophotometer 
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Research Plan 
 
A. Specific Aims 
 
The hemophilias are congenital disorders characterized by frequent bleeding episodes, 
especially into the joints and muscles, that cause severe arthritis and crippling.  Untreated patients 
rarely survive past adolescence. The most common hemophilias are caused by congenital deficiency in 
the clotting proteins Factor VIII (Type A) or Factor IX (Type B), which occur in about 1:5,000 and 
1:23,000 male children, respectively. These patients are currently treated with replacement therapy 
using intravenous administration of purified Factor VIII or IX produced by purification from donor plasma 
or in cell culture bioreactors.  According to a 1995 audit in the state of California, the average 
healthcare cost for hemophilia patients receiving what is now considered suboptimal care was 
$140,000/patient/year-of-life, of which the overwhelming majority represents the direct cost of Factor 
VIII or Factor IX replacement therapy.  Replacement of clotting factor after a hemorrhage is recognized 
as suboptimal as some damage still ensues. Optimal therapy consists of regular replacement of the 
clotting factor to prevent bleeding episodes. Other urgent problems further complicate the clinical 
situation: 
1. Optimal care of patients in the United States is not possible because of the high cost and 
insufficient supply of clotting factors for replacement therapy. 
2. There is currently no access to clotting factors for replacement therapy for 80% of the world’s 
hemophiliacs. 
3. Clotting factor shortages occur and are exacerbated by raw material shortages (i.e., plasma) 
and production plant shutdowns.  
4. There is a lack of affordable and adequate amounts of clotting factors for alternative routes of 
administration, such as oral dosage, which would circumvent the complications and difficulties 
of intravenous therapy.  
Therefore, innovative bioengineering efforts that would provide effective and affordable supplies of 
replacement clotting factors to treat hemophilia are needed. 
 
The long-term goal of this project is to fulfill the objectives of the National Hemophilia 
Foundation and the World Federation of Hemophilia that call for the provision of worldwide access to 
prophylactic therapy for both hemophilia A and B. The objective of this research is the rapid 
development of a safe, efficacious, abundant, and inexpensive source of recombinant human Factor IX 
(transgenic Factor IX) that is ready to be evaluated in clinical trials. Our approach capitalizes on two 
important features: (1) existing genetically engineered transgenic pigs that synthesize up to 1000 IU/ml 
(4 grams/liter) of transgenic Factor IX in milk; and (2) favorable pharmacokinetic properties of the 
transgenic Factor IX in preliminary studies in a hemophilia B mouse model.  This unique combination of 
abundance and quality is the basis of the need for definitive bioengineering research and development 
that will enable first an intravenous therapy, and subsequently, an oral dosage therapy that can be 
expected to revolutionize treatment of hemophilia B worldwide.  
 
The proposed research is expected to have a high probability of success because of the 
scientific soundness and state of development of the basic research, and the strength, breadth, and 
complimentarity the research team. ProGenetics LLC brings a stable, FDA- and USDA-compliant 
source of transgenic pigs and their milk. Investigators at the University Nebraska-Lincoln (UNL) are 
recognized leaders in bioprocess engineering and current Good Manufacturing Practices (cGMP) 
production of recombinant proteins for Phase I and Phase II clinical trials (UNL Biological Process 
Development Facility - BPDF), transgenic animal bioreactor engineering, characterization of human 
Factor IX from transgenic animals, and co-architect of the FDA’s Points to Consider in the Manufacture 
and Testing of Therapeutic Products for Human Use Derived from Transgenic Animals. Colorado State 
University brings expertise in the formulation of stabilized liquid and lyophilized protein samples for oral 
and injectable delivery.  Dr. Stephan Abramson of LifeSci Partners has two decades of 
biopharmaceutical development experience, and has submitted 18 Investigational New Drug (IND) 
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filings and designed protocols for more than 25 Phase I-IV clinical trials, which led to five new product 
approvals and four license amendments, including AlphaNine®SD (highly purified plasma-derived 
Factor IX).  The University of North Carolina at Chapel Hill (UNC-Chapel Hill) has experience with pre-
clinical mouse and dog experimental hemophilia B models and human clinical trials with the only 
approved recombinant Factor IX produced from cell culture. The University of Nebraska Medical Center 
will serve as the contract research organization to oversee the animal studies at UNC-Chapel Hill in 
preparation for submission of an Investigational New Drug application with the FDA, which will be the 
focus of a second grant application to support Phase I clinical studies. 
 
Three specific aims are proposed: 
 
Specific Aim # 1.  Process engineer and scale-up the recovery and purification of 
transgenic recombinant human Factor IX. The University of Nebraska-Lincoln Biological Process 
Development Facility will complete process development and scale-up, and produce clinical grade 
materials for preclinical studies. The endpoint is a proposed final product specification to help facilitate 
transfer to current Good Manufacturing Practices compliant production of clinical grade material to 
support an Investigational New Drug filing with the United States Food and Drug Administration (FDA) 
leading to clinical trials. 
 
Specific Aim #2.  Characterize and formulate transgenic recombinant human Factor IX for 
intravenous dosage, and evaluate in a hemophilia B dog model.  These activities are directed 
toward characterization of the product important to assure the provision of safe and reproducibly 
effective hemostasis.  The results of these investigations will help support an IND filing with the FDA.   
 
Specific Aim # 3.  Develop an oral dosage form of transgenic recombinant human Factor 
IX, and evaluate in hemophilia B mice and dog models. Oral administration of coagulation therapy 
will obviate the invasiveness, discomfort, potential for opportunistic infection, and complications of 
storage and supplies that accompany intravenous administration.  Oral dosage forms of Factor IX will 
thus greatly increase the proportion of the patient population that can be treated.  There is also 
published evidence suggesting that oral administration may reduce the potential for complicating 
immune responses to replacement therapy, especially in patients with severe hemophilia. 
 
Accomplishment of these specific aims will directly address three recommendations in 
Document #151 of the National Hemophilia Foundation’s Medical and Scientific Advisory Committee 
that are reproduced below:   
 
II. Recommendations to Manufacturers of Coagulation Products 
H. Research and development of improved coagulation products that would expedite the 
transition to total prophylaxis for all persons with coagulation disorders are strongly encouraged. 
1. Licensed and improved products to treat patients with von Willebrand disease and 
patients with inhibitors are urgently needed. 
2. Recombinant products that could be taken less frequently or administered other than 
intravenously would be of tremendous benefit to individuals on prophylaxis regimens. 
3. Methods to manufacture coagulation products more inexpensively, such as use of 
transgenic animals, would increase supply and availability worldwide. 
4. Costs of coagulation products should be reduced. 
(Revised November 2003, Section II, H, 1-4) 
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B. Background and Significance 
 
B.1. Significance of the Proposed Research 
 
The high cost of purified hemophilic factor proteins severely limits treatment in the most 
developed countries to therapy needed when bleeding occurs (Fischer et al., 2002), and, regrettably, 
little to no treatment for 80% of the world’s hemophilia A and B patients in developing countries 
(Mannucci, 2003).  This current therapy is sub-optimal for severe hemophilia but still consumes about 
50,000 international units (IU) of Factor IX or more per patient per year (Barrowcliffe et al., 2002) at an 
average wholesale price of $1.18/IU (Drug Topics Red Book, 2003).  The limited supply of donor 
plasma, the low productivity of cell culture bioreactors, and high development costs of about $800 
million for a new therapeutic product (Frantz, 2003) contribute to the high cost of hemophiliac factor 
proteins. The limited supply also precludes the broad use of prophylactic therapy, which is now 
regarded as the most effective treatment to reduce the number of bleeding episodes and prevent joint 
damage (Miners et al., 2000; Van Den Berg et al., 2001; Panicker et al., 2003). As a combined 
minimum outcome of Specific Aims 1 and 2, we expect to engineer an abundant, economical, and 
potentially long-lasting recombinant Factor IX that is made under current Good Manufacturing Practices 
and is suitable for intravenous delivery and subsequent evaluation in Phase I clinical trials.  The 
successful clinical trial and FDA approval of this product would dramatically increase the availability of 
prophylactic care in the United States and incidence of treatment elsewhere.  We predict that the 
present work with Factor IX will serve as an important catalyst for progress with making a similar 
abundant supply of Factor VIII.  We are already incorporating knowledge of Factor VIII molecular 
designs engineered to be secreted at high levels by mammalian cells (Tendulkar et al., 2001) to 
improve our previous expression in the milk of transgenic pigs (Paleyanda et al., 1997).   
 
An abundant source of a current Good Manufacturing Practices-purified Factor IX in the United 
States would also remove the main obstacle in the development of the most highly desirable drug 
delivery methods for Factor IX such as subcutaneous, intramuscular, intratracheal, and oral 
administration. Currently, all Factor IX products are given intravenously to attain maximal bioavailability.  
Importantly, oral administration of Factor IX in dogs (Horikoshi et al., 1982) and Factor VIII in both dogs 
and humans (Hemker et al., 1980; Horikoshi et al., 1982) is possible, but the low bioavailability makes 
this mode of treatment impossibly expensive with respect to the limited supply of current Factor IX 
sources.  We are confident that the abundance of a highly purified recombinant human Factor IX and 
knowledge from the pharmacokinetics of its intravenous administration derived from a successful 
completion of Specific Aims 1 and 2 will enable us to engineer an optimal Factor IX oral dosage for 
evaluation in preclinical animal models. Successful completion of Specific Aim 3, especially in the 
hemophilia B dog model, will help to justify future human clinical trials. Thus, the ultimate goal would be 
to make an abundant oral dosage form of Factor IX that simplifies treatment of patients worldwide, 
especially of hemophiliac infants.  Because oral administration has already been reported using 
plasma-derived Factor VIII (Hemker et al., 1980), a similar advance in hemophilia A treatment can also 
be catalyzed by the success of the present work with Factor IX.  
 
B.2. Review Of Literature That Is Relevant To This Application 
 
B.2.1. Fundamental biochemical constraints for producing recombinant human Factor IX.  We 
here explain why Factor IX is a scarce protein therapeutic by first describing the relationship between 
its structure-function complexity and the difficulty in making it.  Secondly, we discuss the structure-
function standards needed to define the goals of the proposed work. Figure 1 shows the complex 
molecular structure of Factor IX. Factor IX plays a critical role in the blood-clotting enzymatic cascade 
that results in the formation of a blood clot to restore hemostasis (Kurachi et al., 1993).  Briefly, it 
circulates as a complex precursor protein (i.e., zymogen) at a concentration of 5 µg/ml in plasma.  In 
response to a bleeding event, Factor IX is activated by either Factor XIa or Factor VIIa/Tissue Factor to 
release a 35 amino acid activation peptide (Ala146 to Arg180).  Activated Factor IX (FIXaβ) then acts in 
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concert with Factor VIIIa to proteolytically activate Factor X, which, in turn, activates prothrombin to 
thrombin.  Thrombin cleaves fibrinogen to fibrin, and fibrin polymer forms the clot.   
 
The biological activity of Factor IX requires a complex molecular structure that contains post-
translational modifications.  Factor IX is a member of the Vitamin K-dependent family of proteins, which 
are distinguished by the post-translational γ-carboxylation of glutamate (Glu) to γ-carboxyglutamate 
(Gla).  This post-translational modification requires Vitamin K as a cofactor and the Factor IX 
propeptide (Figure 1) as the binding site for the carboxylase enzyme complex (Suttie, 1993; Furie et al., 
1997; Wu et al., 1997).  After the N-terminal glutamates are γ-carboxylated, the propeptide is removed.  
Both of these two molecular processing steps are required for biological activity (reviewed in Freedman 
et al., 1996; Sunnerhagen et al., 1996).  In terms of a therapeutic product specification, Factor IX 
products must have at least 6 γ-carboxyglutamates/molecule to be functional (Kaufman et al., 1986; 
Lindsay et al., 2004 [see Appendix]), and the existing recombinant Factor IX product, BeneFIX®, has 
10-12 (Gillis et al., 1997, White et al., 1998).  The complexity of these post-translational modifications 
necessitates production of biologically active Factor IX in mammalian cells.  Furthermore, only certain 
mammalian cells are capable of making these post-translational modifications at protein synthesis rates 
sufficient for commercial scale production. Very few mammalian cells can efficiently γ-carboxylate and 
also subsequently remove the propeptide.   
 
BeneFIX® is the only FDA-approved recombinant human Factor IX (transgenic Factor IX), and it 
is produced in Chinese hamster ovary  (CHO) cells.  We review the molecular, functional, and 
production engineering characteristics of BeneFIX® because it serves as the key reference for the 
transgenic recombinant human Factor IX proposed here.  Briefly, BeneFIX® contains a mixture of sub-
populations with 10, 11, and 12 γ-carboxyglutamates (White et al., 1998). This is consistent with the 
reported limitations in the ability of Chinese hamster ovary cells to γ-carboxylate Factor IX (Kaufman et 
al., 1986). The problem of having a mixture of biologically active and inactive Factor IX populations was 
solved by designing a purification process consisting of four chromatographic steps designed to purify 
and select for γ-carboxylated transgenic Factor IX (Harrison 
et al., 1998).  Another salient feature of BeneFIX® is that, 
unlike plasma-derived Factor IX products, it contains 
essentially no phosphorylation at Ser-158, and only 15% 
sulfation of Tyr-155 (Bond et al., 1998).  Pharmacokinetic 
studies in humans indicate that the lack of phosphorylation 
and sulfation may lead to a 33% lower initial recovery of 
activity in plasma after intravenous infusion for BeneFIX®, 
as compared to plasma-derived Factor IX (White et al., 
1998; Berntorp and Bjorkman, 2003).  Other post-
translational modifications made to Factor IX include β-
hydroxylation Asp-63, two N-linked glycosylation sites at 
Asn-157 and Asn-167 within the activation peptide, and four 
O-linked glycosylation sites at Ser-53, Ser-61, Thr-159, and 
Thr-169 (Figure 1).  The specific contributions of these post-
translational modifications to Factor IX biological activity 
have not yet been determined.  However, N-linked 
oligosaccharides of the “complex” designation that contain 
terminal sialic acid monosaccharides have been shown to 
significantly improve the circulation half-life of therapeutic 
proteins (Varki et al., 1999).  Plasma-derived Factor IX has 
complex N-linked oligosaccharides that are tri- and tetra-
antennary and terminated with sialic acid (N-
acetylneuraminic acid, Makino et al., 2000).  N-linked 
oligosaccharides of BeneFIX® were similar to plasma-
derived Factor IX (Bond et al., 1998). In summary, our basis 
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Figure 1.  Factor IX amino acid sequence, 
indicating the propeptide (Thr[-18]-Arg[-1]),  
post-translational modifications in the “Gla 
domain” (Tyr1-Glu40), and the activation 
peptide (Ala146-Arg180). 
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for determining product specifications suitable for the transgenic recombinant Factor IX will utilize the 
above-mentioned molecular, biological activity and process engineering knowledge base provided by 
BeneFIX®. 
 
B.2.2. Transgenic mammary tissue and the advantages of pig mammary tissue to produce 
human recombinant Factor IX.  We here discuss the reasons why the milk of the transgenic pig can 
be a prodigious and expedient source of recombinant Factor IX relative to cell culture bioreactors. 
Transgenic animals already have been used to produce many recombinant proteins that are secreted 
into milk at a research and pilot plant level (Rosen et al., 1996; Lubon, 1998; Clark, 1998; Houdebine et 
al., 2000).  The reason why mammary cells make high concentrations of milk proteins is due to their 
high cell density, about 109 cells/ml, which results in protein production rates of about 1-15 
grams/liter/hour. This cell density is two to three orders of magnitude greater than what is possible in 
mammalian cell culture production such as used to make BeneFIX® and other complex recombinant 
therapeutic proteins. The specific choice of using the pig relative to 
other milking livestock is based upon the combination of high volume of 
milk that can be harvested per day (2-3 liters) and the quality of post-
translational processing of complex proteins. Figure 2 shows a 
transgenic pig being milked by a pig milking machine that typically 
yields about 0.4 to 1.25 liters per milking. Pigs can be milked up to five 
times per day over two 50-day lactations per year, and so the total milk 
yield from the average sow is 200-300 liters/year. 
   
 The current scarcity of Factor IX protein is predictable due to 
the low concentrations in both human plasma (5 µg/ml) and animal cell 
culture bioreactors (~ 10 µg/ml).  Presently, less than 10% of the 
United States hemophilia B patients receive prophylaxis.  The 
projected process volumes needed to scale-up to satisfy the clinical 
demand in the United States translate to large capital investment costs 
because the facilities to produce and process these source materials 
do not currently exist (Garber, 2001).  Figure 3 on the next page 
compares the amounts of Factor IX source materials needed to meet 
the demand for prophylactic therapy for the estimated 3,000 patients at 
a level of 200,000 IU/patient/year.  More than 1 million liters of plasma 
per year would be required to satisfy this demand.  An animal cell 
culture bioreactor facility producing approximately 600,000 liters of 
supernatant/year and costing in excess of about $50 million capital 
investment would be required to generate a similar amount of Factor 
IX.  In contrast, using milk from existing transgenic pigs 
(conservatively, 100 IU/ml), only 60 pigs would be needed supply prophylactic treatment to the 3,000 
patients in the United States. The capital investment for this pig production facility is less than $2 
million, and importantly, the marginal cost for scaling up transgenic animal production is very low 
compared to animal cell culture bioreactor facilities. This is the key advantage of using transgenic pigs 
for rapidly achieving an abundance of economical Factor IX − the costs for purification per unit of 
material are similar between mammalian cell culture and transgenic bioreactors.  
 
In addition to the consideration of milk volume, the mammary epithelial cells of the pig are 
unique among livestock in making complex post-translational modifications needed for Factor IX 
biological activity. From a broad biochemical and physiological perspective, the pig is more closely 
related to humans than the ruminants, which include the cow, sheep, and goat. As an example of the 
differences between ruminant and pig biochemistry, recombinant Factor IX production in sheep was 
unsuccessful with only low levels of biologically active Factor IX being produced – less than 1 
nanogram of biologically active Factor IX could be recovered from each milliliter of milk (Clark et al., 
1989); the sheep was even less productive than donor plasma. In contrast, porcine mammary epithelial 
 
Figure 2. Lactating sows have 
a milk letdown every hour 
during daylight hours and can 
be milked 3-5 times/day.  About 
2-3 liters/day/sow can be 
collected over two 50-day 
lactations/year.  Milk can be 
collected by hand or by 
machine as shown. 
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cells have been found to 
be capable of making the 
post-translational 
processing required for 
making biologically active 
Protein C (Velander et al., 
1992), a Vitamin K-
dependent protein 
homologous to Factor IX, 
and we have recently 
confirmed this result in 
recombinant human Factor 
IX (Van Cott et al., 1999 
and Lindsay et al., 2004).  
In addition, the N-linked 
glycans added to the 
endogenous porcine milk 
glycoprotein lactoferrin are 
complex glycans terminated with N-acetylneuraminic acid (sialic acid), which is needed for long 
circulation half-life of therapeutic proteins.  In contrast, ruminant lactoferrins contain undesirable high-
mannose glycans (Spik et al., 1994).  Thus, ruminants will likely not be able to make a recombinant 
Factor IX having glycosylation needed for long half-life. In summary, we propose that the combination 
of the abundance and quality of the recombinant Factor IX made by the transgenic pig mammary gland 
will be the most important features needed for future development.   
 
B.2.3.  The safety requirements for FDA approval of a transgenic pig supply of recombinant 
human Factor IX.  We here review the knowledge base needed to anticipate regulatory concerns and 
make production specifications to assure the safety of products derived from transgenic pigs.  In 
recognition of the feasibility of this production method, the United States FDA has issued a document 
addressing the Points to Consider in the Manufacture and Testing of Therapeutic Products for Human 
Use Derived from Transgenic Animals. Importantly, pioneering work on the safety and efficacy of 
recombinant anti-thrombin III produced in the milk of transgenic animals has been demonstrated in 
clinical trials by Genzyme Transgenics Corporation (Levy et al., 2001).  To reduce risks of disease 
transmission from milk, multiple barriers are placed in the purification process that provide logs of 
pathogen removal and/or inactivation of common classes of lipid envelope and non-lipid envelope 
viruses:  chromatography (Hay, 2002), solvent/detergent treatment (Horowitz et al., 1992), and 
nanofiltration (Van Holten et al., 2002).  Maintenance of specific pathogen-free production herds is also 
an important requirement.  Many of these steps are currently in place for many human plasma-derived 
Factor IX products, animal-cell-derived products such as BeneFIX®, and animal products such as 
heparin and porcine Factor VIII (Hyate:C).  The process technology for implementing these steps with 
transgenic-animal-derived products has been demonstrated to be directly transferable (Ziomek, 1996). 
 
Clinical experience with the porcine-derived Factor VIII product called Hyate:C is instructive for 
assessing and reducing the risks involved in zoonosis from porcine-derived therapeutic protein 
products.  Hyate:C is a product alternative used to treat hemophilia A patients that develop an immune 
response to plasma-derived or recombinant-derived human Factor VIII.  These patients produce 
antibodies that neutralize the activity of these Factor VIII products.  Hyate:C was originally produced 
using largely unregulated slaughterhouse pigs and has been given to patients since 1984 without any 
viral inactivation steps in the purification process. In 1996, detection of porcine parvovirus (PPV) DNA 
in multiple batches halted production (Soucie et al., 2000).  In a comprehensive retrospective study of 
hemophiliacs receiving Hyate:C prior to 1996, it was concluded there was not a single case of 
transmission of a porcine virus to a patient receiving Hyate:C (Giangrande et al., 2002).  Thus, the 
threat of one of most common pathogens that occurs in pigs has been evaluated.  Another example of 
0 200,000 400,000 600,000 800,000 1,000,000 1,200,000 1,400,000
Volumes of Source Material Required to Meet US Prophylaxis Needs
Milk of  Transgenic Pigs - Liters/year
(12,000 Liters)
CHO Cell Supernatant -Liters/year
 Plasma Donations - Liters/year
Figure 3.  Volumes of source materials for Factor IX required to meet the needs 
for prophylactic therapy of all hemophilia B patients in the United States (3,000 
patients @ 200,000 IU/patient/year).  The amount of Factor IX in each source is 
- plasma (1 IU/ml); CHO cell bioreactor (2 IU/ml), and transgenic pig milk (100 
IU/ml).  A 50% purification yield for each source is assumed.  The milk of 60 
pigs (12,000 liters/year) could supply the entire amount of Factor IX needed for 
prophylaxis in the United States. 
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a safety concern for parenteral therapeutics is transmissible spongiform encephalopathies such as 
BSE.  It has been recently shown that swine are resistant to nutritional challenges of highly infective 
tissue homogenates from BSE-infected cattle (Wells et al., 2003).  In addition, specific pathogen-free 
transgenic production herds are fed only plant-derived diets.   
 
 Additional safety issues are specific to the biochemistry and physiologic action of Factor IX.  
These safety issues have been well addressed in both plasma-derived and recombinant Factor IX 
products that are currently available.  The primary issues concern the presence of activated Factor IX 
species that could induce hypercoagulopathy, a dangerous phenomenon caused by excessive blood 
clotting usually occurring immediately or shortly after infusion.  Most product specifications meet this 
safety requirement by using purification processing and formulations that minimize the presence and 
generation of activated Factor IX during storage.  The presence of heparin contamination could also 
lead to bleeding events caused by suddenly depressed platelet cell count.  While many plasma-derived 
Factor IX products contain heparin, increased safety can be likely be attained by minimizing heparin 
content arising from heparin affinity chromatography. The above mentioned process technology should 
be directly applicable to a recombinant human Factor IX product derived from transgenic pig milk.   
 
B.2.4.  Alternative delivery routes for Factor VIII and Factor IX enabled by abundant supply.  
 
B.2.4.1.  General extravascular Factor IX delivery alternatives. We here discuss alternative delivery 
methods that might be made possible due to the abundance of purified transgenic Factor IX supply 
made possible as a result of successfully completing our research objectives.  Hemophilia clinicians 
treating patients in economically depressed locations have stated that ensuring patient compliance 
would likely be improved if alternatives to intravenous infusion could be implemented (Dr. Carol Kasper, 
personal communication).  These delivery alternatives differ from intravenous infusion with respect to 
the balance between ease of administration and bioavailability.  It has previously been demonstrated 
that Factor IX can be transported across endothelial and epithelial cell layers.  For example, 
aerosolization of Factor IX may provide an alternative, needle-free therapeutic option for delivery of 
Factor IX across the epithelial cell layer in the lungs (Russell et al., 2001).  This recent study 
demonstrated that bioavailabilities of 11% (relative to intravenous administration) were obtained in 
hemophilia B dogs using 200 IU/kg-bodyweight intratracheal dosing regimen.  The pharmacokinetic 
results were consistent with a slow release from a deposition site in the lungs.  The intra-tracheal 
administration produced therapeutic levels of both antigen and activity, and this activity was detected 
through 72 hours post-administration.  In addition, there has been a group of studies to determine the 
absorption rate and bioavailability of plasma-derived Factor IX administered through other 
extravascular routes: subcutaneous, intramuscular, and intraperitoneal (Liles et al., 1997; McCarthy et 
al., 2002).  While all of these routes resulted in measurable Factor IX activity, the subcutaneous and 
intramuscular injections resulted in bioavailabilities of 63.5% and 82.8%, respectively (Liles et al., 
1997).  Subcutaneous administration of high concentrations of up to 4000 IU/ml resulted in 
bioavailabilities of 35% in cynomolgus monkeys and 46% in hemophilia B dogs (McCarthy et al., 2002).  
Importantly, while all of these extravascular delivery routes are less efficient than intravenous, they 
provide a combination of simplicity of administration and sustained Factor IX activity.  Thus, if an 
abundant and economical source of Factor IX were available, then the advantage of clinical simplicity 
becomes more of an important and feasible consideration.   
 
B.2.4.2.  Oral dosage formulations.  Oral dosage form of Factor IX may provide the most facile and 
convenient delivery of Factor IX. In general, low bioavailabilty of oral protein dosage forms arise from 
degradation within the gastrointestinal environment and the resistance of high molecular weight 
proteins to be transported through the mucus gel layer and epithelia and into the bloodstream 
(Heizmann et al., 1996; Bernkop-Schnurch et al., 1999).  The inefficiency due to the gastrointestinal 
environment can be mitigated by the following: modifying the pH of the stomach; competitively inhibiting 
pancreatic proteases with inhibitors such as soybean trypsin inhibitor, aprotinin, or casein; and high 
dosage regimens (Anderle et al., 2002).  However, even with optimal formulations, high oral dosage 
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may provide the lowest bioavailability of the alternative delivery formulations. Thus, oral dosage is 
feasible only when abundance and cost are favorable and low patient plasma levels are needed to 
achieve effective therapy.  A low bioavailability may also be more feasible in children and infants, where 
total body weight is low and intravenous delivery is more problematic.  In the case of Factor IX and 
Factor VIII, only about 5% of normal plasma levels are needed to maintain normal hemostasis.  This 
translates to only about 250 and 12 nanograms per milliliter of plasma for Factor IX and Factor VIII, 
respectively. These levels have been achieved in human and dog plasma levels using liposome and 
enzyme inhibitor formulations of oral dosages of human plasma-derived Factor VIII and Factor IX 
(Hemker et al., 1980; Horikoshi et al, 1982). Since both Factor VIII and Factor IX naturally adsorb to cell 
surfaces, these data suggest that once delivered to the intestinal mucosal surface, these proteins would 
be amenable to an absorption process that could result in passage into the bloodstream.   
 
Hemker et al. (1980) used Factor VIII 
formulated in liposomes, administered a dose of 
290 Units to a hemophilia A adult patient, and 
obtained greater than 5% Factor VIII activity in 
plasma for 50 hours after dosing (Figure 4).  
The profile is consistent with a slow absorption 
process resulting in a broad plasma level 
response.  In the case of hemophilia, where 
clotting factor levels of only 0.05 IU/ml (which is 
5% of the activity in normal plasma) are needed 
for normal hemostasis, a broad plateau of 5% 
activity or greater sustained over more than 48 
hours is desirable.  Horikoshi et al. (1982) also 
used a liposomal formulation and administered 
a dose of 14 Units of plasma-derived Factor 
IX/kg bodyweight in a 9.2 kg dog and measured 
125% of normal Factor IX activity by aPTT. In 
both these Factor VIII and Factor IX oral dosage studies, however, sufficient numbers of animal or 
human subjects were not investigated to assess the variability in bioavailability that would be expected 
using oral dosage.  We assume that at that time, the supply of plasma-derived materials precluded the 
effective parametric study of appropriate formulations to determine optimum bioavailability. In the 
following section, we will also review our success in oral dosage of transgenic recombinant Factor IX to 
adult mice and dogs. 
 
In summary, there is mounting evidence in humans and in experimental animals that suggests 
intact therapeutic proteins can be absorbed from the gut into plasma (Mayer, 2003).  In addition to the 
above examples, the absorption of biologically active protein from the gut to plasma has been 
demonstrated with oral administration of erythropoietin in 10-day-old rats (Miller-Gilbert et al., 2001) 
and TGFβ1 in neonatal mice (Letterio et al. 1994).  In the context of these experiments, we propose to 
supply an abundant source of recombinant human Factor IX, which, under more optimal formulation, 
should minimally prove useful in the treatment of infants where only small amounts of units will be 
needed to achieve prophylaxis due to small body weight.   
 
B.3.  Important Conclusions From Knowledge Base About Current Factor IX Supplies and 
Production Methods  
 
The relationship of the structure and function of Factor IX requires it be made in a mammalian 
cell. The pig mammary epithelial cell can effectively make the post-translational modifications needed 
for a functional, recombinant human Factor IX.  The high cell density of the mammary gland enables 
prodigious concentrations of Factor IX to be made in the milk. The estimated milk volumes will enable a 
rapid scale-up to production levels of Factor IX that would meet clinical demand for prophylactic 
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Figure 4. Reproduction of the results from Hemker et al. 
(1980): “Factor VIII activity in plasma after oral and 
intravenous administration of Factor VIII to a patient with 
severe hemophilia.  Concentrations... are expressed as 
percentage of Factor VIII concentration in pooled normal 
plasma (n=30). Each sample was tested four times.” 
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treatment that is not now being met by conventional animal cell bioreactor technology.  The abundance 
of Factor IX produced by the pig would make feasible alternative delivery methods that are greatly more 
desirable than intravenous delivery, especially for infants and small children.   
 
C. Preliminary Studies  
C.1.  Description of the Transgenic Pigs:  Molecular Genetics, Specific Pathogen-Free Pedigree 
 
C.1.1. Molecular genetics of transgenic Factor IX pigs: genotype and phenotype. We here present 
preliminary data that describe the existence of transgenic pigs that produce high levels of Factor IX in 
their milk. We have used two regulatory motifs utilizing genetic elements from the murine Whey Acidic 
Protein gene to express two levels of transgenic Factor IX cDNA.  We previously reported the high-level 
expression of transgenic Factor IX at 0.1-0.2 grams/liter in the milk of transgenic pigs using a 2.5 kbp 
murine Whey Acidic Protein promoter (Van Cott et el., 1999).  We have recently made transgenic pigs 
containing a murine Whey Acidic Protein regulatory element consisting of 4.1 kbp of 5’ promoter region.  
This construct directs mammary-specific expression of transgenic Factor IX at 3-4 grams/liter in milk.  
This transgene construct uses no viral DNA elements.   
 
Two different genotypic signatures have been detected through fourth generation outbreeding of 
a single founder transgenic male made by microinjection. In preparation for microinjection, the construct 
was excised from the plasmid by Not I restriction digest and extracted and purified to remove vector 
contaminants. The propagation of the original transgenic founder male is shown in Figure 5.  Pigs have 
been characterized by PCR and Southern Analysis for head-to-head, tail-to-tail, and head-to-tail 
transgene content.  The genotype designated A contains a head-to-head integration within a single 
integration site of about eight transgene copies.  This head-to-head site is spontaneously deleted to 
form a B genotype.  The B genotype has not shown this instability.   
 
Figure 5. Family tree of transgenic pig bioreactors with expression of transgenic Factor IX at 3-4 
grams/liter.  
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The phenotype of these animals lends itself to an engineering analysis of transgenic Factor IX 
throughput.  In particular, the phenotype of both A and B genotypic animals appears to be the same 
with both genotypes exhibiting a constant expression of the recombinant human Factor IX at 3-4 
grams/liter throughout a lactation of up to 70 days. The amount of Factor IX activity in the milk ranges 
from 100-1000 IU/ml; because Factor IX has a theoretical activity of 200 IU/mg, some Factor IX being 
produced by the pig at these high levels is not biologically active.  We have found that Vitamin K 
nutritional supply and Vitamin K bioavailability to the mammary gland significantly impact the extent of 
γ-carboxylation of transgenic Factor IX, and, hence, the amount of biologically active transgenic Factor 
IX that is produced.  ProGenetics will supply milk from animals who have had already have an 
optimized regimen of Vitamin K nutritional supplementation.  The team at the University of Nebraska-
Lincoln will determine the variability of γ-carboxylated product and respective specific activities within 
defined product milk pools.  Thus, a key task will be to define the milk pool specifications that will give a 
reproducible product quality in terms of specific activity and reproducibility. 
 
C.1.2. Specific pathogen-free pedigree of currently available transgenic Factor IX pigs. The 
suitability of the transgenic pigs to be used in this proposed research for materials intended to 
eventually be used in clinical trials derives from their specific pathogen-free pedigree and the 
maintenance of biosecurity at ProGenetics’ facilities.  ProGenetics maintains fourth generation 
transgenic animals (ProGenetics FDA INAD filing no. 11-045) and a semen bank at a restricted access, 
commercial research animal facility located in the mountains of southwest Virginia.  The mountains of 
southwest Virginia are a low livestock animal density location virtually free of standing water, and so 
there is also a low density of biting insect vectors.  This facility is in compliance with currently accepted 
FDA and USDA practices. Under the guidelines in NIH Guidelines for Research Involving Recombinant 
DNA Molecules (April 2002) the transgenic swine fall under the category of biosafety level 1 (BL1-N 
animals).  Current facilities at ProGenetics fulfill all requirements established in Appendix Q sub 
headings Q-I-B-2 through Q-II-A-2-a for such BL1-N animals.  Any future facility for housing the animals 
would meet or exceed the same guidelines.  Transgenic animals are permanently identified by tattoo 
and ear notch along with semi-permanent identification by ear tagging.  An animal record is maintained 
where each animal identification record contains date of birth, sex, genotype, and complete health 
history.  Each animal record is contained in a database consisting of both electronic and paper forms.  
Also included in the record, when timely, will be the date of death and cause, if known.   
 
The specific pathogen-free pedigree of the transgenic pigs has been determined by 
ProGenetics, and the herd is free of Brucellosis, Pseudorabies, and porcine Parvovirus. The 
Commonwealth of Virginia is Brucellosis-, Tuberculosis- and Pseudorabies-free. Nine sentinel animals 
have been recently screened for Porcine Reproductive and Respiratory Syndrome (PRRS) and 
Transmissible Gastroenteritis and found to be negative.  There has not been a case of swine dysentery 
(vibrionic dysentery), salmonellosis, erysipelas, transmissible gastroenteritis, PRRS, porcine 
encephalomyocarditis, aino and akabane viruses, pseudorabies, or enzootic polyserositis in either this 
herds or in any herds within 10 miles of the facilities. These animals were born and raised in the United 
States and have not been fed garbage or rendered animal products at anytime. The United States is 
currently validated as free of Foot and Mouth Disease, Akabane Virus, African Swine Fever, Classical 
Swine Fever, Swine Vesicular Disease, Japanese Encephalitis and Teschen’s Disease, which are 
considered serious diseases of zoonotic origin from pigs to humans. 
 
Transgenic females are artificially inseminated with semen from a commercial semen supplier 
(Birchwood Farms, OH) that is certified to be free of Pseudorabies, PRRS, Brucellosis, SIV, and 
mycoplasma. Transgenic boars are bred to nontransgenic females purchased from commercial facilities 
that are certified free of Pseudorabies, porcine parvovirus, PRRS, Brucellosis, SIV and mycoplasma, 
such as those provide by P.I.C.(Franklin, KY). 
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C.2.  cGMP Production of Biologicals at the University of Nebraska-Lincoln Biological Process 
Development Facility 
 
The University of Nebraska-Lincoln Biological Process Development Facility is a turn-key 
academic process development facility with a full-time staff of 36 scientists and technicians dedicated to 
research and development and the rapid transition of human biologics into Phase I clinical testing.  It is 
capable of producing Phase I injectables and Phase II oral biologics at the 500 L bioreactor-scale 
(http://bpdf.unl.edu).  It requires 9 to 12 months to develop a scalable process for current Good 
Manufacturing Practices (cGMP) manufacturing and 2 to 3 months to produce Phase I clinical material.  
The Biological Process Development Facility recommends technology transfer to a commercial partner 
between Phase I and II, and continues to produce early Phase II material until technology transfer is 
completed. 
 
The Biological Process Development Facility has eight groups: molecular biology, fermentation 
development, cell culture development, purification development, analytical methods development, 
quality control (analytical and microbiology), cGMP manufacturing (fermentation and purification pilot 
plant), and quality assurance.  It has worked with 25 companies over the last 10 years on 29 clinical 
products.  The Biological Process Development Facility has been under contract with the United States 
Army Medical Research and Materiel Command on the botulinum and ricin vaccine and human 
antibodies against botulinum.  Recently, Dynport Vaccine Company was awarded $11 million to fast-
track the development of a heptavalent vaccine against botulinum of which $6.5 million was awarded to 
the University of Nebraska-Lincoln.  In addition, the Biological Process Development Facility is 
producing at the 500 L scale recombinant protein for Phase II oral studies and was responsible for all 
aspects of process development.  It has successfully completed Quality Assurance audits by Cato 
Research (8/02/03) and Bioprocess Consultants (9/15/03) for early phase cGMP production 
agreements.  The Biological Process Development Facility has the experience to develop, transition, 
and produce cGMP transgenic recombinant Factor IX for clinical trials.  
 
C.3.  Molecular Characterization of Factor IX Produced in the Milk of Transgenic Pigs  
 
Factor IX, whether purified from 
human plasma or produced in Chinese 
Hamster Ovary cells, exists as a 
spectrum of subpopulations that differ in 
the nature and extent of post-
translational modifications. The 
fundamental challenge to the 
bioengineer is to develop a product 
specification that results in a safe and 
efficacious product and a process that 
can reproducibly make the specified 
product.  
 
We have purified Factor IX from 
two lineages of transgenic pigs at the 
laboratory bench scale (Van Cott et al., 
1999; Lindsay et al., 2004).  The design 
of the purification process for the lineage 
producing 3-4 grams/liter was to capture the majority of sub-populations that occur in the milk so that 
they could be studied. Skim milk was first treated with ethylenediaminetetraacetic acidic (EDTA) to 
dissolve casein micelles and micelle-adsorbed Factor IX prior to application to a heparin-affinity 
chromatography column. Starting with milk having 150 U/ml of Factor IX activity, a product activity yield 
of >95% was obtained at a purity of >98%, as judged by HPLC and sodium dodecyl sulfate 
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Figure 6. Recombinant Factor IX from the milk of transgenic pigs 
can be purified to high purity by heparin-affinity chromatography, 
as shown by reverse-phase HPLC analysis of the product 
(Lindsay et al., 2004).  For comparison, plasma-derived Factor 
IX purified by immunoaffinity chromatography (Mononine®) was 
also analyzed. 
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polyacrylamide gel electrophoresis (Figure 6). Once this pure product was obtained, the 
subpopulations of the recombinant Factor IX were fractionated by high-resolution anion exchange 
chromatography. In Lindsay et al. (2004; see Appendix), we used gradient elution from anion exchange 
columns to selectively purify the recombinant Factor IX populations.  We produced a Factor IX product 
having a biological activity that was 200 IU/mg, similar to that of plasma-derived Factor IX.  We 
assumed a reference Factor IX concentration in plasma of 5 µg/ml and an activity level of 1 IU/ml and, 
therefore, a reference specific activity of 200 IU/mg of Factor IX. 
 
We have begun preliminary structural analysis of the biologically active transgenic Factor IX.  
While sialic acid content in N-linked and O-linked glycans is not linked to enzymatic activity (Bharadwaj 
et al., 1995), in general, it can have a significant impact on pharmacokinetics as de-sialylated proteins 
are rapidly cleared by receptors in hepatic cells (Goochee and Monica, 1990).  Plasma-derived Factor 
IX has complex N-linked glycans that are tri- and tetra-antennary and terminated with N-
acetylneuraminic acid (NANA) (Makino et al., 2000).  The sialic acid content of transgenic Factor IX 
was measured by the Warren assay (Warren, 1959) and by fluorescent labeling and capillary 
electrophoretic separation/detection (Chen et al., 1998).  Using both methods, 6-9 moles NANA/mole 
transgenic Factor IX were measured.  Importantly, the sialic acid was confirmed to be NANA by 
capillary electrophoresis, and not N-glycolylneuraminic acid (NGNA), which is commonly added to 
recombinant proteins produced in transgenic goats (Edmunds et al., 1998). 
 
The phosphorylation of Ser-158 in Factor IX is thought to be an important determinant of 
pharmacokinetic properties (White et al., 1998).  BeneFIX® is produced in Chinese Hamster Ovary 
cells and has essentially no phosphorylation (Bond et al., 1998) while plasma-derived Factor IX 
products such as Mononine® and AlphaNine®SD have one phosphoserine/molecule.  Using a 
colorimetric phosphorylation assay from Pierce Chemical (Rockford, IL), we measured two 
phosphoserines/molecule in transgenic Factor IX, and one phosphoserine/molecule for Mononine®.  
Mammary epithelial cells have an enormous capacity for phosphorylating peptide sequences having a 
motif of Ser-X-Asp/Glu motifs in the endogenous caseins that are secreted at a level of 30-40 
grams/liter (Alexander et al., 1992), and Factor IX has four of these sequence motifs, including one in 
the γ-carboxyglutamate domain (Figure 1).  
 
C.4 The Hemophilia B Mouse Model Used to Evaluate Hemostatic Effects of Factor IX and its 
Pharmacokinetic Properties  
 
We here discuss preliminary data that help to show the potential for using transgenic 
recombinant Factor IX as a post-bleeding event treatment and as a therapeutic for prophylaxis.  We 
used hemophilia B mice that have a gene sequence knock-out that prevents Factor IX antigen from 
being produced, and, therefore, represents an animal model that is Factor IX cross-reactive-material-
negative (CRM-, Lin et al., 1997). Thus, this model has no endogenous Factor IX species able to 
compete for biological and physiological activities of infused Factor IX.  As assayed by the Factor IX-
specific activated partial thromboplastin time (aPTT) assay (an in vitro coagulation assay), the clotting 
time is greatly prolonged.  Mice will develop muscle and joint bleeding after fighting with littermates, and 
Factor IX-knockout mice (in contrast to wild-type mice) will exsanguinate (bleed to death) following a 
bleeding challenge such as the tail transections described below. Although clotting factors from one 
species are not always fully functional in plasma of another species, human Factor IX is functional in 
the murine coagulation system. Human Factor IX corrects murine factor IX-deficient plasma in the in 
vitro aPTT assay (Kung et al., 1998) and corrects the Factor IX-knockout hemophilic phenotype in a 
bleeding challenge (Kung et al., 1998; Chao et al., 2001). However, infused Factor IX induces an 
immune response and generation of inhibiting antibodies after about seven days of post-intravenous 
exposure.  
 
C.4.1.  Hemostatic effects of transgenic Factor IX. Factor IX is most often administered to patients 
after a bleeding event has occurred, which is signaled by pain and stiffening in a joint. Thus, it is 
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important that the recombinant Factor IX made by the transgenic pig efficiently stop a bleeding event, 
as well as prophylactically prevent bleeding.  We have used a tail transection in a hemophilia B mouse 
as a model to evaluate the effectiveness of infused transgenic Factor IX to stop a serious bleeding 
event.  Transgenic Factor IX purified according to the method of Lindsay et al. (2004), having a specific 
activity of 200 IU/mg, was formulated into a buffer similar to BeneFIX®.  The model consists of the 
following sequential steps:  (1) anesthetize the mice and collect 30 µl blood to obtain an initial 
hematocrit reading; (2) transect the tail at time = 0, and then every 30 seconds begin touching the filter 
paper to the drop of blood forming without disrupting the clot that is forming; (3) at t = 1 minute, inject 
either transgenic Factor IX or normal saline.  Bleeding was halted at 15 minutes if necessary, and six 
hours post-infusion, a blood sample was taken to determine hematocrit levels.  Figure 7A shows the 
typical clotting response for a wild-type mouse with normal hemostasis, a hemophilia B mouse that 
received no Factor IX treatment, and a hemophilia B mouse that received a 50 IU/kg-bodyweight dose 
of purified transgenic Factor IX, which is a typical dosage for treating a bleeding event in hemophiliac 
patients. With this tail transection method, wild-type mice showed a steady decrease in the amount of 
bleeding, with cessation of bleeding within 13 minutes.  The untreated hemophilia B mice receiving no 
treatment bled profusely for 14 minutes, and the tails were cauterized to prevent exsanguination. The 
hemophilia B mice receiving 50 IU/kg-bodyweight of transgenic Factor IX showed a steady decrease in 
bleeding, with cessation of bleeding within about 10 minutes.  The decrease in the hematocrit 
(decrease in the percentage of red blood cell volume, a measure of the total blood loss as a result of 
the injury) for these mice six hours post-infusion is shown in Figure 7B.  The wild-type mice having 
normal hemostasis had an average decrease of 7%±1% (n = 5), untreated hemophilia B mice had an 
average decrease of 16%±1% (n = 3), and the hemophilia B mice treated with 50 IU/kg of transgenic 
Factor IX had an average decrease of 3%±1% (n = 5).  Thus, the hemostatic effect of intravenous 
infusion of transgenic Factor IX intravenous into the hemophilia B mouse is equivalent or greater to that 
of the hemostatic response observed in the normal mouse. We anticipate that transgenic Factor IX 
produced by cGMP will show similar effects in this and other hemostatic animal models needed prior to 
Phase I clinical trials. 
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Figure 7.  (A). Demonstration of the 
hemostatic effectiveness of 
transgenic Factor IX to a significant 
bleeding challenge – tail transection.  
Anesthetized mice were treated with 
normal saline or 50 IU/kg transgenic 
Factor IX one minute after tail 
transection.  Blood was blotted onto 
the filter paper at 30 second intervals 
without disrupting the forming clot.  
(B). Percent decrease in hematocrit of 
the mice 6 hours after the bleeding 
experiment.    
 
C.4.2.  Pharmacokinetic behavior of Factor IX and it potential as a prophylactic therapy.  In the 
United States, the most important potential contribution of the abundance of recombinant Factor IX 
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derived from transgenic pigs is the enabling of prophylactic therapy.  As a first step in evaluating the 
feasibility of prophylactic therapy, we measured the pharmacokinetics of transgenic-derived Factor IX in 
hemophilia B mice, as assayed by activated partial thromboplastin time. As a reference, it has been 
recently been reported (Gui et al., 2002) that the pharmacokinetics of human Factor IX in this Factor IX-
knock-out mouse are not markedly different from those seen in humans, and it is reasonable to assume 
that this animal model will allow comparative studies of the activity and kinetics of the transgenic Factor 
IX versus currently available Factor IX products. In this respect, the Factor IX-knockout mouse model is 
similar to the hemophilia B dog model, which also demonstrates Factor IX pharmacokinetics similar to 
those seen in humans (Schaub et al., 1998). Thus, the mouse can be used for studies with large 
numbers of animals to suggest more optimal approaches for testing in the large animal model. 
 
 For all Factor IX products evaluated to date the initial recovery of Factor IX activity immediately 
after infusion is low, and there is a very large variation among patients.  For example, initial recoveries 
ranging from 21-62% were reported for BeneFIX®, and 31-69% for plasma-derived Mononine® 
(Morfini, 2003).  It is also well known that Factor IX specifically adsorbs to receptors on the vascular 
endothelium (Heimark and Schwartz, 1983; Stern 
et al., 1987; Cheung et al., 1996), which likely 
accounts for the low initial recoveries − the 
endothelium is an additional reservoir for infused 
Factor IX.  Thus, simple one-compartment 
pharmacokinetic models are not accurate for 
Factor IX.  “Non-compartment” models have been 
suggested to be more appropriate for Factor IX 
pharmacokinetic analysis (Morfini, 2003).  These 
models simply describe the response that is 
observed and include an inherent assumption of at 
least one central compartment that is linked to the 
plasma concentration vs. time profile of the drug 
(Riviere, 1999).  The data are analyzed by 
calculating areas under the curves, using either 
the trapezoid rule or curve-fitting techniques to 
integrate the area under the curve (AUC) of the 
concentration vs. time profile, and area under the 
first moment curve (AUMC).  From this 
information, a Mean Residence Time (MRT), the 
average total length of time that all Factor IX 
molecules spend in the body, can be calculated 
(Herman, 2002) as shown in Table 1. 
 
 We formulated transgenic Factor IX 
purified by the method of Lindsay et al. 
(2004) into a buffer similar to that of 
BeneFIX®.  The Factor IX was injected into 
the hemophilia B mice in replicate treatment 
groups of 7-8 mice each for plasma-derived 
Factor IX (Mononine®) and transgenic 
Factor IX.  Factor IX activity and antigen levels recovered at 15 minutes post infusion ranged from 34-
65% for plasma-derived Factor IX and 22-26% for the transgenic Factor IX.  Shown in Figure 8 is a 
semi-log plot of Factor IX activity vs. time for one representative set of experiments comparing 
transgenic Factor IX and Mononine® (% Plasma Activity, where 100% = 1 IU/ml).  While plasma-
derived material had a higher post-infusion recovery of activity and antigen, the decay of Factor IX 
activity in the mouse was faster than for the transgenic-derived Factor IX. The Mean Residence Time of 
transgenic-derived Factor IX was calculated to be 40.0 hours using an arbitrary two-term exponential fit 
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Figure 8. Semi-log plot of Factor IX activity measured 
in plasma samples taken after intravenous injection of 
Mononine® (■, n = 8) and transgenic-derived Factor 
IX (♦, n = 8) in the Factor IX-knockout hemophilia B 
mouse model.  Factor IX activity in collected mouse 
plasma was measured by the aPTT assay.   
Table 1.   Mean Residence Times (MRT) of Factor IX in 
Factor IX-knockout mice after intravenous infusion with 
Mononine® and transgenic-derived Factor IX, calculated from 
the AUC and AUMC of the data in Figure 8.   
Factor IX IV Infusion MRT  [hours] 
Mononine® (n = 8) 19.8 
Transgenic Factor IX (n = 8)  40.0 
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of the data (residuals of fit vs. data were < 2%).  The corresponding Mean Residence Time of 
Mononine® was 19.8 hours.  A similar analysis of BeneFIX® yielded a recovery of about 42% and a 
Mean Residence Time similar to Mononine®.  All Factor IX products were able to sustain about 5% of 
normal Factor IX activity (0.05 IU/ml) in plasma for 72 hours post-infusion.  A level of 5% or more is 
considered sufficient to render normal blood clotting. 
 
This lower recovery of transgenic Factor IX suggests it is distributed into extra- and circulatory 
spaces differently than plasma-derived Factor IX or BeneFIX®.  We postulate that the long half-life and 
lower initial recovery in plasma may be an indication that the transgenic recombinant Factor IX 
accumulates to a greater amount in extra-circulatory compartments that are in equilibrium with plasma. 
If this is true, the transgenic-derived Factor IX appears to redistribute itself into plasma at a rate that is 
able to maintain ample amounts of Factor IX needed for normal blood clotting. 
 
C.5. Postprandial, Oral Dosage of Transgenic Factor IX in a Hemophilia B Mouse and Normal 
Dog Model 
 
We have fed raw transgenic Factor IX milk to Factor IX-knockout mice to broadly and in a facile 
way confirm that biologically active Factor IX could be transported from gut to plasma.  Mice were fed 
0.5 ml of transgenic milk after a meal (postprandial), and two methods were used to assess the 
appearance of biologically active Factor IX in plasma:  (1) a combination of ELISA (enzyme linked 
immunosorbent assay) and aPTT assay of plasma samples taken one hour after post-prandial dosing; 
(2) bleeding times using a tail transection as a high sensitivity method of in vivo hemostasis.  It is 
important to note that no Factor IX activity or Factor IX antigen was detected in mice that were 
administered Factor IX transgenic milk prior to a meal.  Only those mice administered Factor IX 
transgenic milk after a meal showed levels of Factor IX activity and antigen.  Thus, the data below are 
for postprandial administration. 
 
Table 2.  Oral dosage of transgenic Factor IX in raw milk to FIX-knockout mice (n = 4).   
Mouse Total FIX Antigen 
by ELISA 
[µg/ml plasma] 
aPTT Time 
[sec] 
% FIX activity in 
plasma 
(100% = 1 IU/ml) 
Effective 
concentration of 
functional transgenic 
Factor IX 
[µg/ml plasma] 
1 2.3 73.6 2.7% 0.14 
2 7.8 68.4 4.2% 0.21 
3 6.4 67.3 4.6% 0.23 
4 Not detected - - - 
 
Table 2 shows the distribution between total transgenic Factor IX antigen and biologically active 
transgenic Factor IX absorbed from the raw milk dosing. In three out of four mice, high levels of total 
transgenic Factor IX antigen were detected in the mouse plasma.  In addition, the Factor IX aPTT 
activities of the plasma samples for these same three mice were increased.  The raw milk fed to these 
mice contained 100 IU/ml of Factor IX activity, but about 3-4 grams per liter of total Factor IX antigen, 
as verified by the purification data discussed above.  Importantly, the ELISA and aPTT values indicate 
that relative ratios of total transgenic Factor IX antigen and biologically active transgenic Factor IX 
appearing in the plasma were the about same as the raw milk fed to them.  The results show that 0.2-
0.6% of both the total Factor IX antigen and the biologically active Factor IX are transported into the 
plasma even without the aid of formulation.  Thus, there was no selective transport differences between 
biologically active vs. inactive transgenic Factor IX populations, and it demonstrates that transgenic 
Factor IX can be transported across the gut and into the plasma. The design of this experiment does 
not yield how much Factor IX was potentially transported to extra-circulatory reservoirs.   
 
In addition to aPTT and ELISA analysis of plasma samples, we evaluated the more sensitive tail 
bleeding time in the Factor IX-knockout hemophilia type B mouse model.  This enabled us to observe 
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longer-term effects of milk feeding on hemostasis. In this experimental model, normal mice usually stop 
bleeding after a tail cut within minutes (Figure 10A, open squares), whereas hemophilic mice do not 
stop bleeding and require cauterization of the tail tip after 15 minutes (open circles).  When the 
hemophilia B mice were tested 12 hours after drinking the transgenic milk, the bleeding time was 
corrected (closed circles).  In three mice, we continued the feedings every other day for 1-2 months, 
and found that the mice did not develop any resistance to the therapy (Figure 10B).  Intravenous 
dosages normally results in a 100% incidence of Factor IX-neutralizing antibodies after only 10-12 days 
in these Factor IX-knockout mice. Importantly, these data indicate two promising potential benefits of 
oral Factor IX dosing:  (1) the ability to maintain hemostasis even with significant bleeding challenges, 
and (2) the mitigation of the generation of inhibitory antibodies to Factor IX. 
 
(A)                                                                 (B) 
Figure 10.   Feeding of transgenic Factor IX in raw pig milk to mice.  (A) tail bleeding times of unfed wild type 
mice (WT or FIX+/-), unfed Factor IX-knockout mice (FIX-/-), tails were cauterized after 15 minutes to prevent 
death), and fed Factor IX-knockout mice.  (B) Tail bleeding times during long term feeding of transgenic Factor 
IX in milk for three Factor IX-knockout mice. 
 
The above mouse experiments using raw Factor IX-containing transgenic pig milk broadly 
confirm the previous phenomenon of plasma-derived Factor IX transport across the gut in a normal dog 
that used formulated Factor IX (Horikoshi et al., 1982).  We used a similar raw milk feeding experiment 
in a normal adult dog to further confirm the phenomena of transgenic Factor IX transport from gut to 
plasma.  A 4-year-old, normal mixed-breed dog weighing 20 kg was post-prandially dosed with 50 ml of 
raw milk containing about 250 IU/ml of transgenic Factor IX activity (about 500 Units of transgenic 
Factor IX per kilogram of bodyweight).  Figure 11 shows that by two hours, the Factor IX activity in 
plasma as measured by aPTT was raised by about 20-30%.  ELISA values were also raised a similar 
amount.  Based on these results, we calculated that approximately 4% of the administered biologically 
active transgenic Factor IX was transport into plasma. While this was a preliminary experiment using 
unformulated transgenic Factor IX, we were able to confirm the general phenomena of biologically 
active transgenic Factor IX transport from the gut to plasma, as shown by Horikoshi et al. (1982) using 
liposome-formulated Factor IX.  Importantly, we now anticipate that the efficiency of Factor IX 
appearing in plasma will increase with volume-reduced, highly purified transgenic Factor IX that is 
optimally formulated for oral dosage.  Even with the same low bioavailability shown in the dog 
experiments, normal blood clotting could be sustained for infants while using a minimal amount of 
material.  For example, consider only the case of infants up to about age 2 having body weights less 
than 15 kg. It is feasible that normal hemostasis may be achievable in a hemophiliac infant by daily 
consumption of a purified and formulated Factor IX that is derived from only 50 ml of pig milk.  From the 
point of view of an abundant supply for oral delivery dosage for hemophilia B infants, the Factor IX 
purified from one day’s harvest of milk from one pig (2 liters) could potentially supply 40 oral dosages. 
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Figure 11.  Oral dosage of transgenic Factor IX in raw transgenic pig milk in a normal adult dog.  
(A).  Factor IX activity in collected citrated plasma samples measured by the aPTT assay – 
duplicates of two dilutions of each sample were measured (100% activity = 1 IU = activity in 1 ml 
normal plasma). Data from Horikoshi et al. (1982) are added for comparison.  (B). Relative 
transgenic Factor IX antigen ELISA signal in plasma samples.  
 
C.6.  Summary of Preliminary Data  
 
The above preliminary animal model data show that the recombinant human factor IX from 
transgenic pig milk is functional from the perspective of an intravenously administered hemostatic agent 
and resultant pharmacokinetic behavior. The above studies in the hemophilia B mouse model showed 
that transgenic Factor IX was kinetically efficient in stopping bleeding after intravenous administration, 
has an effectively long residence time, and also that it can be transported in a functional form across 
the gut to plasma at levels that render normal hemostasis. Importantly, the adult hemophilia B mouse 
model also showed that the oral dosage appeared to confer immune tolerization over a long period of 
administration as intravenous dosages resulted in a 100% incidence of Factor IX activity neutralizing 
antibodies after only 10-12 days.    
 
D.  Research Design and Methods  
 
The steps that will be required to produce candidate transgenic Factor IX intravenous and oral 
dosage therapies so that clinical trials can be initiated are as follows: 
 
1. Analytical methods development. 
2. Large-scale bioprocess engineering and development. 
3. cGMP production. 
4. Formulation for intravenous and oral dosage. 
5. Comprehensive testing in hemophilia B mouse and dog models.   
 
The minimum goal of this work will be a transgenic Factor IX intravenous therapy that is ready 
to enter clinical trials.  The experience we will gain from achieving this objective will be used to develop 
an oral dosage transgenic Factor IX.  Preparation for cGMP production, IND filing, clinical trials, and 
successful FDA approval requires thorough documentation at all levels.  Thus, our program 
emphasizes leading-edge document management technology and specialized staff for its 
implementation.  This has also been a key consideration in other University of Nebraska-Lincoln 
Biological Process Development Facility funded projects (NIAID and US Army) whose goal is the 
generation of Phase I and II clinical materials.  We also have specialized and centralized program 
managerial staff to coordinate and document activities of each site relative to monthly milestones.  
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D.1.  Specific Aim # 1. Process engineer and scale-up the recovery and purification of 
transgenic recombinant human Factor IX 
 
The justification for Specific Aim #1 is that a large-scale cGMP purification process and a matrix 
of analytical methods are needed to produce transgenic Factor IX suitable for clinical trials. A further 
advantage is that the material used for preclinical studies in dog models for both intravenous or oral 
dosage applications will be more reflective of the anticipated results in humans.  Furthermore, the 
availability of hemophilia B dogs limits the number of permutations of Factor IX formulations that can be 
studied. Thus, while mice can be used with Factor IX derived from intermediate stages of development, 
the most reliable and highly characterized transgenic Factor IX formulations should be used in dogs.  
cGMP material represents the highest degree of reliability.  The objective of this specific aim is to 
complete all aspects of process development, scale-up, and cGMP manufacturing for production of 
candidate populations of recombinant Factor IX for evaluation in hemophiliac animal models.   
 
There are five critical steps to successful implementation of a cGMP production process.  First, 
ProGenetics LLC will provide a reliable supply of milk from transgenic pigs producing up to 4 grams 
transgenic Factor IX/liter (100-1000 U/ml). Second, analytical methods and in-process testing must be 
established to characterize the milk and all intermediates resulting from process purification. Third, 
standard operating procedures (SOPs) must be written and transferred to a quality control laboratory to 
ensure a consistent and reproducible analysis. All of these methods will eventually be validated prior to 
cGMP manufacturing for clinical trials, but for the work outlined in this proposal, the methods will only 
be qualified.  Fourth, the purification process and formulation must be developed to ensure a consistent 
process that produces a candidate transgenic Factor IX product.  During this process engineering 
phase, we will confirm that candidate products have desired hemostatic and pharmacokinetic properties 
in the hemophilia B mouse model.  Fifth, the Biological Process Development Facility cGMP staff will 
establish standardized production batch records, run at the pilot-scale, finalize the production batch 
records, and finally run the cGMP process to produce transgenic Factor IX suitable for preclinical 
studies in hemophilia B dogs and other animal models used to document safety characteristics prior to 
Phase I clinical trials.  
 
In summary, the rationale for Specific Aim #1 is that successful completion of the proposed 
research will produce two necessary Factor IX products:  intermediate transgenic Factor IX that will 
guide process development that will result in a Factor IX candidate product with desirable hemostatic 
and pharmacokinetic properties; and a final transgenic Factor IX product for evaluation in hemophilia B 
dogs. 
 
D.1.1.  Transgenic pig milk. Starting on Day 5 of lactation, piglets will be separated from their mother 
for a period of one hour.  At the end of that period, the mother will be led into a milking pen and 60 units 
of oxytocin (Vedco, 3ml) will be administered intramuscularly to the animal.  The udder will be washed 
and 5 to 8 minutes after administering oxytocin the animal will be milked by hand or by machine for 
approximately 20 minutes.  After milking the animal, it will be released and united with its offspring.  
Milkings will occur up to three times a day.  The animal will have free access to food and water during 
the procedure. 
 
Milk will be shipped frozen according to USDA regulation for transgenic animal-derived 
materials to the University of Nebraska-Lincoln. Fresh-frozen daily milk samples from five animals 
spanning an entire lactation of 50 days will be sent. Aliquots of 10 x 1 ml, 10 x 10 ml, and 1 x 250 ml of 
each sample will be shipped.  An identical set of milk samples will be retained at ProGenetics stored at 
–80oC.  Nontransgenic milk samples will be shipped and used as controls.  Pre-screening of transgenic 
milk samples before they are admitted to process development or production will use routine assays we 
already have in place:  
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1. Measurement of transgenic Factor IX concentrations by ELISA. 
2. Factor IX activity levels by the aPTT assay. 
3. Molecular fingerprint by reduced western blot so that milk samples with high levels of activated 
Factor IX (FIXaβ) are excluded.   
 
D.1.2. Analytical methods development. The justification for our methods development is based 
upon the anticipated requirements for an Investigational New Drug filing needed for clinical trials of 
transgenic Factor IX. These methods are largely based upon the precedent already set by the FDA 
approval of the only recombinant Factor IX product in the United States (BeneFIX®) and the only 
plasma-derived products (Mononine® and AlphaNine®SD).  The Target Product Profile for transgenic 
Factor IX is given in Table 3.  The objective will be to quantify the properties of cGMP-produced 
transgenic Factor IX products and obtain an abundant product that is equivalent to or better than FDA-
approved Factor IX products.  As the project progresses through the Process Development stage 
(beginning in Year 2) and the cGMP Manufacturing stage (through Year 5), these properties in the 
Target Product Profile will be quantified and refined.  This will be an important task of the Lead 
Investigators and the Scientific Steering Group. In subsequent renewal proposals and prior to clinical 
trials, additional specifications regarding product quality, formulation, dosage, and pharmacokinetics will 
be implemented.   
 
Table 3.  Target Product Profile for Transgenic Factor IX.   
Property Specification and Justification 
Biological activity ≥ 150 IU/mg; 
Similar to BeneFIX® and plasma Factor IX products 
γ-carboxyglutamate (Gla) 
content 
≥ 6 moles Gla/mole Factor IX; 
≥ 6 Gla’s are required for biological activity 
Carbohydrate content complex N-linked glycans with terminal sialic acid;  
Similar to BeneFIX® and plasma Factor IX 
Ser-phosphorylation content ≥ 1 mole phosphoserine/mole Factor IX; 
Better than BeneFIX®, similar to plasma Factor IX 
Molecular weight Factor IX monomer; 
Similar to BeneFIX® and plasma Factor IX 
Tyr-sulfation content ≥15%; 
Better than BeneFIX®, similar to plasma Factor IX 
Activated Factor IX To be determined; upper limit will be defined by thrombogenicity in 
large animal model 
Propeptide content To be determined; Similar to BeneFIX® and plasma Factor IX 
Contaminants – host proteins To be determined; Similar to BeneFIX® and plasma Factor IX 
Thrombogenicity – host 
coagulation proteins 
To be determined; Similar to BeneFIX® and plasma Factor IX 
Contaminants – endotoxins To be determined; Similar to BeneFIX® and plasma Factor IX 
Contaminants – host nucleic 
acids* 
To be determined; Similar to BeneFIX® and plasma Factor IX 
Viral pathogens* To be determined; Similar to BeneFIX® and plasma Factor IX 
Pharmacokinetics To be determined for animal models; Similar to BeneFIX® and 
plasma Factor IX 
Long-term stability* Two-year shelf life for lyophilized product  
* Quantitatively determining these product specifications will not be part of this proposed project 
 
The methods that will be used in this project to evaluate our transgenic Factor IX products 
relative to these specifications are listed in Table 4.  We have prioritized product characteristics that are 
directly related to producing a consistent and high quality transgenic Factor IX product that is suitable 
for evaluation in the hemophilia B mouse and dog models.  We recognize that before clinical trials are 
initiated, additional methods will need to be put in place to verify that higher standards will be met.  
Results obtained from these assays will provide important information about the following issues: 
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1. Efficacy of the transgenic Factor IX as a procoagulant enzyme 
2. Safety of the molecule with regard to 
a. sterility and pyrogenicity 
b. thrombogenicity (in vitro assays only) 
c. host protein contamination 
3. Stability of the transgenic Factor IX product candidates (in the timeframe of the project) 
4. Structure of post-translational modification features of transgenic Factor IX that determine 
biological activity and pharmacokinetic properties. 
 
Table 4. Analytical Methods that will be developed and used to characterize transgenic Factor IX for this 
project and support activities in Process Development, Quality Control, and cGMP Manufacturing.   
Purpose Assays 
Factor IX Characterization 
(structure and function) 
 aPTT activity (Barrow et al., 1959; Lindsay et al., 2004) 
 Chromogenic activity  (Prasa and Sturzebecher, 1998) 
 Propeptide ELISA  (Bristol et al., 1994) 
 Carbohydrate analysis (Chen et al., 1998) 
 Phosphorylation (Schulenberg et al., 2003; Bennett et al., 2002) 
 Tyr-sulfation (Severs et al., 1999) 
 γ-carboxylglutamate content (Ware et al., 1989; Bond et al., 1998) 
 N-terminal sequencing (Bond et al., 1998) - at University of 
Nebraska Medical Center Protein Structure Core Facility 
 Amino acid analysis – at University of Nebraska Medical Center 
Protein Structure Core Facility 
 Peptide map – oxidation, deamidation, proteolysis (Bond et al., 
1998) 
In-Process Assays 
(to confirm product purity and 
biological activity of 
intermediate products) 
 
 aPTT activity (Barrow et al., 1959; Lindsay et al., 2004) 
 Chromogenic activity (Prasa and Sturzebecher, 1998) 
 Factor IX concentration (HPLC) (Lindsay et al., 2004) 
 Molecular weight (SDS PAGE; Size exclusion chromatography) 
(Bond et al., 1998) 
Process Characterization 
Assays 
 Host protein – Albumin (Van Cott et al., 2001) 
 Host protein – IgG  (Van Cott et al., 2001) 
 Host protein – IgA  (Van Cott et al., 2001) 
 Host protein – IgM  (Van Cott et al., 2001) 
 Thrombogenicity – porcine coagulation factors by factor-specific in 
vitro coagulation assays. 
 Endotoxins – LAL assay at Univ. Nebraska-Lincoln BPDF 
 Hemophilia B mouse model bioassay – at UNC-Chapel Hill 
Product Release Assays 
(includes product stability 
assays) 
 aPTT activity (Barrow et al., 1959; Lindsay et al., 2004) 
 Chromogenic activity (Prasa and Sturzebecher, 1998) 
 Factor IX concentration (HPLC) (Lindsay et al., 2004) 
 Molecular weight (SDS PAGE; Size exclusion chromatography) 
(Bond et al., 1998) 
 N-terminal sequencing (Bond et al., 1998) 
 Amino acid analysis  
 Peptide map (Bond et al., 1998) 
 Host proteins (Van Cott et al., 2001) 
 Thrombogenicity – porcine coagulation factors by factor-specific in 
vitro coagulation assays. 
 Endotoxins - LAL assay at Univ. Nebraska-Lincoln BPDF 
 Bioburden - at Univ. Nebraska-Lincoln BPDF 
Raw Material Release Assay 
for cGMP production 
 IR, LAL, bioburden, pH, conductivity, HPLC - at Univ. Nebraska-
Lincoln BPDF 
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BeneFIX®, AlphaNine®SD, and Mononine® will be used as standards for all Factor IX 
structure/function assays.  Nontransgenic milk samples will be used as controls where warranted.  The 
investigators and staff at the University of Nebraska-Lincoln Biological Process Development Facility 
will focus heavily on method development in Years 1-2 of this project.  Standard Operating Procedures 
(SOPs) will be developed and transferred to the Quality Control group, and these methods will be used 
to support efforts in Process Development, Formulation, and cGMP Manufacturing. 
 
D.1.3. Process development – bioseparations engineering and scale-up. The justification for a 
pilot-scale purification process is that a candidate material must be reliably produced within a defined 
product specification, in a quantity sufficient for preclinical evaluation in hemophilia B dog models, and 
a quality to later supply subsequent clinical trials.  The advantage of using cGMP material is having a 
defined product that can reliably be correlated with in vivo behavior and that will be less subject to 
artifacts that can occur in products made at a less regulated lab bench environment. This advantage 
speeds the leap to supplying material for clinical trials. 
 
D.1.3.1.  Initial recovery of transgenic Factor IX. The goal of the recovery step is to remove milk fat 
and somatic cells, producing a “skim milk” stream that maximizes the recovery of transgenic Factor IX.  
The centrifuge, i.e., cream separator, is used in the dairy industry to produce skim milk.  Another 
technology that has potential for this separation is crossflow membrane filtration.  The advantage of 
crossflow membrane filtration is that it can facilitate the separation of other milk proteins from 
transgenic Factor IX, which could dramatically impact the first capture column, since skim milk contains 
up to 60 g/L of “contaminating” proteins.  Parameters that will be evaluated are membrane pore size, 
pH, ionic strength, and linear velocity, which can affect the membrane gel layer and separation 
efficiency.  Given the right conditions, it is possible to separate proteins based on size and charge using 
crossflow membrane filtration.  Precipitation will also be evaluated to reduce the level of milk proteins. A 
successful recovery method will be determined by the impact on the binding capacity of the first capture 
column.  Centrifugation will be the “bench-mark” to which the other methods will be compared.  
 
D.1.3.2.  Capture step. The goal of the capture step is to volume-reduce and achieve some level of 
purification. The method should be robust and simple with elution of the desired transgenic Factor IX-
containing product with step changes in buffer conditions.  As discussed above, heparin affinity 
chromatography has proven to be an effective capture step because it selectively and quantitatively 
adsorbs transgenic Factor IX.  However, heparin columns are expensive and potentially leach porcine 
heparin as a contaminant into the product.  Thus, we will investigate mimetics of heparin affinity 
matrices such as dextran sulfate and sulfated cellulose.  Anion exchange chromatography can also be 
used to quantitatively bind transgenic Factor IX, but nonspecific, strong adsorption of milk proteins such 
as caseins occurs.  In particular, beta-casein is very difficult to partition away from transgenic Factor IX. 
Thus, heparin mimetics will be prioritized. 
 
D.1.3.3.  Viral reduction. The goal of viral reduction processing steps is to achieve log decreases of 
the viral activity in specific classes of viruses with minimal loss of product activity.  Typically, viral 
reduction steps are applied after the capture step to benefit from volume-reduction.  These 
technologies differ in the class of viral pathogen that is inactivated. Model viruses of specific classes 
are typically spiked into the feedstream and the amount of reduction measured. Typical technologies for 
viral reduction used in commercial available therapeutics are solvent/detergent for lipid envelope 
viruses, nanofiltration for non-lipid envelope viruses, and heat treatment for all viruses. 
Chromatographic processing can also provide a barrier to pathogens (Hay, 2002).  As a barrier to lipid 
envelope viruses, we will adapt a solvent/detergent reduction step using tri-n-butylphosphate (TNBP) 
and Triton X-100 (Horowitz et al., 1992). In addition, while ProGenetics’ transgenic pig herd is of free 
porcine parvovirus, the transgenic Factor IX product from the polishing step will treated by nanofiltration 
to provide an additional barrier to non-lipid-coated viruses such as parvovirus (Van Holten et al., 2002).  
In this work, we will determine the stability of transgenic Factor IX activity in response to 
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solvent/detergent treatment and nanofiltration. The validation of viral reduction will be the subject of a 
subsequent grant proposal. 
 
D.1.3.4.  Purification and polishing steps. The goal of the purification and polishing steps is to 
produce a final transgenic Factor IX bulk product having the purity, biological activity, and 
pharmacokinetic properties given in the bulk product specifications.  Important contaminants that must 
be removed include inappropriate proteases such as activated transgenic Factor IX, porcine 
prothrombin, porcine Factor VII, and porcine Factor X.  As mentioned earlier, the purification and 
polishing of transgenic Factor IX produced by Lindsay et al. (2004) using high resolution anion 
exchange chromatography yielded a transgenic Factor IX product with a 40-hour Mean Residence 
Time in hemophilia B mice, nearly double that of BeneFIX® and Mononine® in the same model.  
Because this polishing step is scalable, we will use this technique as a starting point.  The analytical 
methods described above will be critical to evaluating the effectiveness of the polishing step, especially 
with respect to removal of thrombogenic contaminants.   
 
Process development at the bench-scale will be conducted with 7.8 to 100 ml columns packed 
with matrices suitable for process-scale using Perseptive Biosystems BioCad process chromatography 
systems, which are capable of 100 ml/min flow rates.  Once a process has been finalized at the 100 ml 
column-scale, it will be scaled to the 1 to 2 L column scale using pilot-scale chromatography equipment 
in the BPDF Purification Development Laboratory.  For its scale-up efforts, the Purification 
Development Lab has an Amicon K-prime 40 chromatography system (500 ml/min) and a North 
Carolina SRT chromatography system capable of 1000 ml/min. A North Carolina SRT Model 50 
crossflow membrane filtration system capable of running 2 to 3 m2 of ultrafiltration membrane is 
capable of processing 5 to 20 liters of sample.  The process will be run three successive times at the 
pilot-scale, with all of the supporting analytical testing to confirm the process and provide all of the 
information necessary for technology transfer to cGMP manufacturing of the final bulk product. 
 
The BPDF will also be supporting formulation activities at Colorado State University (described 
in Specific Aims #2 & #3).  It will be responsibility of the BPDF to produce transgenic Factor IX for 
Colorado State as needed during the grant for formulation and lyophilization studies. Both non-cGMP 
and cGMP sterile bulk will be produced at UNL, and lyophilized final Drug Substance will be produced 
at Colorado State in a fashion that guarantees material suitable for preclinical trials in hemophilia B 
dogs. 
 
D.1.4.  Factor IX-knockout hemophilia B mouse bioassay for process development.  The Factor 
IX-knockout mouse is an excellent model of the human hemophilia B phenotype and will be used for 
evaluating transgenic Factor IX candidate preparations made during Process Development. As 
reviewed above, the Factor IX-knockout mouse produces no mRNA transcript, has no circulating factor 
IX antigen, and has a bleeding phenotype. Also, human Factor IX is active in the murine coagulation 
system, and the pharmacokinetics of infused human Factor IX in this mouse model are similar to the 
hemophilia B dog model and humans (Gui et al., 2002).  
 
D.1.4.1.  Infusing and sampling. Samples of transgenic Factor IX from Process Development will be 
formulated in a buffer similar to BeneFIX® (or in a more optimal formulation as the formulation studies 
progress) and shipped to Prof. Monahan. Commercially available Factor IX (Mononine®, BeneFIX®) 
and transgenic Factor IX preparations will be injected intravenously (external jugular; 5-7 mice per 
group).  On the day prior to injection, mice will be tagged and weighed, and a plasma sample will be 
taken to establish baseline Factor IX clotting activity.  Mice will be anesthetized with intraperitoneal 
avertin prior to injection, and the Factor IX sample diluted into a total volume of 100 µl using sterile 
normal saline.  After injection, the injection site will be sutured closed. Plasma samples will be taken at 
15 min, 1 hour, 4 hours, 24 hours, 48 hours, and 72 hours from retroorbital venous plexus into citrated 
collection tubes.   
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D.1.4.2.  Factor IX activity and antigen assays.  Samples will be analyzed at UNC-Chapel Hill by 
aPTT (Start4 Coagulometer) for Factor IX activity and ELISA for Factor IX antigen levels. Thirty minutes 
after injection, the level of anesthesia will be checked, and avertin dosing will be repeated if it is 
necessary to keep the animal sedated past 1-hour timepoint. For each subsequent sample, collection 
will alternate between eyes for retroorbital venous plexus to minimize any effect of partial activation of 
coagulation via tissue factor exposure.  The mice will be euthanized after the 72-hour timepoint.  The 
data will be plotted and analyzed to determine the pharmacokinetic properties of the transgenic Factor 
IX – e.g., area under the curve, Mean Residence Time, volume of distribution, and half-life.  The 
pharmacokinetic parameters will be determined using the commercially available software package 
(e.g., PK Solutions or PCNONLIN). These results will then guide decisions by the Process 
Development team, whose goal is to purify transgenic Factor IX having optimal pharmacokinetics.  
 
D.1.5. cGMP manufacturing and quality assurance. The process development information from the 
pilot-scale studies completed in the Purification Development Laboratory of the Biological Process 
Development Facility will be used to write the Production Batch Records.  This activity is a three-way 
process among the purification development staff, the cGMP production staff, and the quality 
assurance staff.  Prior to this phase in the project, all of the analytical methods required for in-process 
testing and release testing are expected to have been completed and reference to these methods will 
be made in the Production Batch Records.  Production Batch Records include all aspects of the 
production process, from facility change control (facility and equipment cleaning and elastomer change 
out prior to the cGMP production), specifying all raw materials, buffer preparation, and finally the 
process to produce Final Bulk Product. 
 
Once the Production Batch Records are completed and signed-off from the Quality Assurance 
group, they will be issued to the cGMP staff.  It is expected that changes will be made to the Production 
Batch Records prior to the final cGMP run.  To this end, one engineering run will be completed using 
the Production Batch Records to ensure that the batch records accurately reflect the process using the 
cGMP pilot plant equipment.  The typical engineering run will be up to 10 liters of milk in scale for the 
purposes of hemophilia B dog studies.  Changes made to the Production Batch Records during the first 
engineering run will be incorporated and reissued prior to the second engineering run.  Based on the 
three non-cGMP runs in the Purification Development Laboratory, it is expected that the new batch 
records will be in sufficient shape to support a successful second engineering run that will produce 
Factor IX suitable for preclinical studies.  Equally important is that product from the second engineering 
run will meet final product specifications that are decided upon in Section D.1.2. 
 
The product from the first engineering run will be used to finalize the formulation batch records 
and to “shake down” the lyophilization process.  The material from the second engineering run will be 
used to produce the preclinical cGMP Final Drug Substance that will be used for both the IV and oral 
dosage canine studies.  Once the production phase begins and product candidates have been chosen, 
we will initiate stability studies of sterile bulk and formulated candidate intravenous products.  The 
sterile bulk stability will serve as a source material for the final formulation of oral dosage candidate 
formulations. The assays used will be aimed at determining if aggregation, deglycosylation, oxidation, 
and proteolysis are occurring for sterile bulk and formulated, vialed candidate products (Table 4). 
 
D.1.6. Electronic data capture and technology transfer.  The Biological Process Development 
Facility uses CyberLAB®, an electronic data management system to collect, organize, warehouse, 
index, and safely archive all structured and unstructured electronic records from raw data and 
laboratory reports into compliance records, putting the information the BPDF needs to improve 
operations in one, convenient, easily accessible location.  CyberLAB® provides a secure, Part 11-
compliant, centralized electronic library for any and all electronic data files of any size. Not only can 
machine readable instrument data files be stored, but also images, multimedia files, presentations, 
human readable word processing and Adobe PDF documents, spreadsheets, and hundreds of other 
formats. CyberLAB® automatically extracts searchable metadata from each of the files using 
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CyberLAB® SmartFilters.  Using a Web-based Virtual Personal Network (VPN), all members of the 
grant, including administrative personnel from the NIH, will be able to search for any records of interest 
using an integrated Quick or Advanced query and view the files in the browser without the need for data 
generating applications for most file types. The BPDF will be able search and retrieve vital information 
quickly and easily and spend more time using information than searching for it.  
 
All of the work proposed has the primary objective of transitioning transgenic Factor IX into 
cGMP manufacturing and clinical trials.  All process development information is a critical component of 
the life cycle of the product and is subject to FDA inspection.  Having a single repository of this 
information in a validated electronic format that is completely searchable will have a significant impact 
on this project and in the future as transgenic Factor IX becomes a commercial product.   
 
D.2.  Specific Aim #2. Characterize and formulate transgenic recombinant human Factor IX for 
intravenous dosage, and evaluate in a hemophilia B dog model 
 
The justification for Specific Aim #2 is that the hemophilia B dog model is an established 
preclinical evaluation needed prior to Phase I clinical trials. The objective of this Specific Aim is to 
evaluate the pharmacokinetics of a cGMP-produced transgenic Factor IX product formulation. The 
cGMP-produced transgenic Factor IX will be formulated for intravenous delivery using existing 
information known for BeneFIX® and administered to hemophilia B dogs. Our rationale for Specific Aim 
#2 is based upon past experience with plasma-derived Factor IX and BeneFIX®; an intravenous 
product that is efficacious in hemophilia B dogs is expected to be efficacious in humans (Brinkhous et 
al., 1996).  
 
D.2.1.  Intravenous formulation.  The justification for this task is that freeze-dried protein formulations 
display the most desirable long-term physical and chemical stability for intravenous formulations. In our 
hemophilia B mouse experiments reported in Section C.4, we used the BeneFIX® formulation 
conditions reported in Bush et al. (1998) for storing and shipping frozen liquid transgenic Factor IX 
samples.  The objective here is to formulate transgenic Factor IX in a similar fashion to BeneFIX® for a 
lyophilized product.  The excipients and Factor IX concentrations that were used to minimize 
aggregation and obtain the best cake formation for BeneFIX® are as follows: 
¾ 500 and 1000 IU vials: 10 mM l-histidine, 260 mM glycine, 1% sucrose, 0.005% polysorbate 
80, pH 6.8. 
¾ 250 IU vials:  5 mM l-histidine, 130 mM glycine, 0.5% sucrose, 0.0025% polysorbate 80, pH 
6.8. 
The formulation of plasma-derived Factor IX products is also available in their product labels, and they 
contain similar constituents.  Briefly, these formulations are designed to prevent protein unfolding, 
protein aggregation, and protein degradation. Excipients, especially sugars, replace the water 
molecules during drying (Carpenter et al., 1997, 2002).  
 
Formulation experiments will begin in Year 2 as products from Process Development are made 
available. Our initial intravenous formulation will mimic the BeneFIX® formulation, and the following 
properties of formulated and lyophilized transgenic Factor IX will be measured: 
1. Biological activity of reconstituted Factor IX – determined by aPTT after reconstitution.  
2. Native protein structure – determined by Fourier transform infrared spectroscopy and circular 
dichroism. 
3. Glass transition temperature of the lyophilized cake – determined by Differential Scanning 
Calorimetry (a higher glass transition temperature reduces the rate of diffusion controlled 
reactions such as unfolding and aggregation).   
4. Proteolytic damage of reconstituted transgenic Factor IX – by SDS-PAGE 
5. Aggregation of reconstituted transgenic Factor IX – by size exclusion chromatography and 
dynamic light scattering. 
 
                                                                                       Principal Investigator/Program Director (Last, first, middle): Velander, William H. 
110 
Chemical degradation, such as deamidation and oxidation, is also possible and will monitored 
by peptide mapping and LC-MS of reconstituted transgenic Factor IX. If deamidation of transgenic 
Factor IX is problematic, it can be significantly retarded by choice of pH, using minimal buffer 
concentrations, and restricting mobility (have a high glass transition temperature).  Although these 
steps, along with proper lyophilization, will slow most all deamidation processes, it can still proceed in 
some proteins, especially if they are stored near the glass transition temperature (Carpenter and 
Chang, 1996).  Oxidation of transgenic Factor IX is likely to be more problematic. Methionine oxidation 
can be minimized by sealing vials under nitrogen and/or using ‘sacrificial additives’ (e.g., free 
methionine) to compete with protein residues for reactive oxygen species.  
 
D.2.2.  Hemophilia B dogs at UNC-Chapel Hill – IV delivery and pharmacokinetics.  The 
justification for this study is that pharmacokinetic studies in hemophilia B dogs are a necessary 
preclinical model as recognized by the FDA in approved Factor IX products (Mononine®, 
Alphanine®SD, BeneFIX®), where all of these products were evaluated in hemophilia B dog models 
prior to human clinical trials.  The preclinical evaluation of BeneFIX® was studied in the same lineage 
of hemophilia B dogs at UNC-Chapel Hill (Brinkhous et al., 1996), and we will perform a similarly 
designed study. These dogs do not produce Factor IX or cross-reactive material that could compete 
with exogenously administered Factor IX.  However, these dogs will produce inhibiting antibodies to 
Factor IX within 14 days after IV administration. While IV administration of human Factor IX products 
acutely corrects coagulopathy in these hemophilia B dogs, the inhibitors occurring in the majority of 
exposed animals make it impossible to conduct long-term studies (>14 days) that determine the effects 
of therapy on bleeding frequency.  Subsequent proposal applications will focus on studying the 
pharmacokinetics of transgenic Factor IX in pretolerized hemophilia B dogs (Russell et al., 2003).  
 
D.2.2.1.  Short-term cross-over study. A short-term cross-over study is planned in Year 4 to measure 
the pharmacokinetics of cGMP-produced transgenic Factor IX product. Three hemophilic dogs in a 
cross-over design is sufficient for a given dose in a non-tolerized dog (Brinkhous et al., 1996).  In the 
first two dogs, plasma-derived Factor IX (Mononine®) will be given on Day 1 and transgenic Factor IX 
will be given on Day 3 (i.e., 72 hours after infusing Mononine®). For the third dog, transgenic Factor IX 
will be administered on Day 1 and Mononine® on Day 3. These studies will provide pharmacokinetic 
data (recovery and half-life) that normalize for individual dog responses to exogenous Factor IX, 
because each dog serves as its own control.  The goal is to give 100 IU/kg based on activity 
determined by using canine deficient plasma.  It is anticipated that both commercial products will be 
infused according to the commercial manufacturers’ recommendations on the package inserts in terms 
of time and reconstitution, but dosing will be done based on activity in canine plasma.   
 
D.2.2.2.  14-day infusion study.  In Year, 5 we will perform a longer-term study with daily intravenous 
administration of transgenic Factor IX, as was also performed by Brinkhous et al. (1996) for BeneFIX®.  
This objective of this study will be to evaluate the pharmacokinetics of transgenic Factor IX in a dosing 
regimen that models prophylaxis – it was found that the initial recovery of BeneFIX® in a daily dosing 
regimen increased by more than double that of a single bolus.  Doses of 50 IU/kg for up to 14 
consecutive days will be administered to three dogs.  Based on previous experience with BeneFIX®, 
we expect that there will be no immune response or reactions during the first 9 days.  Treatment will be 
halted if the dogs develop reactions.   
 
D.2.2.3.  Sampling. Platelet-poor plasma will be prepared by double centrifugation of blood 
anticoagulated with 3.2% sodium citrate. Plasma samples will be assayed immediately or frozen at 
negative 80oC until assayed.  Pools of normal dog plasma and plasma from four hemophilia B dogs that 
have not been treated with any plasma products will be prepared as controls.  The assays will include 
the whole blood clotting time (WBCT), aPTT, and Factor IX activity and antigen assays.  A sufficient 
number of samples will be drawn to be able to calculate pharmacokinetic parameters including the 
maximal plasma concentration, half-life, area under the curve, bioavailability, and volume of distribution.  
If these Factor IX products have a longer half-life, sampling will be modified to be able to detect this 
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outcome and allow washout before cross-over.  It is possible that the transgenic Factor IX will prolong 
the half-life beyond the stated sampling interval; additional samples will be taken twice daily until the 
whole blood clotting time becomes prolonged.  Serum samples will be prepared to assess the degree 
the immune response to the Factor IX products and for clinical chemistry analyses (liver enzymes, 
serum electrolytes, glucose, creatine, amylase, BUN). 
 
Except for the WBCT, all assays will be done at the same time after the infusion and sampling is 
completed. To detect any systemic toxicity of the infusates, serum for clinical chemistry will be drawn at 
baseline and daily during the infusion period.  The clinical chemistry analyses will be performed every 
other day by automated methods by Antech, a commercial veterinarian clinical chemistry laboratory. If 
any toxicity is detected, then all samples surrounding the days in question will be processed.  All dogs 
will be maintained for at least 30 days.  Samples will be drawn at days 7, 14, 21, and 28 to assay anti-
Factor IX inhibitory antibodies. After the study is completed, the dogs will either be returned to the 
colony or euthanized. 
 
D.2.2.4.  Inhibitory antibody assays. The possibility of an anti-human coagulation factor antibody 
developing by Day 10 is acknowledged in this study design.  The development of this inhibitory 
antibody may mask persistent activity. All bleeder animals will be tested for pre-existing anti-Factor IX 
neutralizing antibodies before being assigned to protocols. Factor IX antibody assays will be performed 
using two procedures, the Bethesda inhibitor assay (Kasper et al., 1975) and a direct binding ELISA 
with immobilized human Factor IX and enzyme-coupled anti-immunoglobulin reagents (Russell et al., 
2003).  For the Bethesda inhibitor assay, a patient’s plasma with a residual Factor IX activity of 50% of 
the normal control is defined as one “Bethesda unit” of inhibitor per ml.  For ELISA, values will be 
determined as described (Russell et al., 2003).  All of these assays are currently available at the 
Frances Owen Blood Research Lab (FOBRL), where the hemophilia B dogs are produced, maintained, 
and given the experimental Factor IX preparations.  
 
D.2.2.5.  Thrombogenic potential and coagulation assays. Potential procoagulant effects including 
disseminated intravascular coagulation will be assessed by measuring platelet counts at baseline, 4, 8, 
24, 48, and 72 hours post infusion.  The prothrombin time, fibrinogen, fibrin split products, and 
prothrombin fragment 1+2 levels will be measured at baseline, 4, 8, 24, 48, and 72 hours by Esoterix, 
Aurora, Colorado.   
 
Correction of the whole blood clotting times (WBCT) has now been shown to correlate with 
reduced bleeding in the hemophilic dogs (Russell et al., 2003).  The WBCT will be assayed at baseline, 
1 hour, 8 hours, 24 hours, and daily until prolonged to a significant length (i.e., at least doubled from the 
nadir following treatment).  More frequent assaying will be attempted when the WBCT begins to 
prolong. 
 
Factor IX coagulant activities will be determined by a modified one-stage partial thromboplastin 
time using canine Factor IX-deficient substrate plasma assay (Barrow et al., 1959).  Normal canine 
reference plasma consists of pools from 5-10 normal dogs from our inbred colony.  The test sample will 
be diluted several fold and compared to the same dilutions for a normal curve. The results will be 
reported as a percent of normal.  Activated Partial thromboplastin times (aPTT) will be determined in 
the ST4 coagulation instrument (Diagnostica Stago, Asnsieres, France) or the Multiple Discrete 
Analyzer (MDA) 180 (bioMerieux, Durham, NC) that has the capacity to process rapidly a large number 
of samples.  Whether the aPTTs are determined on the ST4 coagulation instrument or the bioMerieux 
MDA 180 (previously Orgenon Teknika), the controls and reagents will be of the same type.  For the 
aPTT test, mixtures will consist of equal portions of partial thromboplastin (Automated aPTT, 
bioMerieux), 0.025 M CaCl2, and citrated test plasma (Langdell et al., 1953).  
 
D.2.2.6.  Factor IX antigen assays. The ELISA testing for canine Factor IX antigen has been 
performed using commercially available reagents (Herzog et al., 2000).  The ELISA for transgenic 
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Factor IX has been developed by Dr. Van Cott and has a very low cross-reactivity with canine Factor IX 
in normal dog plasma.  
 
D.2.2.7.  Pharmacokinetic analyses.  The pharmacokinetic parameters will be analyzed using the 
commercially available software package (e.g., PK Solutions or PCNONLIN). 
 
D.3. Specific Aim #3.  Develop an oral dosage form of transgenic Factor IX, and evaluate in 
hemophilia B mice and dog models 
 
 The justification for developing oral dosage forms of transgenic Factor IX is to use defined 
transgenic Factor IX material to evaluate the bioavailability in mouse and dog models. Our approach is 
to formulate highly purified transgenic Factor IX in a pharmaceutically acceptable carrier for oral 
dosage, and to evaluate these formulations in a sequence of a normal mouse model, the hemophilia B 
mouse model, a normal dog model, and finally the hemophilia B dog model. We expect that 
bioavailabilities obtained with defined product material in hemophilia B mice and dog models will lead to 
more advanced animal models, such as primates, and eventually to human clinical trials.  
 
D.3.1.  Oral dosage formulation.  In anticipation of an oral dosage of transgenic Factor IX that will be 
first targeted for treating infants, we will focus on lyophilized formulations that are reconstituted as 
liquids for oral administration. In future studies, gel capsule formulations that are more appropriate for 
adults will be investigated.  The oral dosage formulation of transgenic Factor IX will be guided by our 
prior results in hemophilia B mice and normal dogs and by previously published results of liposomal 
formulations of plasma-derived Factor IX and Factor VIII (Hemker et al., 1980; Horikoshi et al., 1982).  
We expect it is likely that the combination of protease inhibitors and encapsulation of Factor IX in 
liposomes increased the bioavailability obtained by Horikoshi et al. (1982).  While our preliminary study 
used raw transgenic milk as a delivery vehicle, it is clear that the simple presence of a lipophilic mixture 
is insufficient to obtain the bioavailabilities found by Horikoshi and Hemker.  Thus, a specific formulation 
process to encapsulate transgenic Factor IX, along with addition of inexpensive protease inhibitors like 
soybean trypsin inhibitor, should increase the bioavailability above that found with raw milk.  In addition, 
transgenic Factor IX was only detected in the plasma of mice and dogs if the milk was fed after a meal.  
Thus, it is likely that titration of gastric pH by the buffering effects of dissolved protein, and competitive 
inhibition of proteases by food proteins and added protease inhibitors naturally found in foods (such as 
the caseins in milk), will enhance bioavailability.  
 
The primary research goals of this stage will be to ensure efficient encapsulation occurs and 
that transgenic Factor IX activity is recoverable from the formulated product and can be standardized 
by in vitro methods. We will use the standard liposome preparations methods used by Hemker et al. 
(1980) and Horikoshi et al. (1982) that achieved bioavailabilities in excess of 5% for oral dosage of 
plasma-derived Factor IX and Factor VIII in dogs and humans. Briefly, a mixture of phospholipids 
(synthetic or derived from egg lecithin) will be dissolved in ethanol, dried under nitrogen, and 
reconstituted in an neutral aqueous buffer containing the transgenic Factor IX and protease inhibitors 
(aprotinin, soybean trypsin inhibitor).  At neutral pH, transgenic Factor IX interacts very strongly with 
alkyl HPLC stationary phases (Van Cott, unpublished observations), and so it is expected that 
transgenic Factor IX will be incorporated into the liposomes with a high efficiency.  Agitation and forced 
flow through filter membranes will be used to emulsify the mixture.  The liposome-encapsulated 
transgenic Factor IX will be isolated and concentrated using centrifugation.  Isolated liposomes will then 
be lyophilized.  After reconstitution, we will quantify the recovery of encapsulated Factor IX activity by 
aPTT analysis of the liposome fraction isolated by centrifugation.  
 
The formulations will be  
1. lyophilized Factor IX liposomes (Hemker et al., 1980), reconstituted in an aqueous syrup, 
buffered with calcium carbonate, and no added protease inhibitors. 
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2. lyophilized Factor IX liposomes (Hemker et al., 1980), reconstituted in an aqueous syrup, 
buffered with calcium carbonate, and added soybean trypsin inhibitor. 
3. lyophilized Factor IX liposomes (Hemker et al., 1980), reconstituted in bovine milk (Horikoshi 
et al., 1982), buffered with calcium carbonate, and no added protease inhibitors. 
4. lyophilized Factor IX liposomes (Hemker et al., 1980), reconstituted in bovine milk (Horikoshi 
et al., 1982), buffered with calcium carbonate, and added soybean trypsin inhibitor. 
 
The aqueous syrup and milk will be used to enhance palatability for younger children and mask 
the taste of other excipients.  USP syrup consists of 85% sucrose (w/v) in water, with a small amount of 
a preservative (0.1% sodium benzoate).  Proteins are known to be stabilized in high concentrations of 
sucrose.  If necessary, modifications of the syrup formulation will include addition of other polyols 
(mannitol, glycerol). 
 
D.3.2.  Postprandial, oral dosage – normal mouse and Factor IX-knockout mouse.  The 
justification for these experiments is that the oral dosage formulations in normal and Factor IX-knockout 
mice will help determine the most efficient formulations for use in normal and hemophilia B dog models. 
The first objective will be to statistically assess the bioavailability of candidate formulations of 
transgenic Factor IX in normal mice.  The second objective will be to then assess the most efficient oral 
dosage formulations in the Factor IX-knockout mouse, which is a more expensive and fragile animal 
model.  The Factor IX-knockout mouse data are needed to evaluate the effectiveness of the transgenic 
Factor IX in establishing and maintaining hemostasis.  Due to cost, we will not assess plasma-derived 
or BeneFIX® with this oral delivery experimental design. 
 
D.3.2.1. Administration and sampling. Lyophilized formulations will be reconstituted as described 
above and administered postprandially.  Single-dose studies will be conducted first, and transgenic 
Factor IX formulations will be administered by gavage.  Long-term studies will consist of treatment for 
one month with administration every other day.  It is desirable to train the animals to drink the 
formulated transgenic Factor IX from a small Petri dish, as we have done in the past when feeding raw 
transgenic milk.  The goal will be to determine how much transgenic Factor IX must be administered to 
obtain >5% Factor IX activity levels in the plasma over a 48-72 hour period.  A control group of vehicle-
only administration will be done in parallel for both normal and Factor IX-knockout mice.   
 
On the day prior to feeding, mice will be tagged and weighed, and a plasma sample will be 
taken to establish baseline Factor IX clotting activity.  Five to seven mice will be used in each treatment 
group. Post-administration in single-dose pharmacokinetic studies, mice will be anesthetized with 
intraperitoneal avertin and plasma samples will be taken at 15 min, 1 hour, 4 hours, 24 hours, 48 hours, 
and 72 hours from retroorbital venous plexus into citrated collection tubes.  For long-term studies up to 
six retroorbital bleeds, plasma samples from anesthetized mice will be taken every three days for an 
18-day period. For each subsequent sample, collection will alternate between eyes for retroorbital 
venous plexus to minimize any effect of partial activation of coagulation via tissue factor exposure.  The 
mice will be euthanized at the completion of each study. 
 
D.3.2.2. Factor IX activity and antigen assays.  Factor IX antigen and activity levels in the plasma 
samples and the pharmacokinetics (bioavailability, mean residence time, clearance, etc.) will be 
determined as described above in Section D.1.4. Samples from normal mice at Colorado State will be 
shipped to UNC-Chapel Hill or the University of Nebraska-Lincoln for required assays.  For normal 
mouse plasma samples, the Factor IX activity and antigen levels over baseline will be measured, using 
a pool of normal mouse plasma and the individual mouse plasma samples prior to administration as 
controls. 
 
D.3.3  Postprandial oral dosage of transgenic Factor IX in normal and hemophilia B dogs. The 
justification for these experiments is that, from the perspective of hemostasis (Brinkhous et al., 1996) 
and the precedent of preclinical studies in the hemophilia B dog as accepted by the FDA, these data 
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will be required for our anticipated IND filing. It is also essential that we have a clear understanding of 
the species difference for oral administration of Factor IX. The first objective will be to assess the 
bioavailability in normal dogs of oral dosage formulations that gave the highest bioavailability in 
hemophilia B mice.  The second objective will be to then assess the bioavailability in the hemophilia B 
dog model of the formulations having the highest bioavailability in normal dogs. Due to cost, plasma-
derived Factor IX and BeneFIX® will not be assessed.   
 
D.3.3.1. Postprandial oral administration and sampling.  The goal will be to maintain greater than 
5% Factor IX activity in plasma for at least 72 hours by oral dosage.  In our preliminary work with 
normal dog giving 500 IU/kg in unformulated raw milk, we achieved similar levels of Factor IX activity in 
plasma as Horikoshi et al. (1982), who administered 14 U/kg.  Because of the expected greater 
efficiency of absorption of transgenic Factor IX formulated in liposomes, we will bracket our treatment 
levels between 50-500 IU/kg. 
  
A short-term study will consist of a one-hour, post-prandial administration, followed by sampling 
over a 72-hour period and then cross-over.  An oral dosage cross-over study of vehicle-only and then 
transgenic Factor IX formulation will be done in both normal and hemophilia B dogs.  For normal dogs, 
treatment groups will be four to five animals for each candidate formulation.  For hemophilia B dogs, the 
treatment group will be three dogs.  
 
A long-term study using the best candidate formulation will consist of post-prandial feedings 
every two or three days and plasma sampling every three days for 30 days. For both normal dogs and 
hemophilia B dogs, plasma and serum sampling protocols, coagulation assays, and inhibitor assays will 
be the same as in Section D.3.2.  Samples from normal dogs at Colorado State will be shipped to UNC-
Chapel Hill or the University of Nebraska-Lincoln for required assays.  
 
D.4.  Program Plan  
 
This project will require five years to complete with the final result an evaluation of an oral 
dosage in a canine hemophilia B model. We have established a well thought-out project time line, 
which follows. The success of any product destined for clinical trials is a solid foundation of analytical 
methods that serves four purposes: characterization, in-process testing, stability testing, and methods 
to release the clinical product. The first 2.5 years will be required to establish all of the assays required 
to produce cGMP material for the canine studies. In addition, characterization studies (not typically 
required for final product release, but essential for understanding protein biochemistry) will continue 
during the entire grant period and are shown as a subtask under the cGMP Task. 
 
 Process development will initiate at the beginning of Year 2, which coincides with the 
establishment and transfer of in-process tests to Quality Control. Two years for process development 
will be required, with Year 2 dedicated to developing a process to produce bulk material, developing 
intravenous formulation, and evaluation in hemophilia B mice. We will then be able to initiate the 
process to produce cGMP material for the canine studies. The first canine studies in Year 4 will be 
initiated using the first cGMP material.  Subsequent cGMP materials will be produced for oral 
formulation and administration in Year 5.  Quality Assurance and Quality Control span the entire 
project. Having a continuous presence of Quality Assurance during this project is essential to ensure 
that a quality product is delivered that meets standards for injectables. Including this component in the 
Program Plan will guarantee a rapid transition into clinical testing. 
 
D.4.1. Major milestones for this project are 
1. Establishing Product Specifications and Analytical Methods to determine these specifications – 
2nd Quarter, 2007 
2. Establishing the process to produce Factor IX candidate materials – 4th Quarter, 2007 
3. First material lot of transgenic Factor IX by cGMP production – 3rd-4th Quarter, 2008 
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4. Canine hemophilia model – 4th Quarter, 2009 
 
  
D.5.  Organizational Chart and Leadership Statement 
 
Dr. William Velander is the Principal Investigator of this project and has more than 17 years 
experience and cumulatively more than $6 million of research support in directing transgenic animal 
engineering research and plasma protein purification research. Dr. Velander will oversee all aspects of 
this project and coordinate Factor IX characterization, production, and testing in animal models. Dr. 
Stephan Abramson of LifeSci Partners has two decades of biopharmaceutical product development 
experience encompassing clinical, technical, and regulatory expertise, including AlphaNine®SD 
(purified plasma-derived Factor IX).  Dr. Abramson will be a Lead Investigator coordinating information 
needed for future regulatory approval and clinical evaluation. Dr. Julian Cooper of ProGenetics LLC is a 
Lead Investigator who has extensive experience in the cGMP production of transgenic pigs and sheep 
for production of biotherapeutics, and will supply FDA- and USDA-compliant Factor IX milk. Dr. Michael 
Meagher is a Lead Investigator at the University of Nebraska-Lincoln who provides expertise in 
bioprocess engineering and current Good Manufacturing Practices production of recombinant proteins, 
and is Director of the Biological Process Development Facility. Dr. Kevin Van Cott is a Lead 
Investigator presently at Virginia Tech, but will be at the University of Nebraska-Lincoln beginning May 
2004.  Van Cott will direct characterization and analytical methods development and assist Dr. Todd 
Swanson in transfer of methods to Quality Control.  Dr. Todd Swanson (Key Person) will direct Quality 
Control.  Dr. William Dernell (Key Person) and Dr. Mark Manning (Lead Investigator) of Colorado State 
will formulate Factor IX products that are produced by the UNL Biological Process Development 
Facility, and then forward these formulated products to Drs. Paul Monahan and Timothy Nichols at the 
University of North Carolina at Chapel Hill.  Dr. Paul Monahan is a Lead Investigator and will direct 
hemophilia B mouse model studies.  Dr. Timothy Nichols is a Lead Investigator who will direct 
hemophilia B dog studies.  The individuals listed above, along with technology transfer officials from 
participating institutions, will comprise the Scientific Steering Group for this project.  The Scientific 
Steering Group will meet monthly (by teleconference) to discuss the progress of the project and any 
technical issues. An external BRP Advisory Board has been assembled to discuss the progress of the 
project, suggest alternative strategies if technical problems are encountered, and provide input into 
future directions that the research team should take. 
 
 
Project Timeline - cGMP Recombinant Factor IX for IV and Oral Therapy 
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Organizational Chart – cGMP Recombinant Factor IX for IV and Oral Therapy 
William Velander, Ph.D.
Principal Investigator
Michael Meagher, Ph.D.
Process Development 
Stephan Abramson, Ph.D.
Analytical Methods 
Quality Control 
Characterization
cGMP Manufacturing 
Formulation 
Kevin Van Cott, Ph.D.
Mark Manning, Ph.D.
Timothy Nichols, M.D.
Paul Monahan, M.D.
William Dernell, DVM
Todd Swanson, Ph.D.
Julian Cooper, Ph.D.
Stability
Canine Model 
Murine Model 
Transgenic Milk
Quality Assurance 
Technical and Regulatory 
Program Coordinator
BRP Advisory Board
Robert Langer, Ph.D. - MIT
Kenneth Bauer, M.D. - Harvard Medical School
Paul S. Bajaj, Ph.D. - St. Louis Univ. School of Medicine
Bruce Furie, M.D. - Harvard Medical School
John M. Curling, Ph.D. - John Curling Consulting AB
Scientific Advisory Committee
Kannan Grant – UNL
Marc C. Sedam – UNC-CH
Julian Cooper – ProGenetics
Arundeep S. Pradhan - CSU
Technology Transfer 
 
 
D.6. Expected Outcomes 
 
It is expected that the success we have had in our preliminary studies will translate to 
successful cGMP production and successful preclinical evaluation of transgenic Factor IX in the 
hemophilia B dog model so as to provide rapid transition to Phase I clinical trials. We expect that this 
success will be derived from the product specifications defined as a result of the work, and that the 
compliance with these specifications by the transgenic Factor IX product will be supported by in-
process, lot release, and characterization assays for the production of Purified Drug Substance and 
final formulated Product. Thus, it is our strong expectation that a viable intravenous transgenic Factor 
IX and an oral dosage form of transgenic Factor IX will become available within the projected 
timeframes for future clinical trials.  It is our equal conviction that the same approaches, modified as 
necessary, will lead to the analogous development and production of recombinant Factor VIII ready to 
enter advanced development for manufacture of material for Phase I clinical trials.   
 
D.7. Anticipated Problems and Alternative Strategies 
 
Among potential problems is the geographical separation of culturally distinct partners (industry 
[ProGenetics, LifeSci Partners], academe [University of Nebraska-Lincoln and University of North 
Carolina at Chapel Hill, Colorado State University], and government (NIH NHLBI).  This critical issue 
has been solved by making the University of Nebraska-Lincoln the lead institution on this proposal as a 
result of its extensive experience producing cGMP biologics with collaborators of similar geographical 
separation.  The Principal Investigator, Dr. William Velander (UNL), is a co-architect of the FDA’s Points 
to Consider in the Manufacture and Testing of Therapeutic Products for Human Use Derived from 
Transgenic Animals, and has biopharmaceutical experience of plasma-derived Protein C and Factor IX 
at pilot plant scale of 5,000 Liter batches with the American Red Cross Holland Laboratories, and is, 
therefore, ideal as the project leader.  The Lead Investigators at UNL are demonstrably ready and able 
to coordinate the efforts required for success in this joint effort to produce the transgenic Factor IX 
products.  Dr. Velander’s efforts will be facilitated by the fact that most of the investigators have 
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experience working together and have a long-term interest in accomplishing the overall goal of this 
application.  As evidenced in our preliminary studies, the partners have a track record of working and 
problem-solving together over for a long period of time, and the same approach will underpin this effort.  
Of equal importance will also be the integration of hemophilia treatment staff of the National Heart Lung 
and Blood Institute. 
 
Interdependence of the partners is a strength and, at the same time, a potential weakness.  
Strength lies in the fact that the whole is greater than the sum of the parts; no one of the groups could 
accomplish the overall goal in the same time without the other partners.  Potential weakness lies in the 
fact that loss of one of the key partners, although a remote possibility, could interrupt the overall effort 
for a brief period. However, given the quality of Lead Investigators and Key Persons working in the 
program, coupled with high-quality record-keeping, data management, and availability, the loss of any 
one key individual would not translate into loss of knowledge and, in most cases, little if any time would 
be lost.  In addition, appropriately qualified individuals will be recruited either from within each partner 
organization or from external sources in a timely manner. All information generated by all sites will be 
shared among the project team electronically.  Each site will be required to provide a monthly summary 
of results to the Program Coordinator who will assemble these documents into monthly project 
summary reports.  These reports will be very useful for technology transfer into cGMP and to assist in 
the writing later on of the Investigational New Drug (IND) application.  The monthly reports will serve as 
a basis for mandatory reports to the NIH program director.  All of the reports will reside on the 
CyberLab system at UNL and will be accessible to all participating institutions through the Web.  The 
NIH program director will also have access to this information.  The NIH program director is welcome to 
participate in the weekly phone conferences as well.  
  
Although we do not anticipate issues with the current transgenic pig source material, it is 
possible that the current lineages may not be suitable for producing clinical grade material, and new 
lineages may need to be made.  This is not viewed as a significant hurdle based on our 17 years of 
experience in producing transgenic pigs.  In the case of purification, capture is viewed as the most time-
consuming step in process development and presents the greatest challenges.  Although it is difficult to 
present a solution, the combined experience of this cooperative team will be applied to solve this 
problem.  This group has more combined experience with Factor IX and transgenically expressed, post-
translationally complex proteins than any group in the world.  Detailed immunologic studies concerning 
tolerization are beyond the scope of funding for this project, but our collaborators at NIH NIAID will be 
pursuing separate funding. 
 
The Biological Process Development Facility’s experience with companies that request rapid 
transition of their drug candidate into Phase I clinical trials is that yield and sometimes scalability of the 
process are sacrificed at the expense of “getting enough” material for Phase I studies.  Successful 
Phase I studies translates into an infusion of capital by investors and then the process is “fixed.”  In the 
case of transgenic Factor IX, this model does not apply, because there is a very high probability that 
transgenic Factor IX will succeed.  Eventual Phase I clinical studies will be performed with hemophilia B 
patients, thus, a consistent supply of transgenic Factor IX must be guaranteed so treatment can 
continue past Phase I.  The BPDF will be able to build on the existing knowledge of BeneFIX® and, 
more importantly, the plasma-derived AlphaNine®SD, because Dr. Stephan Abramson was directly 
involved in the organization of clinical trials and commercialization of AlphaNine®SD.  Given all of these 
factors and the fact that commercial-scale is actually pilot-scale, process development at the BPDF will 
be focused on developing a process suitable for commercial production. 
 
At the end of the proposed investigations, it is expected that transgenic Factor IX will be 
formulated into a viable product for intravenous therapy and for oral dosage.  It is, however, recognized 
that these formulations, while starting from the same source material, will be pharmaceutically different, 
and there is the possibility that additional expertise and new technology for oral delivery may be needed 
to increase efficiency of bioavailability for adult oral administration because of the large number of units 
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that may be needed.  In that case, it is possible that only oral dosage for infants may be feasible in the 
context of the proposed budget and research plan.   
 
Finally, we have assembled an external and independent BRP Advisory Board consisting of 
individuals that are experts in biomedical engineering of drug delivery, Factor IX biochemistry, 
hemophilia treatment, and bioprocess engineering of blood plasma proteins and recombinant proteins. 
These individuals have no financial interests in the project and will provide an objective evaluation of 
the progress of the project.  
 
¾ Robert Langer, Ph.D. (Massachusetts Institute of Technology) is a biomedical engineer and an 
expert in drug delivery. 
¾ Kenneth Bauer, M.D. (Harvard Medical School) is a clinician and expert in coagulopathic 
diseases including those related to Factor IX. 
¾ Paul S. Bajaj, Ph.D. (St. Louis University School of Medicine) is an expert in Factor IX 
biochemistry. 
¾ Bruce Furie, M.D. (Harvard Medical School) is an expert in recombinant manipulations of Factor 
IX. 
¾ John M. Curling, Ph.D. (John Curling Consulting AB) is an expert in process purification and 
production of therapeutic proteins derived from plasma and recombinant sources. 
 
D.8.  Technology Transfer Integration Plan 
 
Technology transfer can be a major hurdle for inexperienced groups.  Such problems are highly 
unlikely for the group proposed here, because the principal partners (ProGenetics, LifeSci Partners, 
University of Nebraska-Lincoln, University of North Carolina at Chapel Hill, and Colorado State) have 
direct, successful experience with biologics production.  All are familiar and experienced with operating 
within the framework of Good Laboratory Practices and current Good Manufacturing Practices.  In the 
unlikely event that such problems were to be encountered, additional managerial emphasis would be 
given to overcoming the difficulties and to making sure that they did not continue to be a problem. 
 
Intellectual property issues and the issue of who will get the credit for successful attainment of 
the overall goal have been discussed openly and solved.  All partners are prospectively in agreement 
that their own interests will be subordinated to that of attaining the overall goal.  Clear agreements are 
in place as to how intellectual property and credit for discovery will be assigned.  Technology transfer 
officials from ProGenetics LLC (Julian Cooper), University of Nebraska-Lincoln (Kannan Grant), 
University of North Carolina at Chapel Hill (Marc Sedam), and Colorado State University (TBN) will be 
included as members of the Scientific Steering Group.   
 
D.9.  Data Sharing Plan 
 
Data generated during this project will be published in peer-reviewed journals and presented at 
national and international meetings. Lead and corresponding authors of articles and presenters of 
technical talks will acknowledge all of the project team members who contributed to the work.  
Assignment of lead and corresponding authorship will be agreed upon by the Scientific Steering Group.  
Data generated in this project that are not proprietary will be made available to the public at the 
University of Nebraska-Lincoln Biological Process Development Facility web site (http://bpdf.unl.edu).  
Data that will be posted on the web site will include slides from technical presentations and seminars, 
reprints of journal articles and conference proceedings, and links to the National Hemophilia 
Foundation and World Federation of Hemophilia web sites. 
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D.10.  Dissemination Plan 
 
The audiences most suitable for viewing the research results of this project are the hemophiliac 
community and clinicians treating hemophilia.  Our activities to reach this audience will include travel to 
national meetings and international meetings for the World Federation of Hemophilia, the American 
Society of Hematology, and the National Hemophilia Foundation.  Dr. Velander will be giving an invited 
plenary talk at the WFH meeting in Thailand in 2004 and has routinely given talks to the NHF Gene 
Therapy workshops and the Hemophilia World Congress meetings.  Travel money is requested to 
support these activities throughout the duration of the project.  In addition, slides and brochures from 
these presentations will be made available on our web site, with links to the web sites of the National 
Hemophilia Foundation and the World Federation of Hemophilia.  Part of the Program Coordinator’s 
and IT support staff’s duties will be to ensure that our web site at the University of Nebraska-Lincoln is 
maintained and up-to-date.   
 
D.11.  Future Directions 
 
Prior to human clinical trials, there will be additional preclinical studies such as 
hypercoagulopathic potential evaluated in the Wessler rabbit model and pigs.  In addition, long-term 
pharmacokinetic and immunologic studies, especially for oral dosage forms with gel capsules, will be 
needed.  These studies are beyond the scope of funding for the current five-year BRP project.  
However, at the completion of the presently proposed studies, we will make an application for studying 
long-term pharmacokinetic and immunologic effects of transgenic Factor IX.  In addition, validation of 
viral pathogen reduction will be required prior to clinical trials.  There are also additional regulatory 
requirements involving process validation prior to clinical trials that are beyond the scope of this 
funding.  
 
We anticipate that the successful production of clinical-grade transgenic Factor IX and proof in 
the hemophilia B dog animal model of a quality that includes long half-life and an abundance that will 
enable prophylaxis to be explored worldwide will serve as a blueprint for analogous work with Factor 
VIII and von Willebrand Factor (vWF).  Our confidence in this direction derives from our successful 
work with the expression of Factor VIII and vWF in the milk of transgenic pigs and mice, respectively 
(Paleyanda et al., 1997; Velander et al., unpublished results).  This work includes the bioengineering 
necessary to optimize the post-translational modifications using the balance of genetic control over 
expression levels of the target protein as well as the insertion of recombinant post-translational 
processing enzymes such as furin (Drews et al., 1995).  While we are confident that even with the low 
bioavailability, oral administration will be practical for infants of hemophilia A and B, as discussed 
previously. Based upon expression of new molecular designs of Factor VIII that overcome restricted 
secretion, we expect to have a supply of Factor VIII-containing milk produced in pigs within two years.  
We also expect to have vWF-containing pig milk within two years.   
 
E.  Human Subjects 
 Not applicable 
 
F.  Vertebrate Animals 
 
F.1.  Provide a detailed description of the proposed use of the animals in the work outlined in 
the Research Design and Methods section.  Identify the species, strains, ages, sex, and 
numbers of animals to be used in the proposed work. 
 
ProGenetics: Transgenic pigs. IACUC approval number and date: pending; Animal welfare 
assurance number: 52-R-0108.  
The project would require the use of five adult transgenic female pigs (Sus. scrofa).  Animals will be of 
normal breeding age (eight months) or older.  The pigs will be bred through artificial insemination as per 
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standard agriculture technique.  Animals will be maintained through gestation and allowed to farrow per 
industry standard. 
 
Colorado State University.  IACUC approval number and date: pending; Animal welfare assurance 
number: A3572-01. 
Animals (dogs, mice) will be purchased from class A vendors; the specific vendor will be chosen based 
on availability.  Specific strains will be as follows: a) dogs will be Walker hounds and b) mice will be 
C3HeJ.  These strains are chosen for their hardiness and our familiarity with their response to 
procedures performed.  All animals will be examined upon arrival to determine health status.  A 
complete blood count, biochemical profile, and urinalysis will be performed on each dog to obtain 
baseline values.  Upon arrival at Colorado State University (CSU), all animals will be allowed to 
acclimate for 7 days (minimum) prior to additional procedures being performed.  All animals will be 
housed at the laboratory animal facilities at the CSU James L. Voss Veterinary Teaching Hospital.  
Dogs will be adult animals between 1-2 years of age, weighing approximately 10 kg.  We expect to use 
3-4 animals in each treatment group for testing each oral formulation - about 12 dogs total.  For mice, 
we will use about 60 total animals, 4-6 weeks old.  
 
UNC-Chapel Hill: Hemophilia B mice. IACUC approval number and date: pending (application 
number is 04-002.0A); Animal welfare assurance number: A-3410-01. 
The following strains of mice will be maintained at the Gene Therapy Center of the University of North 
Carolina at Chapel Hill for these studies: normal C57BL/6, normal BalbC, and hemophilia B (Factor IX 
knockout mice in C57BL/6, BalbC, and mixed C57BL/129 strain backgrounds).  We will use mice 
between 2 and 5 months old for experiments and will maintain breeding pairs between 2-12 months of 
age. We will use 12 breeding pairs plus four to five treatment groups of seven to eight mice in each 
budgeted year. 
 
UNC-Chapel Hill: Hemophilia B dogs. IACUC approval number and date: 02-135.0-B, 1-7-04; Animal 
welfare assurance number: A-3410-01. 
The following phenotypes of the dogs will be maintained at the Francis Owen Blood Research 
Laboratory at the University of North Carolina at Chapel Hill for these studies: normal and hemophilia B 
(Factor IX deficient).  We will use male and female dogs predominantly between 2 and 12 months old 
for experiments, and older dogs as breeders and blood product donors.  Each hemophilic dog has an 
average of ~six bleeds per year that require these blood products (Russell et al., 2003).  We anticipate 
maintaining an average census of 10 to 20 dogs and including 10 to 20 puppies.  The goal of this grant 
application is to test Factor IX made in transgenic pigs for its ability to correct the hemophilic 
coagulopathy.  The hypothesis we are testing is that replacement of the missing proteins with these 
new transgenic Factor IX formulations will correct the bleeder phenotype.  In addition to the use of 
these animals in the described protocols, blood will be used in the in vitro studies and tissue in ex vivo 
studies. 
 
F.2.  Justify the use of animals, the choice of species, and the numbers to be used.  If animals 
are in short supply, costly, or to be used in large numbers, provide an additional rationale for 
their selection and numbers. 
 
ProGenetics: Transgenic pigs. Previous research of transgenic swine has indicated their ability to 
produce and secrete functional vitamin K depend proteins into milk.  Currently, ProGenetics LLC 
maintains a herd of transgenic swine at its class R research facility (USDA # 19485) that produces 
transgenic Factor IX. Results from previous research have indicated the production capability of these 
transgenic swine under the current milking protocol to be 100 liters per year.  While only one animal is 
need to fulfill the required amount of milk need for this project, a pool from at least five animals will be 
used to ensure reproducibility. 
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Colorado State University.  Animals (dogs, mice) will be purchased from class A vendors; the specific 
vendor will be chosen based on availability.  Specific strains will be as follows: a) dogs will be Walker 
hounds and b) mice will be C3HeJ.  These strains are chosen for their hardiness and our familiarity with 
their response to procedures performed. The number of animals that we have specified, 12 dogs and 
about 60 mice, are needed to obtain a statistical significance in the evaluation of each oral formulation.   
 
UNC-Chapel Hill: Hemophilia B mice.  We will examine the ability of transgenic pig-derived 
recombinant human Factor IX, when compared with commercially available human plasma-derived or 
CHO cell-derived Factor IX, to function in the blood coagulation cascade. To adequately compare 
efficacy of the new human Factor IX preparation with the currently available products, testing in vivo the 
coordinated interactions of the clotting system (coagulation Factors I-XIII and von Willebrand factor 
interacting with platelets and the vascular endothelial system) is required. In addition, an intact immune 
system is required for comparative testing of the incidence of anti-Factor IX humoral immune responses 
(“inhibitor antibody” development) with the transgenic-derived Factor IX as compared to available 
products. To do this, we may need to characterize and vary the immune background of the recipient 
species (requiring inbred strains of mice) and the genotype of the disease model (requiring transgenic 
hemophilic mice), while keeping intact the immune and coagulation systems. A non-animal alternative 
is not available. We will use 12 breeding pairs plus four to five treatment groups of seven to eight mice 
in each budgeted year. This number of animals is required to obtain the statistical significance of 
pharmacokinetic properties in the mice. 
 
The hemophilia B mouse model was created at the University of North Carolina by Dr. Darrel 
Stafford, using a strategy of homologous recombination that knocked out the promoter through the 
fourth exon of the mouse Factor IX gene. The mouse has no Factor IX activity and has no circulating 
Factor IX protein. As a result, the mouse has a bleeding tendency that resembles human Factor IX 
deficiency. Specifically, the mouse has abnormal (prolonged) in vitro blood clotting results, joint and 
muscle hemorrhages with trauma, and both difficulty forming a stable initial clotting and late re-bleeding 
after injury. The hypothesis we are testing is that replacement of the missing mouse Factor IX with the 
new transgenic Factor IX formulations will correct the bleeder phenotype. In addition, we will test the 
hypothesis that transgenic Factor IX, when compared to commercially available Factor IX products, will 
not be more immunogenic; i.e., transgenic Factor IX will be no more likely to stimulate the development 
of anti-Factor IX inhibitor antibodies in the hemophilic mouse. 
 
UNC-Chapel Hill: Hemophilia B dogs. We have chosen hemophilic dogs for this study for several 
reasons.  First, the bleeder phenotype of these dogs recapitulates the human disease of the same type.  
Second, other related products that have been successful at correcting the hemophilic coagulopathy in 
these dogs have also been found to work in human hemophiliacs. The availability of an established 
animal model of hemophilia with a track record of predicting success in treating human hemophiliacs is 
an important facet of this grant application. Murine models of hemophilia B are also available and will 
be used for screening various Factor IX formulations.  However, an average mouse weighs 25 grams 
and has a circulating blood volume of ~1.5 cc.  This small size limits the volume and frequency of blood 
drawing. Frequent blood sampling is essential in these studies because we are trying to determine the 
half-life of these new Factor IX products.  The availability of these dogs with these well-characterized 
bleeding disorders represents a unique opportunity to perform these preclinical studies to treat 
deficiencies in blood coagulation proteins.  The number of dogs chosen is the number required to 
ensure the availability of experimental and control dogs.  Our strategy for accomplishing this goal is to 
maintain three dogs for every two experimental and control dogs to ensure that an orderly sequence of 
studies can be conducted without costly delays. 
 
F.3.   Provide information on the veterinary care of the animals involved. 
 
ProGenetics: Transgenic pigs. Animals will be inspected at least twice annually by a certified 
veterinarian that specializes in large animal medicine.  Currently, ProGenetics LLC has a contractual 
                                                                                       Principal Investigator/Program Director (Last, first, middle): Velander, William H. 
122 
arrangement with Bold Springs Veterinary Services (Blacksburg, Virginia) for both emergency and non-
emergency care.  The attending veterinarian has established and maintained programs of disease 
control and prevention, pest and parasite control, procedural care, nutrition, and euthanasia on the 
premises of ProGenetics LLC. 
 
Colorado State University.  All animals will be handled and cared for by trained personnel, either from 
the Dr. John Venners Pharmacology laboratory or Laboratory Animal Resources at CSU according to 
the GUIDE FOR THE CARE AND USE OF LABORATORY ANIMALS (National Institutes of Health 
publication no 85-23). Laboratory animal facilities at CSU are accredited by the American Association 
for the Accreditation of Laboratory Animal Care. Dogs will be housed in elevated runs and fed a 
standard dry ration.  Dogs will be allowed 7 days to acclimate to their surroundings prior to 
experiments.  Mice will be housed in an AALAC-approved facility in cages of five animals each, and 
kept in a temperature-controlled environment with 12 hour cycles of light and darkness.  Animal care at 
the facility is designed and supervised by the veterinary staff of the Division of Laboratory Animal 
Medicine, including Dr. Don Maul, who is a board-certified laboratory animal veterinarian.  The majority 
of the veterinary care and supervision at the laboratory will be performed by Dr. Dernell, the laboratory 
co-director and a licensed veterinarian. 
 
UNC-Chapel Hill: Hemophilia B mice. Mouse breeding and experiments will be conducted under the 
direct supervision of Dr. Monahan and under the auspices of the Division of Laboratory Animal 
Medicine at the University of North Carolina.  Mice are maintained in a virus- and pathogen-free facility 
of the University of North Carolina Department of Laboratory Animal Medicine in the building of the 
Lead Investigator (Monahan). Animal care at the facility is designed and supervised by the veterinary 
staff of the Division of Laboratory Animal Medicine, including Dr. Dwight Bellinger, who is a board-
certified laboratory animal veterinarian.  Dr. Bellinger has more than 20 years experience in the use of 
animals for study of human coagulation proteins and advises experimental design in mice as well as in 
the colonies of hemophilic canines maintained at the UNC-CH Francis Owen Blood Research 
Laboratory. 
 
UNC-Chapel Hill: Hemophilia B dogs. The dogs will be raised under the auspices of the Division of 
Laboratory Animal Medicine at the University of North Carolina.  The dogs are born and reared at the 
Francis Owen Blood Research Laboratory, a facility of The University of North Carolina Department of 
Pathology and Laboratory Medicine.  This laboratory has been dedicated to the production and care of 
dogs and pigs with inherited bleeding disorders for more than 40 years.  The laboratory is accredited by 
the American Association for the Accreditation of Laboratory Animal Care and operates according to 
the GUIDE FOR THE CARE AND USE OF LABORATORY ANIMALS (National Institutes of Health 
publication no 85-23).  Animal care at the facility is designed and supervised by the veterinary staff of 
the Division of Laboratory Animal Medicine, including Dr. Dwight Bellinger, who is a board-certified 
laboratory animal veterinarian.  The majority of the veterinary care and supervision at the laboratory is 
done by Dr. Bellinger who has done this work for more than 20 years. 
 
F.4.  Describe the procedures for ensuring that discomfort, distress, pain, and injury will be 
limited to that which is unavoidable in the conduct of scientifically sound research.  Describe 
the use of analgesic, anesthetic, and tranquilizing drugs and/or comfortable restraining devices, 
where appropriate, to minimize discomfort, distress, pain, and injury. 
 
ProGenetics: Transgenic pigs. Transgenic pigs used in this study will not be subjected to discomfort, 
distress, pain, or injury.  Animals will be allowed free access to food and water during the procedure.  
During the past 17 years, we have shown that piglets of lactating females that are milked up to five 
times/day have normal growth rates when provided with industry-standard milk replacement. 
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Colorado State University.  Sedation or anesthesia will be used to minimize discomfort and distress 
when necessary.  Animals are handled by experienced personnel and anesthesia is supervised by 
professional staff.   
Dogs: Morphine (1-2 mg/kg subcutaneously) and acepromazine (0.01-.2mg/kg subcutaneously) is 
used to sedate the dogs for minor procedures such as intravenous injections and blood withdrawal.   
Mice: Intravenous (tail vein) injections will be performed under isoflourane gas anesthesia by nose 
cone (mask) induction and maintenance. 
 
UNC-Chapel Hill: Hemophilia B mice. Anesthesia and sedation will be used to minimize discomfort 
and distress.  Animals are handled by experienced personnel whose proficiency with procedures is 
evaluated by the Compliance Coordinators of the Office of Institutional Animal Care and Use of UNC-
CH. For minor procedures (e.g., phlebotomy) anesthesia is accomplished with inhaled isoflurane to 
effect. For surgical procedures anesthesia is accomplished by giving avertin 0.017-.018 ml/gram or 
inhaled isoflurane to effect. Anesthesia is evaluated by respiratory rate and persistence or absence of 
withdrawal reflexes (toe pinch withdrawal). 
 
UNC-Chapel Hill: Hemophilia B dogs.  Anesthesia and sedation will be used to minimize discomfort 
and distress.  Animals are handled by experienced personnel and anesthesia is supervised by 
professional staff.  Ketamine (10/mg/IM) or Medetomidine -HCl 750 µg/m BSA IV is used to sedate the 
dogs for minor procedures such as blood withdrawal and determining bleeding times.  For surgical 
procedures anesthesia is accomplished by giving Medetomidine -HCl 750 µg/m BSA IV followed by 
isoflurane to effect (maintenance at around 2%).  Nitrous oxide (50%) is occasionally used during 
induction.  Anesthesia is evaluated by heart rate, blood pressure, and persistence or absence of 
palpebral, corneal, and withdrawal reflexes. 
 
F.5. Describe any method of euthanasia to be used and the reasons for its selection.  State 
whether this method is consistent with the recommendations of the Panel on Euthanasia of the 
American Veterinary Medical Association.  If not, present a justification for not following the 
recommendations. 
 
ProGenetics: Transgenic pigs.  Euthanasia is performed with an overdose of TKX to render the 
animal unconscious, followed by a lethal electric shock.  This method is chosen because it is quick and 
non-stressful to the animals and because it is consistent with the recommendations of the Panel on 
Euthanasia of the American Veterinary Medical Association. 
 
Colorado State University.  Euthanasia (dogs) is performed with an overdose of pentobarbital (88 
mg/kg intravenously).  Euthanasia (mice) will be performed by cervical dislocation under isoflourane 
anesthesia. These methods are chosen because they are quick and non-stressful to the animals and 
because they are consistent with the recommendations of the Panel on Euthanasia of the American 
Veterinary Medical Association. 
 
UNC-Chapel Hill: Hemophilia B mice.  Euthanasia is performed with an overdose of avertin (0.035 
ml/gm body weight) or ketamine (0.2 mg/gram body weight), followed by cervical dislocation. This 
method is chosen because it is quick and non-stressful to the animals and because it is consistent with 
the recommendations of the Panel on Euthanasia of the American Veterinary Medical Association. 
 
UNC-Chapel Hill: Hemophilia B dogs. Euthanasia is performed with an overdose of pentobarbital (6 
grains/10 lbs).  This method was chosen because it is quick and non-stressful to the animals and 
because it is consistent with the recommendations of the Panel on Euthanasia of the American 
Veterinary Medical Association. 
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Abstract
Transgenic animal bioreactors can be engineered to make gram per liter quantities of complex recombinant glycoproteins in milk. However,
little is known about the limitations in post-translational processing that occurs for very complex proteins and how this impacts the task of
purification. We report on the purification of recombinant factor IX (rFIX) from the milk of transgenic pigs having an expression level of 2–3 g
rFIX/(l−1 h−1), an expression level that is about 20-fold higher than previously reported. This purification process efficiently recovers highly ac-
tive rFIX and shows that even complex mixtures like pig milk, which contains 60 g/l total endogenous milk protein and multiple subpopulations
of rFIX, can be processed using conventional, non-immunoaffinity chromatographic methods. Without prior removal of caseins, heparin-affinity
chromatography was used to first purify the total population of rFIX at greater than 90% yield. After the total population was isolated, the bio-
logically active and inactive subpopulations were fractionated by high-resolution anion exchange chromatography using an ammonium acetate
elution. Capillary isoelectric focusing of the active and inactive rFIX fractions demonstrated that the active subpopulations are the most acidic.
© 2003 Elsevier B.V. All rights reserved.
Keywords: Milk; Tansgenic animals; Factor IX; Heparin; Proteins
1. Introduction
Hemophilia B is a bleeding disorder caused by a con-
genital deficiency in circulating factor IX activity. The ideal
treatment of hemophilia B is prophylactic treatment, which
significantly reduces complications and improves the qual-
ity of life [1]. Unfortunately, this regimen is unavailable
for many hemophiliacs because the only sources of replace-
ment factor IX are plasma-derived factor IX (pd-FIX) and
recombinant factor IX (rFIX) produced in Chinese hamster
ovary (CHO) cells (BeneFIX) [2]. Pathogen safety concerns
with pd-FIX, combined with the limited supply of pd-FIX
and rFIX from CHO cells make prophylactic treatment of
hemophilia B expensive. Safer and more productive sources
of rFIX are thus desired.
∗ Corresponding author. Fax: +1-540-231-5022.
E-mail address: kvancott@vt.edu (K.E. Van Cott).
1 Department of Chemical Engineering, University of Nebraska,
Lincoln, NE 68588, USA.
Factor IX is a complex protein with numerous post-
translational modifications (PTMs). These PTMs are
required for biological activity and pharmacokinetics,
and include propeptide removal, vitamin K-dependent
-carboxylation of Glu to -carboxyglutamate (Gla), Ser-
phosphorylation, Tyr-sulfation, and glycosylation [3]. In par-
ticular, -carboxylation and propeptide removal are required
for the procoagulant activity of factor IX (Fig. 1). The com-
plexity of these multiple PTMs also necessitates production
of rFIX in mammalian cells. However, not all mammalian
cells are equally proficient in performing all of these PTMs.
For example, CHO cells were shown to have significant
rate limitations in propeptide removal, -carboxylation, and
Ser-phosphorylation [4–6]. Additionally, transgenic sheep
were not able to produce any significant amounts of biolog-
ically active rFIX in milk [7]. We have previously published
immunoaffinity methods for purification of biologically ac-
tive rFIX from transgenic pig milk having lower expression
levels of 100–200g/ml containing 35–70 U/ml [8]. The
rFIX was fully -carboxylated at this level of production.
0021-9673/$ – see front matter © 2003 Elsevier B.V. All rights reserved.
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Fig. 1. Amino acid sequence of the factor IX propeptide and Gla domain. E represents potential -carboxyglutamate (Gla) residues (12 in total). The
propeptide is cleaved prior to secretion.
Immunoaffinity chromatography was also used to purify bi-
ologically active rFIX from the milk of transgenic mice [9].
In this work, we report on the purification of rFIX from
a new lineage of transgenic pigs having expression levels
of 2–3 g rFIX/l milk containing about 70–140 U/ml FIX
activity. With the ability to translate and secrete higher
levels of recombinant polypeptide by transgenic meth-
ods comes the need for economical purification methods
that can selectively isolate populations that have preferred
post-translational structure. We demonstrate that non-
immunoaffinity chromatographic methods are able to purify
select rFIX populations to a high purity and a high specific
activity. Importantly, we also demonstrate a rate limita-
tion in -carboxylation occurs at rFIX expression levels of
0.2–0.3 g/l.
2. Experimental
2.1. Reagents
All buffer components were purchased from Sigma (St.
Louis, MO, USA) or Fisher Scientific (Pittsburgh, PA, USA),
unless otherwise noted. The following buffers were used.
(i) Heparin loading buffer: 20 mM Tris, 50 mM NaCl, pH
7.2.
(ii) Heparin wash buffer: 20 mM Tris, 200 mM NaCl, pH
7.2.
(iii) Heparin elution buffer: 20 mM Tris, 500 mM NaCl,
pH 7.2.
(iv) Heparin regeneration buffer: 4 M NaCl.
(v) Matrex Cellufine sulfate loading buffer: 20 mM Tris,
125 mM NaCl, pH 7.4.
(vi) Matrex Cellufine sulfate wash buffer: 20 mM Tris,
250 mM NaCl, pH 7.4.
(vii) Matrex Cellufine sulfate elution buffer: 20 mM Tris,
500 mM NaCl, pH 7.4.
(viii) Q loading buffer: 20 mM Tris, pH 9.0.
2.2. Transgenic milk collection and storage
Transgenic pigs were generated as described previously
[8], but using a 4.2 kb mouse whey acid protein promoter
for the factor IX cDNA construct [10]. Milk was collected
from lactating pigs in accordance with protocols approved
by the Virginia Tech Animal Care Committee. Lactating
sows were injected intramuscularly with 60 units of oxytocin
(Vedco, St. Joseph, MO), and milked by hand. The milk
was immediately aliquoted and frozen at −50 ◦C. Milk used
in this study had a factor X activity level of 100–140 U/ml
milk, as measured by the activated partial thromboplastin
time (APTT) assay.
2.3. Purification of rFIX
2.3.1. Heparin chromatography
Heparin-Sepharose FF (Amersham Biosciences, Piscat-
away, NJ, USA) was packed in Bio-Rad Econo-columns
(Hercules, CA, USA) and the columns were run on a
Bio-Rad BioLogic DuoFlow chromatography system with
280 nm detection. Aliquots of milk were thawed and mixed
1:1 (v:v) with 200 mM EDTA pH 7.4 (to dissolve the ca-
sein micelles) and centrifuged for 15 min at 3000 × g at
4 ◦C to separate the fat. The skim milk/EDTA was diluted
five-fold with heparin loading buffer, and loaded onto the
column (9 cm × 2.5 cm i.d.). All columns in this work
were run at room temperature. In order to minimize rFIX
losses in the flow-through and wash steps, the column was
loaded to only 1 mg rFIX/ml matrix at a linear velocity of
1 cm/min. The column was subsequently washed with hep-
arin loading buffer at 2 ml/min until the baseline absorbance
was reached, and then washed with heparin wash buffer
at 2 ml/min to remove adsorbed caseins. Recombinant fac-
tor IX was eluted with heparin elution buffer at 3 ml/min.
The heparin product was either immediately diluted and
processed by anion exchange chromatography, or else im-
mediately frozen at −70 ◦C. The heparin-Sepharose column
was regenerated with 4 M NaCl, and re-equilibrated.
A synthetic heparin analogue matrix, Matrex Cellufine
sulfate (Millipore, Billerica, MA, USA), was also tested.
The column was packed in a Bio-Rad Econo-Column
(8 cm × 1 cm i.d.). The Cellufine sulfate column was first
equilibrated with sulfate loading buffer and subsequently
loaded at 1.5 ml/min with skim milk diluted identically as
with the heparin-Sepharose columns. The column was then
washed with Cellufine sulfate loading buffer until base-
line was reached, and then washed using Cellufine sulfate
wash buffer. Factor IX was eluted using Cellufine sulfate
elution buffer. All steps were performed at 1.5 ml/min. As
with heparin-Sepharose, the Cellufine sulfate column was
regenerated with 4 M NaCl and re-equilibrated.
The purity of the heparin-Sepharose product was ana-
lyzed by reversed-phase HPLC on a Vydac 218TP5415
column (C18 stationary phase, 15 cm × 4.6 mM i.d., 5m
particles, 300 Å pores, Hesperia, CA, USA) with a Supelco
Supelguard LC318 guard column (C18, 5m particles,
300 Å pores, St. Louis, MO, USA). The solvents used
were: (A) 0.1% (w/v) trifluoroacetic acid (TFA) in water,
and (B) 0.1% (w/v) TFA in acetonitrile. The heparin-
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Sepharose product and immunoaffinity purified pd-FIX
standard (Mononine, Centeon LLC, Kankakee, IL, USA)
were diluted in deionized water and 200l were injected.
The solvent program was as follows: 5 min, 5% B, followed
by 5–95% B over 45 min (2%/min), followed by 5 min of
95% B. The flow rate was constant at 1 ml/min. Data were
collected on a Beckman System Gold HPLC system with a
Model 126 solvent delivery system and a Model 168 diode
array detector. An Isco Foxy programmable fraction collec-
tor was used to collect fractions. Peak areas at 220 nm were
integrated by the System Gold software.
2.4. Anion-exchange chromatography
A Mini Q 4.6/5.0 column (5 cm × 4.6 mM i.d. non-
porous 3m particles, Amersham Biosciences) was used to
fractionate active from inactive rFIX subpopulations. The
heparin-Sepharose product was diluted with two parts Q
loading buffer, and loaded at a flow rate of 0.4 ml/min. The
column was washed with 90%:10% Q loading buffer:Q
elution buffer for 10 column volumes (CVs) at 0.8 ml/min.
Adsorbed rFIX was eluted by either a linear gradient or
by a combination of gradient and isocratic elutions. Data
were collected on the Beckman HPLC system. The spe-
cific conditions are given in the figure captions for the
chromatograms shown.
2.5. Sodium dodecylsulfate-polyacrylamide gel
electrophoresis (SDS-PAGE)
Column fractions were analyzed by SDS-PAGE (silver-
stained) using Invitrogen (Carlsbad, CA, USA) gels and
the Invitrogen Minicell apparatus. All gels were NuPage
10% bis-Tris run with 2-(N-morpholino)ethanesulfonic acid
(MES) running buffer (Invitrogen). Briefly, samples were
mixed with 4× LDS sample buffer (Invitrogen) and deion-
ized water followed by heating at 95 ◦C for 10 min. For re-
duced gels, samples were adjusted to 0.05 M dithiothreitol
(DTT) prior to heating.
2.6. Factor IX activity—APTT assay
The biological activity of the rFIX fractions was deter-
mined by the APTT assay [11]. Briefly, 100l each of
Alexin (cephalin from rabbit brain, Sigma), factor IX defi-
cient plasma (Biomerieux, Durham, NC, USA), and sample
of interest were added to a cuvette and incubated at 37 ◦C
for 3 min. One hundred microlitres of 20 mM CaCl2 (Sigma)
was then added and the clotting time was measured using a
MLA Electra Coag-a-Mate coagulation timer. Units of factor
IX activity were calculated by comparison of the unknown
sample to a standard curve created from dilutions of normal
reference plasma (Biomerieux, 1 U/ml plasma) made using
the same protocol. The concentration of purified rFIX was
determined by measuring the optical density at 280 nm in
a 1 cm quartz cuvette and using an extinction coefficient of
1.33 for a 1 mg/ml factor IX solution.
2.7. Total Gla analysis
Total Gla content of the purified rFIX fractions was de-
termined by amino acid analysis from basic hydrolysis.
Column fractions were dialyzed overnight against deionized
water in a cold room (4 ◦C) and then lyophilized to dryness
in a Savant Speed-Vac system. The rFIX was then reconsti-
tuted in deionized water, frozen, and shipped to Common-
wealth Biotechnologies (Richmond, VA, USA) for analysis.
Briefly, 83l of 4 M NaOH and 117l of water were added
to 100l of sample. The tubes were sealed under vacuum
and hydrolyzed for 20 h at 100 ◦C. The samples were then
neutralized with 4 M acetic acid, diluted with a borate buffer,
and then subjected to analysis. The molar ratio R = Glu/Gla
for each sample was obtained from the respective peak areas
of the chromatogram. Factor IX has 40 total Glx residues
(28 Glu+ 12 potential Gla). The (moles Gla)/(moles factor
IX) was obtained by solving the simple set of equations:
Glu+ Gla = 40
Glu
Gla
= R
where R is the experimentally determined ratio of (moles of
Glu)/(moles of Gla) for the sample.
2.8. Isoelectric focusing
The isoelectric point (pI) of rFIX subpopulations was de-
termined by a two-step capillary isoelectric focusing and
mobilization based on the method reported by Huang et al.
[12]. A two step method was necessary because factor IX
is a very acidic protein. Polyacrylamide coated capillaries
(eCAP Neutral, Beckman Coulter, Fullerton, CA, USA) of
27 cm total length × 50m i.d. were used with a Beckman
PACE/5000 instrument with UV absorbance detection. The
anolyte used was 60 mM phosphoric acid in 0.4% (w/v) hy-
droxypropylmethylcellulose (HPMC, Sigma). The catholyte
was 20 mM NaOH. All solutions were filtered with a 0.2m
syringe filter before use. Ampholytes (pI 3–10) were pur-
chased from Fluka (St. Louis, MO, USA). Two standards,
carbonic anhydrase I (Sigma, pI = 6.6) and amyloglu-
cosidase (Sigma, pI = 3.6) were included in all focusing
experiments. The sample solution was prepared by combin-
ing the factor IX sample, the two protein standards (2l
of 4 mg/ml carbonic anhydrase I and 1l of 4 mg/ml amy-
loglucosidase), ampholytes (1l), and 1% HPMC (80l, for
final 0.4% HPMC) to a total volume of 200l. The capil-
lary was first rinsed with deionized water for 2 min and then
filled with the sample solution by rinse mode (20 psi; 1 psi =
6894.76 Pa) for 1 min. Normal polarity (cathode at detector
end) was used for focusing and mobilization. Focusing was
performed by applying 15 kV for 6 min. After the focusing
step, a low pressure rinse of anolyte (0.5 psi) while maintain-
ing 15 kV was applied for 50 min to mobilize the focused
proteins past the detector window. The separations were car-
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ried out at 20 ◦C with detection at 280 nm. The capillary was
rinsed with deionized water for 5 min after each run.
3. Results and discussion
Efforts to purify factor IX from donor plasma are decades
old, and production of factor IX concentrates by crude
methods such as cryoprecipitation or Cohn fractionation
has been replaced with high purity products using im-
munoaffinity and heparin-affinity chromatography [13–15].
Milk and blood are equally challenging feedstocks for pro-
tein purification as both are multi-phase mixtures. Milk
has a solids phase that includes cell debris and the casein
micelles, an aqueous phase that contains whey proteins,
carbohydrates, minerals and nutrients, and the milkfat phase
that contains triglycerides, phospholipids, and cholesterol
[16]. The caseins are the most prevalent endogenous milk
proteins at about 30 g/l. Other major milk proteins include
whey proteins (lactoferrin, -lactalbumin, -lactoglobulin)
and serum-passover proteins (serum albumin, immunoglob-
ulins, transferrin). Even though rFIX is being produced at
a very high level of 2–3 g/l in the milk, it is still less than
10% of the total protein content. In addition, the numer-
ous variations in the PTMs that are made to this complex
protein add another layer of complexity to the purification
problem—how does one design a purification process that
also selects for only the biologically active subpopulations?
The initial objective was to purify the entire population
of rFIX from the milk so as to understand the nature of
limits in post-translational processing of rFIX that occurs at
these very high expression levels. The use of classical casein
precipitation techniques was problematic, with as much as
Fig. 2. Purification of rFIX from transgenic pig milk by heparin-affinity chromatography on heparin-Sepharose. The feed to the column contained 11 ml
of milk that was diluted with EDTA, centrifuged, and diluted in column loading buffer. The column was washed with 20 mM Tris, 200 mM NaCl, pH
7.2 to remove non-specifically bound milk proteins. Pure rFIX was eluted with 20 mM Tris, 500 mM NaCl, pH 7.2; 31 mg of rFIX were recovered in
the elution peak.
20% of the rFIX partitioning into casein precipitates (data
not shown). Thus, to circumvent this problem, the casein
micelles were solubilized with excess EDTA. The heparin
binding domain of factor IX is located in the C-terminal end
of the molecule, a region devoid of PTMs [17]. We there-
fore used heparin-affinity chromatography as a capture step
so that the entire population could be isolated. The rFIX was
found to strongly bind to the heparin matrix. The column
was underloaded (with respect to factor IX capacity) to re-
sult in complete rFIX capture. Caseins as well as a number
of other milk proteins also adsorbed to the column, but were
washed off with 200 mM NaCl (Fig. 2). Highly pure rFIX
was eluted with 500 mM NaCl. The purity of the rFIX prod-
uct was analyzed by reversed phase HPLC. Using TFA as
an ion pairing agent and a 2%/min acetonitrile gradient, the
isoforms of both plasma-derived factor IX and rFIX were
not resolved, but eluted as a single peak (Fig. 3). The pu-
rity from this single chromatographic step (98% peak area
at 220 nm) was similar to the purity of pd-FIX purified by
immunoaffinity chromatography. Western blots and activity
assays of the column flow-through and 200 mM NaCl frac-
tions had undetectable rFIX antigen and activity.
A synthetic heparin analogue, Matrex Cellufine sulfate,
has also been used in the purification of BeneFIX, a rFIX
produced in CHO cells [18]. We were unable to obtain a
pure rFIX fraction with this heparin analogue when clarified
skim milk was used as the column feed (Fig. 4). Washing the
column with a 250 mM NaCl buffer resulted in the loss of
rFIX, and a significant amount of the caseins co-eluted with
rFIX in a 500 mM NaCl buffer. In fact, caseins remained
adsorbed to the column and had to be removed during the
regeneration step with 4 M NaCl. The data show that the
heparin analogue did not have the specificity to discrimi-
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Fig. 3. HPLC analysis of the purity of the heparin-Sepharose product: 0.35 mg/ml; 100l injected. For comparison, an immunoaffinity purified
plasma-derived factor IX (Mononine): 0.5 mg/ml, 50l injected. Column: Vydac C18, 15 cm× 4.6 mM. Solvents: (A) 0.1% (w/v) TFA in water, and (B)
0.1% (w/v) TFA in acetonitrile. Flow rate: 1 ml/min. Solvent program: 5 min, 5% B, followed by 5–95% B over 45 min, followed by 5 min of 95% B.
nate between rFIX and the caseins, and non-specific ion ex-
change interactions with the sulfated cellulose matrix were
likely dominating for the conditions used. Thus, unless the
caseins are removed, this heparin analogue is not useful for
purification of heparin-binding proteins from porcine milk.
The specific activity of the heparin product was low (typ-
ically 30–35 U/mg protein) compared to the theoretical pd-
FIX specific activity of 200–250 U/mg. This indicated that
only a fraction of the total rFIX population was biologi-
cally active. The biological activity of factor IX is highly
dependent on the nature and extent of PTMs. Of primary
importance are the PTMs that are made to the N-terminal
region of factor IX—the Gla domain. For factor IX to be ac-
tive, the propeptide must be removed, and the Glu residues
in the Gla domain must be -carboxylated [3]. The con-
formation of a fully -carboxylated Gla domain undergoes
a dramatic change in the presence of Ca2+ [19,20]. This
Ca2+-dependent conformational change enables localization
Fig. 4. Silver-stained SDS-PAGE of column fractions from Matrex Cel-
lufine sulfate, a synthetic heparin analogue. Lane 1: column feed (skim
milk/EDTA); lane 2: column flow-through and wash; lane 3: 250 mM
NaCl eluate; lane 4: 500 mM NaCl eluate; lane 5: 4 M NaCl eluate. MW:
molecular mass, scale in kilodaltons.
of factor IX on the endothelial or platelet cell surface, where
it associates with factor VIIIa to activate factor X. Inade-
quate -carboxylation or the presence of propeptide severely
diminishes this metal-dependent conformational change and
renders the factor IX inactive [21,22].
Several different methods have been used to fractionate
highly -carboxylated, active rFIX from inactive rFIX, and
they are all based on the metal-dependent conformational
changes of the Gla domain. Barium citrate adsorption was
one of the earliest methods used [23], but this has the dis-
advantage of long processing times and is not easily scaled
up. More recently, metal-dependent monoclonal antibod-
ies have been raised against the Gla domain [24]. Other
pseudo-affinity chromatographic methods have also been
developed: Yan et al. used a calcium elution off an anion
exchange resin to fractionate fully -carboxylated recom-
binant Protein C from uncarboxylated subpopulations [25].
This method, as well as hydroxyapatite chromatography,
has also been adapted for BeneFIX production [18]. For the
rFIX heparin chromatography product from transgenic pigs,
hydroxyapatite chromatography and the pseudo-affinity cal-
cium elution off an anion exchange column did not cleanly
fractionate active from inactive subpopulations. Barium cit-
rate adsorption was moderately successful in fractionating
active from inactive subpopulations, but the specific activ-
ity of the pellet fraction was low (∼50 U/mg) due to the
fact that propeptide-containing rFIX also partitions into the
pellet fraction [26,27], which was confirmed by N-terminal
amino acid sequencing (data not shown).
-Carboxylated proteins are highly acidic and this favors
the use of anion exchange to obtain the most highly bio-
logically active rFIX species. We adapted the method of
Gillis et al. [28], which used a NaCl gradient elution from a
high-resolution anion-exchange column to partially resolve
rFIX made in CHO cells having 10, 11, or 12 Gla residues.
The chromatogram from a NaCl gradient elution of rFIX on
a Mini Q column is given in Fig. 5A. The factor IX begins
eluting at about 0.2 M NaCl, and multiple subpopulations
elute as the salt concentration is increased at a rate of 5 mM
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Fig. 5. Anion-exchange chromatography of heparin-purified rFIX on a Mini Q column. (A) NaCl gradient elution. Buffer A: 20 mM Tris, pH 9.0. Buffer
B: 20 mM Tris, 1 M NaCl, pH 9.0. Load rFIX at 0.4 ml/min at 10% B. Wash with 10% B at 0.8 ml/min. Elute with linear gradient of 10–50% B
over 80 min (t = 7–87 min). Loaded 0.3 mg rFIX. (B) Ammonium acetate gradient elution. Buffer A: 20 mM Tris, pH 9.0. Buffer B: 20 mM Tris, 1 M
ammonium acetate pH 9.0. Load rFIX at 0.4 ml/min at 10% B. Wash with 10% B at 0.8 ml/min. Elution program: 10–25% B over 2 min, 25–70% B over
45 min, 70–100% B over 5 min, 100% B for 5 min. Loaded 0.6 mg rFIX. (C) Modified ammonium acetate gradient elution. Elution program: 10–25% B
over 2 min, 25–60% B over 35 min, 70–100% B over 2 min, 100% B for 10 min. Loaded 1.6 mg rFIX.
NaCl/CV. Analysis of the fractions showed that the biologi-
cally active subpopulations eluted in the tail end of the peak
that corresponded to about 10% of the peak area. However,
even with this high-resolution column matrix there is poor
resolution between the subpopulations in this region, and low
specific activities of collected fractions indicated that sub-
populations with inadequate Gla content and/or pro-factor
IX were not well resolved. Resolution was not significantly
improved by using a gradient slope of 2.5 mM NaCl/CV,
and resolution was even poorer at higher rFIX loading.
In an effort to obtain better resolution between the active
and inactive subpopulations, a different displacing salt was
tried. Kopaciewicz et al. showed that the resolution between
soybean trypsin inhibitor and ovalbumin on a strong anion
exchange column was dependent on the counterion [29].
We therefore used an elution buffer with ammonium acetate
for gradient elution of rFIX. The results of an ammonium
acetate gradient on the same Mini Q column are shown in
Fig. 5B. Again, the biologically active rFIX eluted in the
last 10% of the peak area (beginning at 61 min). However,
the use of ammonium acetate resulted in better resolution
between subpopulations, especially in the later eluting sub-
populations where biologically active rFIX elutes. There
are several factors that are likely contributing to this result.
The acetate counterion is known to have a weaker elution
strength than chloride, and the ammonium ion is more
chaotropic than the sodium ion. Additionally, in a detailed
study of the effect of salt counterion on protein retention in
anion exchange chromatography, Malmquist and Lundell
concluded that non-specific effects could play an important
role also [30]. A more detailed mechanistic explanation of
the cause of this behavior is beyond the current scope of
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this work, but the data show that the salt species can play a
significant role in improving the resolution between closely
related subpopulations of the same protein.
The elution program was then modified to obtain a more
concentrated product (Fig. 5C). The active rFIX subpop-
ulations were eluted in the triplet peak obtained after the
sharp increase in ammonium acetate from 0.6 to 1.0 M, and
corresponded to 10% of the total elution peak area. The
overall Gla content of a pool of fractions of 63–67 min from
six replicate runs was measured by amino acid analysis
after basic hydrolysis, and was determined to be 6.0 mol
Gla/mol rFIX. Parallel analysis of Mononine gave a re-
sult of 10.5 moles Gla/mole factor IX (theoretical value is
12 moles Gla/mole factor IX). Our results are similar to
Fig. 6. Anion-exchange fractionation of biologically active and inactive subpopulations of rFIX on a Mini Q column. Loaded 1.6 mg rFIX. (A) Purified
rFIX from the heparin-Sepharose column was diluted three-fold with Q loading buffer and loaded at 0.4 ml/min. After washing with 0.1 M ammonium
acetate, the inactive rFIX was eluted by a sharp increase to 0.5 M ammonium acetate over a 2 min period. After holding at 0.5 M ammonium acetate
for 8 min, the ammonium acetate was increased to 0.6 M over a period of 10 min. The biologically active rFIX was then eluted by a sharp increase to
1.0 M ammonium acetate. The effluent from 27 to 44 min was pooled. (B) An expanded view of the biologically active rFIX elution peak, along with
the specific activity of the fractions as determined by the APTT assay. Duplicates of two dilutions of each fraction were submitted to the APTT assay.
rFIX that was produced in CHO cells, where the average
Gla content was 6.5 moles Gla/mol rFIX [5], and again
demonstrate that -carboxylation of all 12 Glu residues in
the Gla domain is not a necessity for biological activity.
The results from the Gla analysis also revealed why pre-
viously published factor IX purification techniques were
unsuccessful in fractionating active from inactive subpop-
ulations. It is known that human -glutamyl carboxylase
modifies human factor IX by a tethered-processive mech-
anism [31,32]. That is, the carboxylase binds to the factor
IX propeptide and sequentially modifies all Glu residues in
the Gla domain during that single binding event. The un-
modified Glu residues in rFIX produced in the pig are most
likely at the C-terminal end of the Gla domain. Zhang et al.
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found that conserved mutations of Glu to Asp in the Gla
domain of Protein C (a protein with a homologous Gla do-
main) did not necessarily abolish biological activity, but did
affect the Ca2+-dependent conformational changes [33,34].
Therefore, subtle differences in the Ca2+-dependent confor-
mation of rFIX caused by partial -carboxylation are likely
the reason why hydroxyapatite and Ca2+-specific pseudo-
affinity fractionation methods were not successful for rFIX
produced at these very high expression levels.
The gradient elution depicted in Fig. 5C was further mod-
ified to obtain a shorter run time and be more amenable
for future scale-up. As shown in Fig. 6A, the majority of
Fig. 7. Capillary isoelectric focusing electropherograms of rFIX subpop-
ulations and plasma-derived factor IX. (A) 40g/ml of rFIX purified
by heparin-Shepharose, (B) 30g/ml of rFIX-inactive fraction pool from
Mini Q column, t = 27–44 min, (C) 50g/ml of rFIX-active fraction
pool from Mini Q column, t = 46–50 min, (D) 40g/ml of Monon-
ine-immunoaffinity purified plasma-derived factor IX. Estimates of the
pI of major rFIX and Mononine subpopulations are given using a linear
interpolation of pI vs. time for the two standards: carbonic anhydrase I
(CA, pI = 6.6) and amyloglucosidase (AMG, pI = 3.6).
the inactive rFIX subpopulations were eluted by a sharp in-
crease to 0.5 M ammonium acetate. The specific activity in
the pooled fraction from 27 to 44 min was 0.3 U/mg. The ex-
panded view of the elution peak is given in Fig. 6B. As the
ammonium acetate was slowly increased up to 0.6 M, rFIX
subpopulations with low specific activity began to elute.
rFIX with high activity was then eluted by a sharp increase to
1 M ammonium acetate. Again, a characteristic triplet peak
was obtained, and the area percentage of this elution peak
(46–50 min) was approximately 10% of the total peak area of
the chromatogram for all replicate runs. The average specific
activity of the fraction from 46–50 min from a representa-
tive isolation was 197 U/mg. This translates to a net amount
of about 0.3 g/l rFIX that is biologically active. Thus, this
level of active rFIX production is similar to the previously
reported lineage of transgenic pigs producing 100% biolog-
ically active rFIX at a total expression level of 0.2 g/l, and
it indicates that a rate limitation in -carboxylation occurs
in the range of 0.2–0.3 g/l.
The anion exchange column with ammonium acetate elu-
tion method is highly reproducible, and results in a cleaner
fractionation of active subpopulations compared to a NaCl
elution. Isoelectric focusing of the products confirmed that
the most active rFIX subpopulations that are fractionated
by anion exchange chromatography are also the most acidic
(Fig. 7). However, the biologically active rFIX produced by
the transgenic pig is less acidic than plasma-derived fac-
tor IX. This is at least partially due to the fact that over-
all Gla content of the entire 46–50 min elution fraction was
lower than pd-FIX. This lower acidity may also be due to
differences in sialic acid content, although Bharadwaj et al.
demonstrated that removal of sialic acid had no effect on
factor IX activity [35]. Further characterization of glycosy-
lation, phosphorylation, and sulfation made to rFIX subpop-
ulations produced in the transgenic pig is in progress.
4. Conclusions
The purification of complex recombinant proteins is com-
plicated by the fact that multiple subpopulations correspond-
ing to differences in post-translational processing are usually
present. In many cases, the PTMs have a significant impact
on the biological activity and pharmacokinetics, and so the
purification process will need to select for the best subpop-
ulations. Heparin-affinity chromatography was found to be
an ideal method for purifying the total rFIX population in a
single chromatographic step. However, a synthetic heparin
analogue, Matrex Cellufine sulfate, did not have the speci-
ficity required for purification of a heparin-binding protein
from milk. Because the rFIX produced at expression levels
of 2–3 g/l was partially -carboxylated, conventional chro-
matographic techniques that have been used in the past for
fractionation of active from inactive factor IX subpopula-
tions were not efficient. The heparin-chromatography prod-
uct was fractionated into active and inactive subpopulations
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by high-resolution anion-exchange chromatography. Chang-
ing the salt displacer from NaCl to ammonium acetate en-
abled us to more cleanly resolve the biologically active and
inactive rFIX subpopulations. In vitro coagulation activity
assays and capillary isoelectric focusing confirmed that the
most acidic subpopulations that eluted at higher acetate con-
centrations were the most active, and accounted for about
10% of the rFIX that is being produced in the milk at an
overall expression level of 2–3 g/l. Thus, a highly pure and
biologically active rFIX product was obtained from trans-
genic animal milk without the use of immunoaffinity chro-
matography.
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